CA2079814C - Cationic lipids for intracellular delivery of biologically active molecules - Google Patents
Cationic lipids for intracellular delivery of biologically active molecules Download PDFInfo
- Publication number
- CA2079814C CA2079814C CA002079814A CA2079814A CA2079814C CA 2079814 C CA2079814 C CA 2079814C CA 002079814 A CA002079814 A CA 002079814A CA 2079814 A CA2079814 A CA 2079814A CA 2079814 C CA2079814 C CA 2079814C
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- alkyl
- cationic lipid
- cationic
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
Disclosed are cationic lipids capable of facilitating transport of biologically active agents into cells, including the transfection of cells by therapeutic polynucleotides, the delivery of antiviral drugs, and the introduction of immunogenic peptides. The cationic lipids, comprising an ammonium group, have general structure (I).
Also disclosed are adducts of these compounds comprising additional cationic sites that enhance the transfective or transport activity. Structure-activity correlations provide for the selection of preferred compounds to be synthesized for this purpose.
Compositions disclosed for use of these cationic lipids include formulations for in vitro transfection and pharmaceutical formulations for parenteral and topical administration of therapeutic agents.
Also disclosed are adducts of these compounds comprising additional cationic sites that enhance the transfective or transport activity. Structure-activity correlations provide for the selection of preferred compounds to be synthesized for this purpose.
Compositions disclosed for use of these cationic lipids include formulations for in vitro transfection and pharmaceutical formulations for parenteral and topical administration of therapeutic agents.
Description
_, CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF
BIOLOGICALLY ACTIVE MOLECULES
S
Background of the Invention The present invention relates to cationic lipids which are used to enhance delivery of biologically active agents, particularly polynucleotides, proteins, peptides, and drug molecules, by facilitating transmembrane transport or by encouraging adhesion to biological surfaces. It relates particularly to cationic lipids comprising ammonium groups.
Some bioactive substances do not need to enter cells to exert their biological effect, because they operate either by acting on cell surfaces through cell surface receptors or to by interacting with extracellular components. However, many natural biological molecules and their analogues, including proteins and polynucleotides, or foreign substances, such as drugs, which are capable of influencing cell function at the subcellular or molecular level are preferably incorporated within the cell in order to produce their effect. nor +:~ese agents the cell membrane presents a selective barr~~er which is impermeable to them.
Just as the plasma membrane of a cell. is a selective barrier preventing random introduction of potentially toxic substances into the cell, the human body is surrcunded by protective membranes which serve a similar defensive function to the whole organism. These membranes include skin, gastric mucosa, nasal mucosa and the like. While these membranes serve a protective function preventing entry of toxic substances, they can also prevent passage of potentially beneficial therapeutic substances into the body. The complex composition of the cell membrane comprises phospholipids, glycolipids, and cholesterol, as well as intrinsic and extrinsic proteins, and its functions are influenced by cytoplasmic components which include Ca" and other metal ions, anions, ATP, microfilaments, microtubules, enzymes, and Ca'~'-binding proteins. Interactions among structural and cytoplasmic cell components and their response to external signals make up transport processes responsible for the membrane selectivity exhibited within and among cell types.
Successful intracellular delivery of agents not naturally taken up by cells has been achieved by exploiting the natural process of intracellular membrane fusion, or by direct access of the cell's natural transport mechanisms which include end~cytosis and pinocytosis (Duzgunes, N., Subcellular Biochemistry 11:195-286 (1985).
The membrane barrier can be overcome in the ~irst instance by associating these substances in complexes with lipid formulations closely resembling the lipid composition of natural cell membranes. These lipids are able to fuse with the cell membranes on contact, and in the process, the associated substances are delivered intracellularly. Lipid complexes can not only facilitate intracellular transfers by fusing with cell membranes but also by overcoming charge repulsions between the cell membrane and the molecule to be inserted. The lipids of the formulations comprise an amphipathic lipid, such as the phospholipids of cell membranes, and forn, hollow lipid vesicles, or liposome=_, in aqueous systems. This property can be used to entrap the substance to be delivered within the liposomes; in other applications, the drug molecule of interest can be incorporated into the lipid vesicle as an intrinsic membrane component, rather than entrapped into the hollow aqueous interior.
Intracellular delivery of beneficial or interesting proteins can be achieved by introducing expressible DcIA and mRNA into the cells of a mammal, a useful technique to ,~ed transfection. Gene sequences introduced in this way can produce the corresponding protein coded for by the gene by using endogenous protein synthetic enzymes. The therapy of SUBSTITUTE SHF~
BIOLOGICALLY ACTIVE MOLECULES
S
Background of the Invention The present invention relates to cationic lipids which are used to enhance delivery of biologically active agents, particularly polynucleotides, proteins, peptides, and drug molecules, by facilitating transmembrane transport or by encouraging adhesion to biological surfaces. It relates particularly to cationic lipids comprising ammonium groups.
Some bioactive substances do not need to enter cells to exert their biological effect, because they operate either by acting on cell surfaces through cell surface receptors or to by interacting with extracellular components. However, many natural biological molecules and their analogues, including proteins and polynucleotides, or foreign substances, such as drugs, which are capable of influencing cell function at the subcellular or molecular level are preferably incorporated within the cell in order to produce their effect. nor +:~ese agents the cell membrane presents a selective barr~~er which is impermeable to them.
Just as the plasma membrane of a cell. is a selective barrier preventing random introduction of potentially toxic substances into the cell, the human body is surrcunded by protective membranes which serve a similar defensive function to the whole organism. These membranes include skin, gastric mucosa, nasal mucosa and the like. While these membranes serve a protective function preventing entry of toxic substances, they can also prevent passage of potentially beneficial therapeutic substances into the body. The complex composition of the cell membrane comprises phospholipids, glycolipids, and cholesterol, as well as intrinsic and extrinsic proteins, and its functions are influenced by cytoplasmic components which include Ca" and other metal ions, anions, ATP, microfilaments, microtubules, enzymes, and Ca'~'-binding proteins. Interactions among structural and cytoplasmic cell components and their response to external signals make up transport processes responsible for the membrane selectivity exhibited within and among cell types.
Successful intracellular delivery of agents not naturally taken up by cells has been achieved by exploiting the natural process of intracellular membrane fusion, or by direct access of the cell's natural transport mechanisms which include end~cytosis and pinocytosis (Duzgunes, N., Subcellular Biochemistry 11:195-286 (1985).
The membrane barrier can be overcome in the ~irst instance by associating these substances in complexes with lipid formulations closely resembling the lipid composition of natural cell membranes. These lipids are able to fuse with the cell membranes on contact, and in the process, the associated substances are delivered intracellularly. Lipid complexes can not only facilitate intracellular transfers by fusing with cell membranes but also by overcoming charge repulsions between the cell membrane and the molecule to be inserted. The lipids of the formulations comprise an amphipathic lipid, such as the phospholipids of cell membranes, and forn, hollow lipid vesicles, or liposome=_, in aqueous systems. This property can be used to entrap the substance to be delivered within the liposomes; in other applications, the drug molecule of interest can be incorporated into the lipid vesicle as an intrinsic membrane component, rather than entrapped into the hollow aqueous interior.
Intracellular delivery of beneficial or interesting proteins can be achieved by introducing expressible DcIA and mRNA into the cells of a mammal, a useful technique to ,~ed transfection. Gene sequences introduced in this way can produce the corresponding protein coded for by the gene by using endogenous protein synthetic enzymes. The therapy of SUBSTITUTE SHF~
many diseases could be enhanced by the induced intracellular production of peptides which could remain inside the target ' cell, be secreted into the local environment of the target cell, or be secreted into the systemic circulation to produce their effect.
Various techniques for introducing the DNA or mRNA
precursors of bioactive peptides into cells include the use of viral vectors, including recombinant vectors and retroviruses, which have the inherent ability to penetrate cell membranes. However, the use of such viral agents to integrate exogenous DNA into the chromosomal material of the cell carries a risk of damage to the genome and the possibility of inducing malignant transformation. Another aspect of this approach which restricts its use in vivo is that the integration of DNA into the genome accomplished by these methods implies a loss of control over the expression of the peptide it codes for, so that transitory therapy is difficult to achieve and potential unwanted side effects of the treatment could be difficult or impossible to reverse or halt.
Liposomes have been discussed as possible in vivo delivery vehicles and some encouraging results using this approach'to the intracellular expression cf DNA have been obtained (Mannino, R.J. Fould-Fogerite, S., Biotechnia~ues 6, 682-690 (1988); Itani, T., Ariga, H., Yamaguchi, N., Tadakuma, T. & Yasuda, T. Gene 56 267-276 (1987); Nicolau, C. , Legrand, A. & Grosse, G.E. Meth. Enz. 149 157-176 (1987) ;
Straubinger, R.M. & Papahadjopoulos, D. Meth. Enz. 101 512-527 X1983); Wang, C.Y. & Huang, L. Proc Natl. Acad. Sci. USA
84 7851-7855 (1987)); however, the methodology has fundamental problems. Chief among the difficulties is the failure of liposomes to fuse with the target cell surface, but to be taken up phagocytically instead. Phagocytized liposomes are delivered to the lysosomal compartment, where polynucleotides are subjected to the action of digestive SUBSTITUTE gHE~
20'79814 enzymes and degraded, leading to low efficiency of expression.
A major advance in this area was the discovery that a positively charged synthetic cationic lipid, N-fl-(2,3 dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), in the form of liposomes, or small vesicles, could interact spontaneously with DNA to form lipid-DNA complexes whi=h are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in both uptake and expression of the DNA (Felgner, P.L. et al. Proc.
Natl. Acad. Sci.. USA 84:7413-7417 (1987) and U.S. Patent No.
4,897,355 to Eppstein, D. et al.). Others have successfully used a DOTMA analogue, 1,2-bis(oleoyloxy)-3-(trimethylammonio)propane (DOTAP) in combination with a phospholipid to form DNA-complexing vesicles. The Lipofectin~' reagent (Bethesda Research Laboratories, Gaithersburg, Maryland), an effective agent for the delivery of highly anionic polynucleotides into living tissue culture cells comprises positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged co.;,plexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional polynucleotide into, for example, tissue culture cells.
Although the use of known cationic lipids overcomes many problems associated with conventional liposome technology for polynucleotide delivery in vitro, several problems related to both in vitro and in vivo applications remain. First, although the efficiency of cationic lipid mediated delivery is relatively high compared to other methods, the absolute level of gene product produced is typically only several hundred copies per cell on average. Thus it would be desirable to improve delivery and expression by a factor of ~~ me-mT~ 1TC cueeT
-S-to 1000-fold to achieve useful methodologies. Secondly, m known cationic lipids such as DOTMA are toxic to tissue culture cells: thus, any improvements that reduce in vitro toxicity would strengthen the methodology.
A significant body of information is emerging regarding the use of other cationic lipids for the delivery of macromolecules into cells. . Loyter prepared vesicles containing a quaternary ammonium surfactant that are capable of transferring functional tobacco mosaic virus into alant l0 protoplasts. (Ballas, N., Zakai, N., Sela, I. and Loyter, A.
Biochim. Biovhys Acta 939 8-18 (1988)). Huang used cetyl-trimethylammonium bromide to obtain functional expression from the chloramphenicol acetyl transferase gene transfected into mouse fibroblasts (Pinnaduwage, P., Schmitt, L. and Huang, L. Biochim. Biophys Acta 985 33-37 (1989)). Behr has shown that a novel lipophilic derivative of spermine can transfect primary pituitary cells (Behr, J-P, Demeneix, B., Loeffler, J-P and Perez-Mutul, J. Proc. Natl. Acad. Sci. USA
86 6982-6986 (1989)). Finally, John Silvius has shown that a cationic lipid (DOTAP), originally synthesized by Eibl (Eibl, H. and Woolley, P. Hiophys. Chem. 10 261-271 (1979)) forms liposomes which can fuse with negatively charged liposomes and can deliver functional DNA and RNA into '-~ssue culture fibroblasts (Stamatatos, L., Leventis, R., Zuckermann, M.J. & Silvius, J.R. Biochemistry 27 3917-3925 (1988)). Other laboratories have studied the physical properties of vesicles formed from synthetic cationic amphophiles (Rupert, L.A.M., Hoekstra, D. and Engberts, J.B.F.N. Am. Chem. Soc. 108: 2628-2631 (1985); Carmona-Ribeiro, A.M., Yoshida, L.S. and Chaimovich, H. J. Phys Chew 39 2928-2933 (1985); Rupert, L.A.M., Engberts, J.B.F.N. and Hoekstra, D. J. Amer. Chem. Soc. 108:3920-3925 (1986)).
It is not feasible to extend in vitro transfection technology to in vivo applications directly. In vivo, the diether lipids; such as DOTMA or Lipofectin the current commercial standard, would be expected to accumulate in the SUaST~TUTE SH~~ s body due to the poorly metabolized ether bonds. And finally, it has been reported that the cationic lipid transfection methodology is inhibited by serum; for in viva applications conditions must be identified which allow transfection to occur in a complex biological milieu such as 100% serum.
Therefore, while the known lipofection technique of transfection described is more efficient and satisfactory than previously known procedures, and permits transient as well as stable trapsfection and peptide expression, it is not understood what-factors regulate the efficiency of the transfection process and how it may be optimized. It would be desirable ~o determine these factors in order to develop an intracellular delivery system having the advantages of the above-described systems but without their inherent limitations.
Accordingly, it is an object of the invention to provide cationic lipids which carry out both stable and transient transfections of polynucleotides such as DNA and mRNA into cells more effectively.
It is also an object of the invention to provide cationic lipids which deliver other molecules of therapeutic interest, including proteins, peptides and small crganic molecules, into cells more effectively.
Further, it is an object of the invention to provide cationic lipids that are not only more effective in accomplishing intracellular delivery but are also metabolizable so as to have reduced in vivo and in vitro toxicity.
It is another object of the invention to provide transfection formulation, comprising novel cationic lipids, that are optimally effective in both in vivo and in vitro transfection.
Brief Description of the FiQUres Figure 1 presents data showing the effect the presence of serum during lipid complex formation on subsequent R21A
transfection.
susST~TU'f~ ~~EET
'~~ ~~814 _,_ Figure 2 demonstrates the effect of serum on the effectiveness of RNA transfection.
Figure 3 demonstrates the effect of cationic lipid concentration on the effectiveness of RNA transfection using DOTAP and DOTMA as cationic lipids.
Figure 4 demonstrates the effect of neutral lipids on the comparative effectiveness of a series cationic lipids in promoting RNA transfection.
Figure 5 demonstrates the comparative effectiveness of DPTMA, DOTMA and corresponding derivatives of the Rosenthal Inhibitor in RNA transfection.
Figures 6a-6d demonstrate the effect of increasing relative concentrations of lysophosphatidylcholine in lipid formulations on DNA transfection efficiency as der.:onstrated by expression of gene product in cell culture.
Figures 7a-7c demonstrate the comparative DNA
transfection activity of various cationic lipid analogs.
Figures 8a-8d demonstrate the effect of neutral phospholipids in the transfection lipid formulation on the efficiency of DNA transfection.
Figures 9a-9c demonstrate the effect of cholesterol in the transfection lipid formulation on the efficiency o~ DNA
transfection.
Summarv of the Invention The present invention provides compositions of novel cationic lipids, suitable for use in the intracellular delivery of bioactive agents, comprising polynucleotides, proteins, small organic molecules and drugs, in both in vivo and in vitro applications, and into the cells of plants and animals.
These compositions have the general structure SUBSTITUTE ~H~~T
0'~ 981 _8_ HZ C - Y 1 - Rl i i3 (I) ( CH2 ) n - N' - R° X_ Rs _ O _ Rs _ R~
wherein Y' and Y2 are the same or different and are -O-CHZ-, -O-C(0)-, or -p-;
R1 and RZ are the same yr different and are H, or C, to Cz3 alkyl or alkenyl; and R', R', Rs, R6, and ~' are as defined below.
Preferred embodiments are compositions wherein R' and R' are individually C: to CZ, alkyl groups, Rs is - ( CH, ) a-, R' is absent, R' is H, and R1 and RZ individually have from 0 to 6 sites of unsaturation, and have the structure CH3- ( CH2 ) a- ( CH=CH-CHZ ) b- ( CHZ ) wherein the sum of a and c is from 1 to 23; and b is 0 to 6.
Particularly preferred embodiments are compositions wherein the long chain alkyl groups are fatty acids, that is, wherein Y1 and YZ are alike and are -O-C(O)-. These co.:,pcunds are easily metabolized by cells and therefore 1ac?: ~he toxicity of presently known transfection agents.
A specific example of this class of compounds is DL-1,2 dioleoyl-3-dimethylaminopropyl-B-hydroxyethylammonium and its salts.
Other particularly preferred embodiments are those compounds wherein Y1 and Y~ are alike and are -O-CH2-. These compounds, having ether-linked alkyl groups, have been found to be superior in transfective properties to presently b:nown cationic lipids. A specific example of a compound cf t::is class is 1, 2-O-dioleyl-3-dimethylaminopropyl-f3-hydroxyethylam.:,cr.iu::~
and its salts. Useful cationic lipids for intracellular delivery also comprise compounds wherein Y' and '~' are SUBSTITUTE SHEEt diffe~rent and are either -O-CH2- or -O-C(0)-. These compounds, having alkyl groups attached by both ether and ester linkages, will have combined properties of low toxicity and improved transfective properties. A particularly preferred composition of this class is 1-O-oleyl-2-oleoyl-3-dimethylaminopropyl-b-hydroxyethylammonium and its salts.
Additional novel cationic lipids provided by the invention are adducts of the general structure comprising additional cationic groups attached at the hydroxyl of the B
hydroxyethanolamine moiety. In preferred embodiments of this class of compounds, the additional cationic groups are provided by lysyl groups attached to the hydroxyl group through a diaminocarboxylic acid linker. A glycyl spacer may connect the linker to the hydroxyl group. Particularly preferred compositions of this class are 3,5-(N,N-dilysyl)-diaminobenzoyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-t3-hydroxyethylamine) and 3,5-(N,N-dilysyl)diaminobenzoyl-glycyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-B-hydroxy-ethylamine).
Alternatively, the additional cationic groups of the adduct can be provided by attaching cationic amine-containing groups such as, for example, spermine, spern,idine, histcnes, or other molecules known to bind DNA. Preferred e:nbodi-:en~s of this class of compositions are L-spermine-5-carboxyl-3-(DL-I,2-dioleoyl-dimethylaminopropyl-f3-hydroxyethylamine).
These cationic groups can in turn provide further hydrophobic regions to the cationic lipid composition through alkyl quaternizing groups on the attached lysine, spermine, or other amine-containing groups.
Also included within the scope of the invention are analogues of known cationic lipids having ester linkages substituted for ether linkages between alkyl substituents and the glycerol moiety of the structure to provide less toxic, more easily metabolized compositions suitable for use in 3~ vivo. These analogues have the general structure s~8sr~rurE sHEET
2079$14 -, o-H2C - Y1 - Ri HC - YZ - RZ
~ R3 (II) HZC - NY - R' X-Rs or an optical isomer thereof, wherein Y1 and YZ are different and are either -O-CH2-, -O-C(O)- or -O-' R1 and R2 are':.individually C~ to C~~ alkyl or alkenyl, or H;
and R', R', Rs and X are as defined below.
According to yet another aspect of the invention there are provided lipid formulations for transfection comprising a cationic lipid and an effective transfection-promoting amount of a lysophosphatide, having the structure HZC - Y - R ~ HZC - OH
HC - OH or HC - Y - R
O ~ 0 H,C--O- P-Z HZC-~-P- Z
wherein Y is selected from the group consisting c° -O-CH2-and -O-C(O)-;
R is Cio to Cz3 alkyl or alkenyl ; and Z is a headgroup.
Preferred formulations for transfection of polynucleotides and peptides into cells comprise novel cationic compounds of the invention having the structure set forth herein, together with an effective transfection promoting amount of a lysophosphatide. The lysophosphatide may have a neutral or a negative hea~3group. Lysophos phatidylcholine and lysophosphatidylethanolamine are preferred, and 1-oleoyl lysophosphatidylcholine is suesTt~~ sHE~
WO 91 / 16024 PtrT/US91 /02691 -"
particularly preferred. Lysophosphatide lipids are advantageously present in the formulation in a molar ratio of 0.5 lyso lipid to cationic lipid.
Lyso forms of cationic lipids, selected from the novel cationic lipids of the invention, DOTMA, or DOTAP can also be used to increase the effectiveness of the transfection.
These lyso forms are advantageously present in effective amounts up to about one-third of the total cationic lipid in the formulations.
According to another aspect of the invention, there is provided a liposomal formulation, comprising a cationic lipid of the invention, wherein the cationic lipid is ir, the fc;-m of vesicles in an aqueous media. The lipids of the liposomal formulation can further comprise a neutral lipid species selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, or cholesterol. A
preferred molar ratio of cationic to neutral lipid species in these formulations is from about 9/1 to 1/9; a molar ratio of about. 5/5 is particularly preferred. The liposomal formulation can further comprise a lyso lipid selected from the group consisting of lysophosphatidylcholine, lyscphos-phatidylethanolamine, or a lyso form of a cationic lipid species.
According to yet another aspect of the invention, there are provided pharmaceutical products comprising the cationic lipids of the invention having any of the structures disclosed herein together with a pharmacologically effective amount of a therapeutic agent. Cationic lipids present in these compositions facilitate the intracellular delivery of 3o the active therapeutic agent. Products are provided for topical, enteral and parenteral uses. In one phar:aceutical product the therapeutic agent is a steroid; in another, the therapeutic agent is a non-steroidal anti-inflammatory agent.
In other pharmaceutical products of the.invention, the therapeutic agent is an antiviral nucleoside analogue or preferably a lipid derivative of an antiviral nucleoside CI tQQTtTI ITi= CLtCtT
20'~9g~
analogue, which is a phosphatidyl derivative, or a diphosphate diglyceride derivative. The aritiviral nucleoside can be a dideoxynucleoside, a didehydronucleoside, a halogenated or azido- derivative of a nucleoside, or an S acyclic nucleoside. In preferred embodiments, the lipid derivatives of antiviral nucleosides are (3'-azido-3'-deoxy)thymidine-5'-diphospho-3-diacylglycerol (AZT
diphosphate diglyceride) and dideoxythymidine diphosphate diglyceride. In particularly preferred embodiments, the lipid derivative of an antiviral nucleoside is an acyclovir or gancyclovir diphosphate diglyceride or diphosphate diglyceride derivatives of 1-(2-deoxy-2'-fluoro-1-f3-D-arabinofuranosyl)-5-iodocytosine (FIAC) or 1(2'-deoxy-2'-fluoro-1-B-D-arabinofuranosyl)5-iodouracil (FIAU).
In other pharmaceutical products of the invention the therapeutic agent is a polynucleotide. In one of these embodiments, the therapeutic polynucleotide is a ribozyme, or an antisense RNA or DNA. In preferred embodiments, the formulation comprises an antisense DNA or RNA or a ribozya~e directed against HIV. In a particularly preferred embodiment, the therapeutic polynucleotide is an antisense DNA or RNA or a ribozyme directed against the rev transactivator of HIV. An example of such an agent is the 28-mer phosphorothioate antisense polynucleotide.
Alternatively, the therapeutic polynucleotide can be one coding for an immunogen, a natural hormone, or a synthetic analogue of a natural hormone; or it can be a polynucleotide sequence coding for a gene product that is deficient or absent in a disease state, and administration of said product to a human in need of therapy relating to said gene product has a therapeutic effect.
The pharmaceutical products disclosed may also comprise a therapeutic protein or polypeptide corresponding to those coded for by the therapeutic polynucleotides described above.
In a preferred embodiment, the invention provides pharmaceutical preparations for topical use comprising a sues~murF s~~r novel cationic lipid of the invention, having any of the structures disclosed herein together with a pharmacologically effective amount of a therapeutic agent in a pha .~aceutically acceptable vehicle. Preferred therapeutic agents are steroids, non-steroidal anti-inflammatory agents, antiviral nucleosides or phospholipid derivatives of these antiviral nucleosides, a therapeutic polynucleotide which is a ribozyme or an antisense RNA or DNA sequence, a polynucleotide coding for a therapeutic protein or polypeptide, or a therapeutic l0 protein or polypeptide itself. The therapeutic protein or polypeptide may be, for example, one that is absent or deficient in a genetic disease, an immunogen, a natural hormone, or a synthetic analogue of a natural hormone.
Included among the particularly preferred embodiments according to this aspect of the invention are topical formulations for the treatment of herpes simplex, comprising a cationic lipid of the invention together with a pharmacologically effective concentration of acyclovir, gancyclovir,l-(2-deoxy-2'-fluoro-1-B-D-arabinofuranosyl)-5 iodocytosine (FIAC) or 1(2'-deoxy-2'-fluoro-1-B-D-arabinofuranosyl)5-iodouracil (FIAU) in an pha .,ace~,aically acceptable vehicle. In preferred embodiments, the preparation comprises phosphoglyceride deriva~ines of acyclovir, gancyclovir, FIAC or FIAU.
According to another aspect of the invention, there is provided a method for introducing a biologically active agent into a cell, either plant or animal, comprising the steps of preparing lipid vesicles comprising a cationic lipid of the invention, and using these lipid vesicles to facilitate the transfection or transport of bioactive agents into the cells.
The intracellular transport may be accomplished by incorporating or encapsulating the bioactive agent in the lipid vesicle and contacting the cell with the lipid vesicles, as in conventional liposome methodology; or alternatively, by contacting the cells simultaneously with empty lipid vesicles, comprising the cationic lipids together svssri~rvrE sHE~r 20"9814 with the bioactive agent, according to conventional transfection methodology. In the process of either strategy, the bioactive agent is taken up by the cell. In preferred embodiments of the method, the bioactive agent is a protein, polynucleotide, antiviral nucleoside or a drug. In particularly preferred embodiments, the bioactive agent is an antisense RNA or DNA sequence or a ribozyme. According to one embodiment of the method, the contacting step occurs in vitro. The method may be applied in the treatment of disease in a vertebrate, comprising the step of administering a pharmaceutical preparation comprising any one of the cationic lipids having the structure set forth above together with a pharmacologically effective amount of a therapeutic agent specific for the treatment of the disease to the vertebrate and permitting the therapeutic agent to be incorporated into a cell, whereby the disease is effectively treated. The bioactive agent is delivered to the cells of the animal in vivo or in vitro. The in vitro delivery of a bioactive agent may be carried out on cells that have been removed from an animal. The cells are returned to the animal body whereby the animal is treated.
The methods according to other embodiments cf the invention include the topical application of a preparation to the skin; the injection of a preparation into a body cavity or into the tissues of said vertebrate; or the oral administration of said preparation. The biologically active agent can be a polynucleotide, such as, for example, DNA or mRNA coding for a polypeptide, and said polypeptide is expressed after said DNA or said mRNA is taken up into said cell. In yet other embodiments, the biologically active agent is a drug.
The cationic lipids of the invention provide more . effective intracellular delivery than the use of presently available agents for the purpose. Further these lipids include species that are less toxic to cells ~ahen used in in vivo and in l~itro procedures .
-14a-An object of the present invention is to provide cationic lipids for intracellular delivery of biologically active molecules. In accordance with an aspect of the present invention, there is provided a composition having the structure Hz C - Y i - Rl HC - Yz - Rz R' ( I ) (CHz) n - 1'T' - R~ X
Rs _ O - Rs _ R~
wherein Yl and Yz are the same or different and are -O-CHz-, -O-C(O)-, or -O-;
R1 and R2 are the same or different and are H, or C: to Cz3 alkyl or alkenyl:
R' and R' are the same or dif ferent and are C1 to Cz alkyl, or H; ' Rs is C1 to Cz' alkyl straight chain or branched chain:
R6 is -C(O)-(CHz)m NH-, a diaminocarboxylic acid which is alkyl, aryl, or aralkyl, or -C(O)-(CHz)m-NH- linked to said diaminocarboxylic acid, or is absent;
R' is H, spermine, spermidine, a histone, or a protein with DNA-binding specificity, or the same groups wherein the amines of the R' moiety are quaternized with R', R', or Rs groups; or R' is an L- or D-alpha amino acid having a positively charged group on the side chain, said amino acids comprising arginine, histidine, lysine or ornithine or analogues thereof, or wherein the amine of the R' moiety is quaternized with R', R' or RS groups; or R' is a polypeptide selected from the group consisting of L-or D-alpha amino acids, wherein at least one of the amino acids residues comprises arginine, histidine, lysine, ornithine, or analogues thereof;
n is 1 to 8 ;
m is 1 to 18 ; and X is a non-toxic anion.
-14b-In accordance with another aspect of the invention, there is provided 3,5-(N,N-dilysyl)-diaminobenzoyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-t3-hydroxyethylamine).
In accordance with another aspect of the invention, there is provided 3,5-(N,N-dilysyl)-diaminobenzoylglycyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-B-hydroxyethylamine).
In accordance with another aspect of the invention, there is provided L-spermine-5-carboxyl-3-(DL-1,2-dioleoyl dimethylaminopropyl-t3-hydroxyethylamine).
In accordance with another aspect of the invention, there is provided a composition having the structure H~ C - Y1 - g,l HC - yz - R2 R3 (II) H~ C - N' - R' X-or an optical isomer thereof, wherein Y1 and YZ are different and are either -O-CH2-, -O-C(O)- or -o-;
R1 and RZ are individually Cl to C23 alkyl or alkenyl, or H;
R3, R' and RS are the same or different and are H, C1 to C1' alkyl , C7 to C11 aryl or alkaryl , or at least two of R' , R' and RS are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino:
n is 1 to 22; and X is a non-toxic anion.
In accordance with another aspect of the invention, there is provided a formulation for transfection of polynucleotides into cells, comprising a cationic lipid and an effective transfection-promoting amount of a lysophosphatide, having the structure -14c-HZ C - Y - R HZ C - OH
HC - OH or HC - Y - R
O O
a H2 C----O P- Z ~ HZ C--O---P- Z
O' O' wherein Y is selected from the group consisting of -O-CH2-and -O-C(O)-;
R is Clo to C2, alkyl or alkenyl; and Z is a headgroup.
1~
These and other advantages and features of the present invention will become more fully apparent from the following description and appended claims.
Detailed Description of the Invention The cationic lipids (CLs) of the invention, comprising compositions having an ammonium group together with hydrophobic alkyl groups, as well as adducts of these cationic lipids, are advantageously used in formulations to prepare lipid vesicles or liposomes to be used in transfection procedures, or to similarly facilitate the intracellular delivery of proteins, polypeptides, small organic molecules, and drugs of therapeutic interest. The adducts further comprise additional cationic and hydrophobic groups that enhance the effectiveness of the lipids in interacting with cell membranes.
We have discovered that certain derivatives and adducts of a compound having the structure l~
H=C--OC ( O ) -R
HC-OC(O)-R
(CHx)" - N' ' CHI
I _ _ CHx CHx OH
wherein R is a long chain fatty acid, are highly effective compounds for use in lipid formulations for transfection and other intracellular delivery procedures. A
single species of a compound of this type, comprising C,g (stearoyl) fatty acids was described by Rosenthal, A. F. and R. P. Geyer, J. Biol. Chem. 235(8):2202-2206 (1960). The Rosenthal compound, which is an inhibitor of phospholipase A
(Rosenthal Inhibitor, RI), is itself ineffective as a promoter of transfection or intracellular delivery. :Modifications to the RI molecule that we have discovered to be most effective in conferring 20'~ 9814 transfective properties are substitution of preferred long chain aliphatic groups, selection of preferred acyl (ester) or alkyl (ether) links between the glycerol moiety of RI and the aliphatic groups, and the addition of groups to the hydroxyl moiety which promote interaction with cell membranes. These compounds have proved to be superior in transfective performance to any presently known, including the cationic lipids described in European Application No. 0 187 702 (1986).
Nomenclature To simplify description, compounds are referred to herein by acronyms, as follows:
RI: The Rosenthal Inhibitor DORI: Dioleoyl derivatives of RI having two C,9 unsaturated (18:1) aliphatic groups, comprising:
DORI diester: DL-1,2-dioleoyl-3-dimethylaminopropyl-s3-hydroxyethylammonium DORIE diether: DL-1,2-0-dioleyl-3-dimethylaminopropyl -B-hydroxyethylammonium DORI ester/ether: DL-1-O-oleyl-2-oleoyl-3-dimethyl-aminopropyl-B-hydroxyethylam~monium OR
DL-1-oleoyl-2-0-oleyl-3-di:~ethyl-aminopropyl-f3-hydroxyethylar"moni ~::"
DPRI: Derivatives of RI having C16 (16:0) aliphatic groups, comprising:
DPRI diester:DL 1,2-dipalmitoyl-3-dimethylaminopropyl-f3-hydroxyethylammonium ~5 DPRI diether:DL 1,2-0-dipalmityl-3-dimethylaminopropyl-B-hydroxyethylammonium DOTMA: N-[1-(2,3-dioleyloxy)propylJ-N,N,N-trimethylammonium DOTAP: DL-1,2-dioleoyl-3-propyl-N,N,N-trimethylammonium DPTMA: DL-(2,3-dipalmityl)-3-propyl-N,N,N-trimethylammonium DLYS-DABA-DORI diesters, diethers, or ester/ethers: Lysine-containing adducts of DORI, having lysine groups attached at SUBSTITUTE ,SHE~r the hydroxyl group of the B-hydroxyethyl moiety through a diaminobenzoic acid linker, which is optionally joined to DORI through a glycyl spacer.
DLYS-DABA-DPRI diesters, diethers, or ester/ethers: analogues of above DORI compounds, but comprising DPRI.
SPC-DORI diesters, diethers, or ester/ethers: Sper:,:ine-containing adducts of DORI, having spermine attached at the hydroxyl group of the B-hydroxyethyl moiety.
SPC-DPRI diesters, diethers, or ester/ethers: analogues of DORI compounds above, but comprising DPRI.
SPC-DABA-DORI diesters, diethers; or ester/ethers: Spernine-containing adducts of DORI, having spermine groups attached at the hydroxyl group of the B-hydroxyethyl moiety through a diaminobenzoic acid linker, which is optionally joined to DORI through a glycyl spacer.
Cationic lipids according to one aspect of the inve.~.tion have the general formula HZC _ yi _ Ri HC - YZ - RZ , R3 (I) 3 0 ( CHZ ) n - N' - R° X_ Rs _ 0 _ R~ _ R~
wherein Y' and YZ are the same or different and are -0-CHI- -, -O-C(0)-, or -O-;
R1 and Rz are the same or different and are H, or C. to Cz3 alkyl or alkenyl;
R3 and R° are the same or different and are C, to alkyl, or H;
R5 is C1 to C2~ alkyl straight chain or branched chain;
R6 is -C (O) - (CHZ) m-NH-, a diaminocarboxylic acid ~~hic:, is alkyl, aryl, or aralkyl, or -C(O)-(CH~)~-NH- linked to said diaminocarboxylic acid, or is absent;
SUgSTiTUTE SHEET
2p'~9814 -, 8-R' is H, spermine, spermidine, a histone, or a protein with DNA-binding specificity, or wherein the amines of the R' moiety are quaternized with R3, R', or RS groups; or R' is an L- or D-alpha amino acids having a positively charged group on the side chain, such amino acids comprising arginine, histidine, lysine or ornithine or analogues thereof, or the same amino acids wherein the amine of the R' moiety is quaternize.d with R', R' or RS groups; or R' is a polypeptide selected from the group comprising L- or l0 D-alpha amino acids, wherein at least one of the amino acids residues comprises arginine, histidine, lysine, ornithine, or analogues thereof;
n is 1 to 8;
m is 1 to 18; and X is a non-toxic anion.
We have determined structure-transfection activity relationships within classes of cationic lipids having a quaternary ammonium group and have, found these relationships to be useful in predicting efficient transfection. We accordingly provide synthetic cationic lipids of this class suitable for use in transfection formulations. CLs having long chain aliphatic (R' and RZ) groups cor""prising ether linkages are preferred to those having ester linkages; CLs having unsaturated R1 and RZ groups are pre~erred to CLs having corresponding saturated groups; and CLs such as analogues of RI, having polar hydroxyethyl group substituents on the quaternary ammonium group are more effective than those substituted with alkyl groups, for example, the methyl substituent of DOTMA.
Therefore, in particularly preferred embodiments, the cationic lipids of the invention are derivatives of RI having a structure comprising at least one alkyl ether group. A
specific memeber of this class of cationic lipids is a DORI
diether (DORIE) having long chain alkyl groups with one site of unsaturation, and having the structure:
S~~E SHE~r 2~'~9814 _19_ H2 i - O - ( CH2 ) a - CH = CH - ( CHZ ) ~ . - CH3 HC - 0 - ( CHZ ) 8 - CH = CH - ( CH2 ) ~ - CH3 HZ C - N' - CH3 X-For applications demanding metabolizable, less toxic compounds, CLs having long chain R1 and RZ aliphatic groups attached by acyl bonds are preferred. Therefore, in other preferred embodiments, the cationic lipids of the invention comprise derivatives of RI having the structural characteristics of Formula I, but comprising at least one acyl group, as, for example, a DORI diester having the structure:
HZ i - O - C ( 0 ) - ( CHZ ) ~ - CH = CH - ( CHI ) . - CH3 HC - O - C ( O ) - ( CH2 ) , - CH = CH - ( CHI ) , - CH3 2 5 ~ CH3 H~ C - N+ - CH3 X-CHI - CH= - OH _ In yet other preferred embodiments, cationic lipids of the invention are substituted at the hydroxyl group of an ethanolamine moiety with various species which act to enhance binding to cell membranes. In preferred embodiments the amine group of ethanolamine is quaternized.
Preferred species for this purpose are 'compounds such as spermines and spermidines, or other compounds having nultiple amino groups, or histones, or similar proteins rich in basic amino acids such as arginine and histidine. Caticnic substances such as the histones, spermines, and spermidines are known to bind and modulate negatively charged cell membrane surfaces. For example, lipid-derivatized soermine-SUBSTITUTE SHEET
like structures are reported to efficiently modulate gene transfer into mammalian 5 endocrine cells (Behr, J.-P. et al. Proc. Natl. Acad. Sci. USA 86:6982-6986 (1989).
We have designed a series of molecules which combine advantageous properties of both cationic lipids and cationic structures derived from amino acids arid spermines.
These molecules are prepared by coupling spermine, through a carboxylic acid group, to the hydroxyl moiety of the ethanolamine group of a lipid such as DORI, DORIE or 10 DPRI.
One such series of compounds, is represented by L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethylaininopropyl-~3-hydethylamine, designated SPC-DPRI-diester, which has the structure 15 ~ Hz -0-C(0)-(CHz ),4-CH3 Hz-0-C(0)-. (CHz), 4-CH3 CHz - +-CM3 CHz-CHz-0-C(0)-~H-(CHz)3-NH-(CHz)3-NHz 20 NH-(CHz)3-NHz In an example of another lipid of this type, the basic amino acid lysine is linked to the same hydroxyl moiety of the lipid through a linker molecule. The linker molecule can be any diaminocarboxylic acid, either alkyl, aryl or aralkyl, having two amino sites by which lysine is anchored as a pendant in a branched molecule that can bind to multiple binding sites simultaneously. In preferred embodiments, the linker molecule is joined to the hydroxyl group of the hydroxy lipid through a spacer arm which can be any alkyl amino acid. Glycine is a preferred spacer arm. A
representative cationic lipid of this type comprises lysine linked to the hydroxyl moiety of DPRI through diaminobenzoic acid and a glycine spacer, to form 3,5-(N,N-di-Ivs~~l)-diaminobenzoyl-V Ivcyl- 3-I DL-1.2-dipalnlit~~w~ -dimethylaminopropyl-B-hydroxyethylamine).. This lipid, designated DLYS-DABA-GLY-DPRI-diester, has the structure CHz-O-C ( O ) - ( CHZ ) 1,,-CH3 CHZ-O-C ( O ) - ( CHZ ) 14 -CHI
CHZ - N''-CH3 CHI-CHZ-O-C ( 0 ) -CHZ-NH-C ( 0 ) -C5H3- ~ NH-C ( 0 ) -CH-NHS 1 ( CHI ) ;, -NH, Particularly preferred compounds of this class are DLYS-DABA-GLY-DORI-diester, having the structure CHI-O-C ( O ) - ( CHZ ) ~-CH = CH- ( CHZ ) ~-CH3 CHZ-O-C ( O ) -CHZ ) ~-CH = CH- ( CHI ) ~-CH3 CHZ -N' - CH3 3 0 CHZ-CH,-O-C ( O ) -CHZ-NH-C ( O ) -CSH~- NH-C ( O ) -CH-NH~
! C ~, ) 4-tli:=
and DLYS-DABA-GLY-DORI-diether, having the struc~~.:re CHZ-O- ( CHZ ) s-CH = CH- ( CHZ ) 7-CH3 4 0 CHZ-O- ( CH2 ) 3-CH = CH- ( CHZ ) ~-CH3 CHZ -N' - CH3 CHz-CHZ-O-C ( O ) -CH2-NH-C ( O ) -CSH3- f NH-C ( O ) -CH-NHS
(CHI) 4-NHS
Other molecules of this type can comprise linkers or spacer arms to which are joined other basic ami:.o acids, such as V~' histidine and arginine or analogues or derivatives or these basic amino acids comprising related molecules, which are structurally modified, for example by having substituent groups, such as 1-methyl histidine or 3-methyl histidine. Polymers of these amino acids or their analogues can be attached to the linker in the same manner.
Amine-containing groups added to the cationic lipids of the invention through spacers and linkers at the (3-hydroxyethylammonium moiety can in turn provide further hydrophobic regions to the lipid structure by quaternization of the amine with the alkyl, alkenyl, aryl and aralkyl groups of R3, R4, and R'. Thus, the assembled lipid adducts, comprising additional cationic groups, and in some cases additional hydrophobic groups as well, incorporate additional sites capable of interaction with the cell membrane, thereby increasing the intracellular delivery potency of the cationic lipid.
For some applications it is important that cationic lipids used are metabolizable and therefore non-toxic, both for in vitro applications and especially when used in vivo, and yet retain the substantial transfective properties associated with lipid species having an ether-linked alkyl group. Accordingly, we have synthesized cationic lipids according to another aspect of the invention having the formula HZC - Y1 - Rl R' (II) H,_C - N' - R' X-Rs 2> or an optical isomer thereof, wherein Y' and Yz are different and are either -)-CH2-, -)-C())-, or OH;
Rl and Rz are individually absent or are C, to C23 alkyl or alkenyl;
R3, R4 and RS are the same or different and are H, C, to C.,~ alkyl, C~ to Cl ~ aryl. or aralkyl, or at least two of R3, R4, and RS are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino;
X is a non-toxic anion.
According to one aspect of the invention, the CLs are combined with other lipids in formulations for the preparation of lipid vesicles or liposomes for use in intracellular delivery systems. The formulations preferably are prepared from a mixture of positively charged lipids, negatively charged lipids, neutral lipids and cholesterol or a similar sterol. The positively charged lipid can be one of the cationic lipids of the invention alone, a mixture of these, or one of the cationic lipids of the invention in combination with the cationic lipids DOTMA, DOTAP, or analogues thereof. Neutral and negatively charged lipids can be any of the natural or synthetic phospholipids or mono-, di-, or triacylglycerols. The natural phospholipids are typically those from animal and plant sources, such as phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, phosphatidylserine, or phosphatidylinositol. Synthetic phospholipids typically are those having identical fatty acid groups, including, but not limited to, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine and the corresponding synthetic phosphatidylethanolainines and phosphatidylglycerols. The neutral lipid can be phosphatidylcholine, cardiolipin, phosphatidylethanolamine, mono-, di- or triacylglycerols, or analogues thereof. The negatively charged lipid can be -24=
phosphatidylglycerol, phosphatidic acid or a similar phospholipid analog. Other additives such as cholesterol, glycolipids, fatty acids, sphingolipids, prostaglandins, gangliosides, neobee, niosomes, or any other natural or synthetic amphophiles can also be used in liposome formulations, as is conventionally known for the preparation of liposomes.
In a formulation for preparing cationic lipid vesicles, the cationic lipid can be present at a concentration of between about 0.1 mole% and 100 mole%, preferably 5 to 100 mole%, and most preferably between 20 and 100 mole%. The neutral lipid can be present in a concentration of between about 0 and 99.9 mole%, preferably 0 to 95 mole%, and ~:ost preferably 0 to 80 mole%. In order to produce lipid vesicles or liposomes having a net positive charge, the quantity of the positively charged component must exceed that of the negatively charged component. The negatively charged lipid can be present at between about 0 to 49 mole% and preferably 0 to 40 mole%. Cholesterol or a similar sterol can be present at 0 to 80 mole%, and preferably 0 to 50 hole%.
Lipid formulations comprising at least one a..~..ahiDathic lipid can spontaneously assemble to form pri:~ary l.iposc.:,es, heterogeneous in size. Therefore, according to a ~re~erred method, the lipid reagents of the invention, comprising at least one cationic lipid species, are prepared as liposomes according to the procedure of Example 12. The component lipids are dissolved in a solvent such as chlorofor:a and the mixture evaporated to dryness as a film on the inner surface of a glass vessel. On suspension in an aqueous solvent, the amphipathic lipid molecules assemble themselves into prinary liposomes. If other molecules are present in the a~_:eous solvent, such as, for example, a bioactive substance, these will be captured within the liposomes. Otherwise, empty liposomes will be formed.
A bioactive substance in the form of its lipid derivative, may be added to the component lipids of the liocso:~e SUBSTITUTE SHEET
20'9814 formulation, to be incorporated into the wall of the liposomes on hydration.
These primary liposomes are reduced to a selected mean diameter by means of the freeze-thaw procedure referred to S above. The CLs of the invention are formed into vesicles of uniform size prior to transfection procedures, according to methods for vesicle production published in the literature and known to those in the art, for example, the sonication of spontaneously formed liposomes comprised of the lipids in aqueous solution described by Felgner, P.L. et al., Proc.
Natl. Acad. Sci.. USA 84:7413-7417 (1987) or the reverse-phase evaporation procedure of J. Wilschut et al.
Biochemistry 19:6011-6021(1980) or freeze-thaw and extrusion (Mayer, L. et al., Biochim. Biophys. Acta 858:161-168 (1986).
To prepare liposomes suitable for physiological in vivo use, having a unilamellar structure and a uniform size of from about 50 to about 200 ~m in diameter, the primary liposomes are preferably processed by the freeze-thaw and extrusion processes.
Other suitable conventional methods of preparation include, but are not limited to, those disclosed by Bangham, A. et al., J. Mol. Biol. 23: 238-252 (1965); Olson, _. et al., Biochim. Biophys. Acta 557: 9-23 (1979), Szoka _. et al., Proc. Natl. Acad. Sci. OSA 75: 4194-4198 (1978), Mayhew, E. et al. Biochim. Bioph~rs. Acta 775: 169-175 (1984), Kim, S.
et al. Hiochim. Biophys. Acta 728:339-348), and Fukunaga, M.
et al. Endocrinol. 115:757-761 (1984).
Transfection Parameters We have discovered that several factors affect the efficiency of cationic lipid-mediated transfection as determined by the level of gene product produced.
1. Cationic Lipid Formulations Lyso lipid compounds Incorporation of a ruantity of a single chaff.~.
phosphatide into the lipid fornulation for transfecticn :gas the effect of increasing the efficiency of transfecticn.
SUBSTITUTE SHEET
2p79814 As demonstrated in Example 20, the addition of monooleoyl lysophosphatidylcholine to~ a transfection formulation comprising DOTMA and DOPE (Lipofectin~'), in amounts up to a molar ratio of lysophosphatide to DOTMA of 0.5, can increase the efficiency of transfecting DNA coding for B-galactosidase into cells by an amount greater than 100%.
According to current theories of self-assembling lipid structures, the combined thermodynamic forces of packing constraints and the~.interactive free energies of lipid polar headgroups with an.~aqueous media determine the geometry and structure of lipid vesicles. Entropy favors small structures, and packing constraints oppose close packing.
Accordingly, in an aqueous media, the entropically favored structures for homogenous systems of single-chain lipids are single layer micelle structures having a relatively small radius of about 15-20 Angstrom units, while those for corresponding systems of double-chain lipids, whose lipid chains cannot be so tightly packed, are double layered structures having aqueous interiors with wall thicknesses of about 50 Angstroms (Israelachvili, J. N. et al., Biochim.
Bioohvs. Acta 470:185-201 (1977).
At high concentrations of lipids, vesicles interact with one another to aggregate, fusing together the outer lipid membranes of each. Membrane fusion is a phenomenon that occurs broadly in biological processes. It is this phenomenon which causes lipid vesicles to fuse with the lipid bilayer of cell membranes whereby the contents of the lipid vesicle are delivered into the cell cytoplasm. However, when the fusogenic properties of lipid vesicles causes their aggregation with each other, their diameter can increase to beyond that of the effective range for transfecticn.
Fusogenic behavior of cationic lipid vesicles resulting in aggregation of the vesicles is induced by the presence of anions in the aqueous media which interact with the cationic SU~~~ SH
polar headgroups of the lipid formulations (Duzgunes, N. et al., Biochemistry 29:9179-9184 (1989).
It is believed that the presence of effective concentrations of single chain lipids in the lipid S formulation opposes fusogenic behavior leading to aggregation, while preserving the fusogenic behavior that allows vesicle contents to be delivered into cells. Single chain lipids can shift the thermodynamic equilibria of lipid systems to allow closer packing and to favor the stability of formed lipid vesicles so as to resist aggregation. As levels of single-chain lipids increase, however, the efficiency of transfection no longer is improved, but decli.~.es. This effect may be due to an increase in the resistance cf the lipid vesicles to fusion which inhibits fusion with cell membranes or to toxic properties of the single-chair. (lyso) lipids, or to both effects.
Accordingly, improved transfection formulations contain amphipathic lipids comprising a polar headgroup and having a single lipid chain in amounts capable of pre:~oting transfection while preserving the ability of the lipid vesicles assembled from the formulation to achieve r~~sion with cell membranes.
Suitable lyso lipids comprise lysophosphat~es of phospholipids having a neutral, positively c::ar~ed, or negatively charged headgroup. Phospholipids having a neutral headgroup are preferred. Particularly preferred lysophosphatide species are lysophosphatidylcholine and lysophosphatidylethanolamine. Other suitable single chain lyso lipids comprise any of the cationic lipid compounds of formula I or formula II wherein either Y1 and R' together or YZ and RZ together are -OH. Preferred cationic li~i~s for this purpose comprise Rosenthal Inhibitor ester and ether derivatives disclosed herein as well as lyso fonas of SOT.~.A, DOTAP, and similar saturated analogues, and co:,~aini.~,a typically C_4, C:S, and C:e alkyl chains.
SU~~.ITE l~W~~r =28-The single chain lyso lipid compounds have been found to be effective in molar ratio concentrations of up to 0.5 relative to the concentration of the double lipid chain cationic lipids of the transfection formulations.
Presence of a neutral lipid Under some conditions, the presence of a neutral lipid in the transfection lipid formulation appears to reduce the efficiency of transfection. The presence of DOPE c_- DOPC
reduced the effectiveness of DOTMA in RNA transfection, while l0 cholesterol was less inhibitory (Examples 17 and 18; FiQUres 3-4). However, DORI was most effective in DNA transfection when combined with DOPE in a molar ratio of 5/S (Exa.~..ple 22;
Figure 8). The effect may be related to the physical structure of the transfected polynucleotide.
2. Transfection Conditions Presence of serum Although the presence of serum appears to i.~.hi:,i~ the formation of cationic lipid/RNA complexes, the presence of serum in the transfection procedure itself, that is, after the addition of cationic lipid/polynucleotide co:~plexes formed in the absence of serum, is only slightl:~ ini~;tcrv (Examples 15 and 22 ) . Previous results seem to indica ~.s the t serum inhibits transfection; however, these evcer_.-..ents (Figures 1-5) shows comparatively good activity even ~.. to 2 ~ presence of seru:a .
Cell density Cationic lipid-mediated transfections can be effec~ivelw carried out over a range of cell densities. Transfecticn o~
pSV2-lacZ into COS.7 cells was carried out accordinc t~ the procedure of Example 14B at cell densities fro:.-. ~,OOC
cells/well to highly confluent cells at 40, 000 cells wel '.
The successful transfection of highly conflue;;~ cells indicates tha t cell division is not rec~;ired f or e; t:~er expression or functional delivery of DNA ; however , cc ti:~al expression was observed at 20,000 cells;Twe''; (°Ov confluency). Further decreasing cell density to S,CC:;
SUBSTITUTE SHEET
_ 2079814 10,000 cells/well led to a shift of optimal expression to lower lipid concentration. This result may be due to higher toxicity (greater amount of cationic lipid per cell) and in general a lower expression corresponding to the lower number of cells.
Choice of cell line for transfection Transfection of pSV2-lacZ using a DORI/DOPE 5/5 lipid formulation under the protocol of Example 14B was carried out for a number of different cell lines. A wide range of Q-l0 galactosidase activity, from 50 pg/well to 20, 000 pg/well was determined among these cells, as follows:
L-M 50 pg L-929 g0 pg CV-1 (ATCC CCL70) 900 pg COS.7 (ATCC CRL 1651) 1000-2000 pg BHK (ATCC 20,000 pg The enormous variation in the level o° expression is probably caused by differences in both DNA uptake as well as intracellular metabolic factors. It is a factor to consider when the yield of gene product isla priority.
ADTJ1 ications The cationic lipids of the invention can be advantageously used, either alone or in combination pith other known cationic lipids such as for example, DOT:~.A or DOTAP, in any procedure comprising the use of liposomes or lipid vesicles to deliver substances intracellularly either in vitro or in vivo. Those lipids having metabolizable ester bonds are preferred for in vivo use.
1. Production of Gene Product Contemplated uses comprise transfection procedures corresponding to those presently known and using amphipathic lipids, including commercial cationic lipid preparations, such as LipofectinT~, and using conventional cationic lipid technology and methods. Accordingly, the lipid compositions disclosed herein can be used to facilitate t~:e intercel?ular delivery of DNA or mRNA sequences coding for therapeutically active polypeptides, as described in detail in ti. S. Patent SUBSTITUTE SHEET
No. 5,703,055. They can be similarly used for the liposomal delivery of the expressed 5 gene product, the polypeptide or protein itself. Thus cationic lipid mediated delivery of DNA and mRNA polynucleotides or proteins can provide therapy for genetic disease by supplying deficient or absent gene products to treat any genetic disease in which the defective gene or its product has been identified, such as Duchenne's dystrophy (Kunkel, L. and Hoffman, E. Brit. Med. Bull. 45(3) : 630-643 (1989) or 10 cystic fibrosis (Goodfellow, P. Nature, 341(6238):102-3 (Sept. 14, 1989).
The cationic lipid-mediated intracellular delivery described above can also provide immunizing polypeptides to the cell, either by delivering a polynucleotide coding for the immunogen, or the immunogen itself.
The transfection procedures described above may be applied by direct 15 injection of cationic lipids together with DNA, RNA or proteins into cells of an animal in vivo. However, it has been recently shown that cationic lipids are particularly effective at facilitating in vitro transfection of cells.
Therefore the above therapies can be alternatively carried out by in vitro transfection of some of the cells of an animal using cationic lipid delivery methods, and reintroduction of the cells into 20 the animal. The ability to transfect cells at high efficiency with cationic lipids thus provides an alternate method for immunization. The gene for an antigen is introduced, by means of cationic lipid-mediated delivery, into cells which have been removed from an animal. The transfected cells, now expressing the antigen, are reinjected into the animal where the immune system can now respond to the (now) 25 endogenous antigen. The process can be enhanced by co-injection of either an adjuvant or lymphokines, or a gene coding for such lymphokines, to further stimulate the lymphoid cells.
Cationic lipid methodology is preferred over other methods: it is more convenient and efficient than calcium phosphate, DEAF dextran or electroporation methods.
Other therapeutically important polynucleotides suitable for cationic lipid mediated delivery are negatively charged novel oligonucleotides of various technologies, including antisense polynucleotide sequences, useful in eliminating or reducing the production of a gene product, as described by Ts'o, P. et al. Annals New York Acad. Sci. 570:220-241 (1987). Many of these oligonucleotide species, which are scarce and expensive to synthesize, are inefficiently captured by encapsulation into liposomes of negatively charged lipids, according to ordinary current methods. We have experimental studies showing that these oligonucleotides are captured within cationic lipvsomes with efficiencies approaching 100%. Also within the scope of the invention is the delivery, by means of the cationic lipids disclosed, of ribozymes, or catalytic RNA species, either of the "hairpin"
type as described by Hampel et al. Nucleic Acids Research 18(2):299-304 (1990); or the "hammerhead" type described by Cech, T. and Bass, H. Annual Rev. Biochem. 55:599-629 (1986) .
Particularly preferred contemplated uses of the invention are deliveries of either an antisense polynucleotide or ribozyme as described above, and having as its target the rev site of the HIV genome Matsukura, M. et al.
Proc. Nat'1. Acad. Sci. 86:4244-4248 (1989 ) describe a 28-mer phosphorothioate compound anti-HIV (anti-rev transactivator) specific for the site.
Other therapeutic uses of cationic lipids herein disclosed include the liposomal delivery of nucleoside or nucleotide analogues having an antiviral effect, such as dideoxynucleotides, didehydronucleotides, nucleoside or nucleotide analogues having halo-substituted purine or pyrimidine rings such as S-trifluoromethyl-2'-deoxyuridine or y 5-flurouracil: nucleoside or nucleotide analogues having , -32-halo- and azido-substituted ribose moieties, such as 3'-azido-3'deoxythymidine (AZT), nucleoside analogues having carbon substituted for oxygen in the ribose moiety (carbocyclic nucleosides), or nucleotide analogues having an acyclic pentose such as acyclovir or gancyclovir (DFiPG) .
The antiviral potency of these analogues is found to be increased when they are presented to the cells as phospholipid derivatives. These derivatives may be incorporated into the liposomal structure for administration to cells thereby forming a more stable liposomal complex which can deliver greater amounts of drugs to target cells with less toxicity. Effective antiviral lipid derivatives of nucleoside analogues comprise phosphatidyl 2',3'-dideoxynucleosides, 2'3'-didehydro-nucleosides, 3'-azido-2'-deoxynucleosides, 3'-fluoro-deoxynucleosides and 3'-fluorodideoxynucleosides, 9-p-D-arabinofuranosyladenine (araA), 1-p-D-arabino-2o furanosylcytidine (araC), nucleosides such as acyclovir and gancyclovir having an acyclic ribose group, or the same nucleoside analogues as diphosphate diglyceride derivatives.
Preferred species of lipid derivatives of antiviral or antiretroviral nucleoside analogues for the treatment of HIV
infection using cationic lipid mediated liposomal delivery are phospholipid derivatives of 3'-azido-2',3'-dideoxypyrimidine, 3'-halopyrimidine dideoxynucleoside, or a 2',3'-didehydro-2',3'-dideoxynucleoside, for example, phosphatidyl 3'-azido-3'deoxythymidine (pAZT) or phosphatidyl 2-chlorodeoxyadenosine. Certain viral infections, comprising herpes, cytomegalovirus, and hepatitis B infections are effectively treated with nucleoside analogues comprising acyclovir, gancyclovir, 1-(2-deoxy-2'-fluoro-1-f3-D-arabinofuranosyl)-5-iodocytosine (FIAC) or 1(2'-deoxy-2'- ' fluoro-i-t3-D-arabinofuranosyl)5-iodouracil (FIAU).
Phospholipid derivatives of these agents, preferably the ' phosphatidyl and diphosphate diglyceride derivatives can be administered in these diseases using cationic lipid liposomal delivery systems, according to the invention. Details of the structures, synthesis and liposomal delivery of lipid derivatives of antiviral nucleosides are presented in U.S.
Patent No. 5,223,263.
Among other therapeutically important agents that can be thus delivered are peptides comprising physiologic species such as interleukin-2, tumor necrosis factor, tissue plasminogen activator, factor VIII, erythropoietin, growth factors such as epidermal growth factor, growth hormone releasing factor, neural growth factor, and hormones such as tissue insulin, calcitonin, and human growth hormone as well as toxic peptides such as ricin, diphtheria toxin, or cobra venom factor, capable of eliminating diseased or malignant cells.
Use of the disclosed lipids is also contemplated for the encapsulation of various other agents to be delivered intracellularly according to methods known to those skilled in the art, and as described in Duzgunes, N., Subcellular Biochemistry 11:195-286 (1985). Materials to be delivered can be proteins or polypeptides, especially negatively charged molecules, monoc14na1 antibodies, RNA-stabilizing factors and other transcription and translation regulating factors, antisense oligonucleotides, ribozymes,and any molecule possessing intracellular activity. Such encapsulation further protects the described agents from non-productive sequestration by substances of the extracellular environment.
Pharmaceutical formulations The cationic lipids of the invention can be used in pharmaceutical formulations to deliver therapeutic agents by various routes and to various sites in the animal body to achieve a desired therapeutic effect. Local or systemic delivery of the therapeutic agent can be achieved by 20'~9g14 administration comprising application or insertion of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, intradermal, peritoneal, subcutaneous and topical administration. The effect of the cationic lipids in these formulations is to enhance the potency and efficiency of -the therapeutic agent contained therein by facilitating its intracellular delivery.
Topical formulations are those advantageously applied to the skin or mucosa. Target mucosa can be that of the gastrointestinal tract, comprising the mouth, naso-pharynx and stomach, or the vaginal or anorectal ~~ucosa. Otter target tissues can be the accessible surfaces and canal of the ear and the ocular tissues. Cationic lipids present in topical formulations can act to facilitate introduction of bioactive molecules into the target tissue, such as the stratum corneum of the skin, by perturbing the barrier properties of the protective membrane, or by introducing perturbing agents or penetration enhancers such as Azone~' or by promoting the activity of these penetration enhancers.
Several classes of drugs consisting of small organic molecules can be delivered in the formulations as described above. One such class comprises steroidal anti-=nflam.-~atory agents which may be prepared in liposomal formulations for topical application. Drugs of this class co:,iprise hydrocortisone, fluocinolone acetonide, available as Synalar"
(Syntex, Palo Alto, California 94303); fluocinonide, available as Lidex~" (Syntex, Palo Alto, California 94303 ) ;
and dexamethasone, available as Decaderm~" (Merck, Sharpe and Dohme, West Point, Pennsylvania 19486).
Other topical formulations comprising the cationic lipids are preparations comprising topical antibiotics such as clindamycin, tobramycin, neomycin, gentamycin, tetracycline, erythromycin; oxidants such as benzoyl peroxide; antifungal agents, such as clotrinazole, miconazole, nystatin, lactoconazole, econazole, and SUBSTtTt~TE SHEET
tolnaftate; retinoic acid for the treatment of acne; and agents for the treatment of herpes simplex and comprising antiviral nucleoside analogues such as acyclovir and gancyclovir. These nucleoside analogue formulations preferably comprise 5 lipid derivatives of the antiviral agents, particularly the phosphatidylglycerol derivatives as disclosed in U.S. Patent No. 5,223,263 and as such may be incorporated into liposomes comprising one or more cationic lipids of the invention.
Other pharmaceutical formulations comprising the cationic lipids of the 10 invention are topical preparations containing an anesthetic or cytostatic agent, immunomodulators, bioactive peptides or oligonucleotides, sunscreens or cosmetics. Preparations for topical use are conveniently prepared with hydrophilic and hydrophobic bases in the form of creams, lotions, ointments or gels;
alternatively, the preparation may be in the form of a liquid that is sprayed on the 15 skin. The effect of the cationic lipids is to facilitate the penetration of the active antiviral agent through the stratum corneum of the dermis.
Similar preparations for opthalmic use are those in which the pharmacologically effective agent is timolol, betaxolol, levobunalol, pilocarpine, and the antibiotics and corticosteroids disclosed for topical applications.
20 Another group of drugs can be delivered orally, topically, or systemically with the cationic lipid materials according to formulations of the invention are non-steroidal anti-inflammatory agents, such as, for example, 1-acetylsalicylic acid (aspirin; Bayer); piroxicam, available as Feldene~ (Pfizere, New York, New York 10017);
(Z)-5-fluoro-2-methyl-1-[[p-alcohol(methylsulfinyl)-phenyl]methylene]1-H-indene-3-acetic acid (sulindac), available as Clinoril~' (Merck, Sharpe and Dohme, West Point, Pennsylvania 19486); 2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid, monosodium salt (diclofenac), available as Voltaren~' (Ciba-Geigy, Summit, New Jersey); 2~
4~-, difluoro-4-hydroxy-3-biphenylcarboxylic acid (diflunisal), available as Dolobid~', (Merck, Sharpe and Dohme); 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid (indomethacin), available as Indocin~' (Merck, Sharpe and Dohme); ()-2-(p-isobutylphenyl)propionic acid (ibuprofen), available as Advil~' (Whitehall Laboratories, Inc., New York , NY 10017); N-(2), 6-dichloro-m-tolyl) anthranilic acid (meclophenomate), available as Meclomen~'(Parke-Davis, Morris Plains, New Jersey 07950; fenoprofen, an arylacetic acic derivative, available as Nalfon~' (Dista Produces Co., Indianapolis, Indiana 46285; 2-naphthaleneacetic acid, 6-methoxy-alpha-methyl-,(+) (naproxyn), available as :daprosyn~' (Syntex, Palo Alto, California 94303); 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetate dihydrate (tolmetin), available as Tolectin~' (McNeil Pharmaceutical, Spring House, Pennsylvania 19477); and derivatives and congeners thereof.
The composition and form of pharmaceutical preparations comprising the cationic lipids disclosed, in combination with SUBSTITUTE SHEET
a drug or other therapeutic agent, can vary according to the intended route of administration.
Orally administered preparations may be in the form of solids, liquids, emulsions, suspensions, or gels, or preferably in dosage unit form, for example as tablets or capsules. Tablets may be compounded in combination with other ingredients customarily used, such as talc, vegetable oils, polyols, gums, gelatin, starch, and other carriers.
The lipid vesicles may be dispersed in or combined wi th a suitable liquid carrier in solutions, suspensions, or emulsions.
Parenteral compositions intended for injection, either subcutaneously, intramuscularly, or intravenously, can be prepared either as liquids or solid forms for solution in liquid prior to injection, or as emulsions. Such preparations are sterile, and liquids to be injected intravenously should be isotonic. Suitable excipients are, for example, water, dextrose, saline, and glycerol.
The cationic lipids of the invention may also be present in liquids, emulsions, or suspensions for delivery of active therapeutic agents in aerosol form to cavities of the body such as the nose, throat, or bronchial passages. The ratio of active ingredient to the cationic lipid and the other compounding agents in these preparations will vary as the dosage form requires.
e~~ ~ocTtT1 ITS CHFF't Preparation of Cationic Lipid Compounds A. Derivatives of the Rosenthal Inhibitor Cationic lipids of the invention which are analogues of the Rosenthal inhibitor may be synthesized by acyl and alkyl substitution of a 3-dimethylaminopropane diol, followed by quaternization of the amino group as described in Examples through 5. Alkyl substitution of the primary and secondary alcohol groups of the diol to from a diether derivative is accomplished by treating the 3-dimethylamino-1,2-propanediol l0 with an alkyl or alkenyl methanesulfonate in a neutral solvent, such as benzene, as described in Exanple ~ ~cr the synthesis of 1,2-0-dioleoyl-3-dimethylamino propyl-B-hydroxyethylammonium acetate. Acyl substitution or the primary and secondary alcohol groups to form a diester derivative is accomplished by treating 3-dimethylaminopropanediol with an acyl halide in a sui~able solvent at an elevated temperature for an exte::ded ti-e, as described in Example 3 for the synthesis of DL-1,2-dicleoyl-3-dimethylaminopropyl-B-hydroxyethylammonium acetate. The synthesis of mixed acyl/alkyl derivatives is accomplished by blocking the primary or secondary alcohol groups of the starting diol, for example by benzylation, to form a lyso compound, which, on condensation with an alkyl or alkenyl methanesulfonate, yields a 1-O-benzyl-, 2-O-alkyl glycerol derivative. Debenzylation, followed by acylation wi~h an acyl halide yields a 1-acyl, 2-O-alkyl deriva~ive.
Alternatively, the diol can be alkylated with an alkyl SUBSTITUTE SNE~.
' -39-methanesulfonate, and the 1-alkyl, 2-lyso derivative isolated and acylated with an acyl anhydride as described in Example 6, part A.
~ Quaternization of the thus-substituted diol is carried out by treatment with a quaternizing group in the form of a halo derivative, and in the presence of a basic catalyst, such as 4-dimethylaminopyridine.
B. Synthesis of Rosenthal Inhibitor adducts comprising additional cationic and hydrophobic moieties One type of cationic lipid composition having multiple amino groups present is prepared by attaching a molecule which is basic in nature and of the type known to bind to DNA, such as for example a histone, spermine or spermidine through a carboxyl group attached to the basic molecule (J.-P. Behr et al., Proc. Natl. Acad. Sci. USA 86:6982-6986 (1989)) to the available hydroxyl group of a DORI or DPRI
diester, diether, or ester/ether using a condensing reagent, as for example, dicyclohexylcarbodiimide (DCC).
Another approach, comprising the attachment of pendant lysine groups, uses a linker molecule capable of bonding to the available hydroxyl group of an hydroxylipid and having at least two sites capable of bonding to lysine. This approach is exemplified by attaching two lysine groups to DPRI-diester through diamino benzoic acid.
C. Synthesis of ester/ether derivatives of DOTMA, DOTAP
and their analogues Cationic lipids corresponding to Formula IT_ and having both an acyl and alkyl group attached thereto are synthesized essentially as described in U.S_ Patent No. 4,897,355, except that 3-(dialkylamino)-1,2-propane diols (designated Formula 3 therein) are converted to mixed acyl/ether derivatives according to the procedure of Example 6.
Any of the cationic lipid molecules of the invention can be synthesized to contain alkyl chains which are linked to the glycerol moiety by either ester linkages or by ether linkages. Accordingly, the molecules may be either diester, diether, 1-ether-2-ester or 1-ester-2-ether. The structure-transfection activity relationships indicate that for optimal polynucleotide delivery the molecules should be ~f the diether type; however, these molecules are difficult to metabolize in vivo and would be expected to result in toxic effects due to accumulation of the lipids in the body. The diester compounds should be readily metabolized; however, these compounds are less active at delivering polynucleotide than the corresponding diether cationic lipids. The ether-ester molecules will have transfection activity that is intermediate between diether and diester molecules, but unlike the diether molecules, ether-ester molecules can be metabolized and excreted by the body. Analogous phospholipids, for example the platelet aggregating factor, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, are metabolized by several cell types, including epithelial cells of the lung and skin fibroblasts (Kumar, R. et al. Biochim.
Bioohvs. Acta 917:33-41 (1987). This feature of the ester/ether species of cationic lipids is sign-ificant ir. view of studies indicating liposome mediated transfection can occur with significant efficiency in vivo, for example in infusion into the trachea (Brigham, K.L. et al. Amer. J. of the Medical Sciences 298(4):278-281 (1989). Due to improved transfection activity and metabolizability of ether/ester molecules, these agents will have particular advantages both in vitro and in vivo.
Non-toxic salts of the compounds described herein are included within the scope of the invention. Such salts may be prepared from pharmaceutically non-toxic acids including inorganic acids and organic acids. Such acids inc'_ude hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, benzoic, citric, glutamic, lactic acid and the like. For the SU8ETITUTE SHEET' preparation of pharmaceutically acceptable salts, see S. M.
Berge et al., Journal of Pharmaceutical Sciences, 66:1-19(I977) which is incorporated herein by reference. Cationic lipid reagents of the invention may be prepared and stored in aqueous solution as empty liposomes, or may be stored dry after formulation to be later used as encapsulating agents for selected bioactive substances.
Optimal transfection and intracellular delivery parameters Accurate evaluation of the effectiveness of cationic lipid species in achieving intracellular delivery requires that structure-activity relationships be determined using an optimized standard formulation and procedure.
we have investigated the optimal conditions using DOTMA, a cationic lipid known to be an effective transfection agent, according to the experiments as follows.
A. Characteristics of the Media The critical procedural issue in cationic lipid mediated transfection relates to how serum is introduced into the transfection procedure. The studies of Examples 15 and 16 show that the presence of serum in a first step, wherein the lipid vesicles form complexes with polynucleotide molecules, is inhibitory to transfection. However, when the complexes are first allowed to form in the absence cf serum, these complexes can be added into tissue culture media containing low concentrations (5 to 15%) of serum without such inhibition. Note that in Figure 2 a dramatic increase in the functional delivery and expression of mRNA occurs in comparison,to Figure 1.
Moreover, cells transfected by the methodology represented in Figure 2 not only express the gene product more efficiently, but they also look visibly healthier under the microscope. Toxicity studies using trypan blue exclusion indicate that cells can withstand higher cationic lipid concentration in the presence of serum.
J
SUBSTITUTE SHEET
2p'~9814 B. Characteristics of the Lipid Formulation The critical formulation features for optimal activity were identified by comparing the effectiveness of 24 cationic lipid formulations in transfecting cells with messenger RNA
containing a luciferase message. Figure 3 shows results from transfections using Lipofectin~' (DOTMA:DOPE 50:50) showing cationic lipid dose-response and serum effects. aigher lipid concentrations are required for the maximum response in the presence of serum.
Since formulations containing increasing ~:antities of a neutral lipid appear to be increasingly less active, some alternative formulations, lacking the neutral p'.~.cspholipid component, were tested. Transfection fo ~,ulations were prepared both with and without a neutral phospholipid component according to the procedures of Examples ~, 3 and 9.
The cationic lipid DOTMA was corlbined in formula=ions either alone or combined with cholesterol and compared :pith similar formulations comprising the neutral lipid DOPE as indicated in the table of Example 18 below. The highest activity occurs in formulations lacking the phospholipid component, particularly in the presence of cholesterol. Figure 4 taken from the same set of transfections, indicates that tZe newly defined cationic lipid composition (DOTMA/DOPE/Cholesterol 70/0/30), containing no phospholipid, gives rise to much higher levels of mRNA expression (compare the scales on the y-axis of the two Figures 3 and 4) and that this reagent has similar activity in the presence and absence of serum.
Comparison of More Polar Species of CorresDOnd~nct Cationic Lipids The transfection effectiveness of a group of cationic lipids was evaluated under optimal transfection conditions determined as described; that is using lipid formulations in the ratio CL/cholesterol of 70/30 with no phospholipid component, and allowing the fist stage associaticn of lipid vesicles and mRNA to occur in the absence of ser~,::~. As in ~, ~ ~ s=~ W- -t-y ., v ~i~~~~E E ~ ~ L. ~~!tF"' 2~ 79814 the previous examples, tissue culture 3T3 mouse cells were transfected with RNA coding for the luciferase enzyme. The commercially available Rosenthal Inhibitor (RI), DL-2,3-distearoyloxypropyl(dimethyl)-8-hydroxyethylammoniumbromide (Sigma, St. Louis, M0.), was prepared as lipid vesicles according to Example 11 and was found to have very weak activity as a cationic lipid for use in transfections. T_he DPRI diester (dipalmitoyl), and DORI diester (dioleoyl) derivatives of RI were synthesized. We also synthesized (2,3-dipalmitoyl)-prop-1-yl-N,N,N-trimethylammonium (DPTMA)), an analogue of DOTMA, a cationic lipid known to be an effective agent. The synthesized lipids as well as DOT:~.A
itself,N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium were evaluated for their ability to transfect the tissue culture cells with luciferase RNA. Data are presented in Figure 5. The primary finding is that the hydroxyethyl moiety present at the hydrophilic site in the Rosenthal inhibitor increases the transfective effectiveness of cationic lipids as compared to corresponding cationic lipids lacking this group. Further, the representative cationic lipid of the invention, DORI, is a more effective transfective agent than DOTMA, even though it lacks the ether groups shown in previous examples, to confer super~cr transfective activity. It should be noted that DOTM.A, under the optimized transfective conditions of these experiments, has greatly enhanced transfective properties as compared to commercial Lipofectin~". Further, the superior transfective agent DORI is superior as a metabolizable, non-toxic transfective agent.
In summary, these studies indicate that effective transfection of cells using CLs requires selecting the most effective cationic lipid for the application, the optimal transfection formulation, and the use of an opti:~al transfection procedure.
The invention can be better understood by way cf ~he following examples which are representative of the preferred ~I ~RSTITUTE SHEET
_2p79814 embodiments thereof, but which are not to be construed as limiting the scope of the invention.
EXAMPLE 1: Synthesis of 1,2-0-dioleyl-3-dimethylamino propyl-B-hydroxyethylammonium acetate (DORI diether) Step (a): Oleylmethanesulfonate In a 500 ml three-necked flask equipped with a dropping funnel, 5.0 g (18.7 mmoles) of oleyl alcohol (Nu Check Prep, Elysian, MN 56028) was dissolved in 6.67 ml of dry pyridine and 100 ml of freshly distilled chloroform. The solution was chilled in an i'ce bath and 3.22 g (28.14 mmoles) of methanesulfonyl chloride (Nu Check Prep) dissolved in 50 ml of dry chloroform was added dropwise during one hour. The reaction mixture was allowed to stir for another 4 hours at room temperature. At the end of the reaction period, 30 ml of ice cold water and 50 ml of diethylether was added. The organic layer was washed twice with 50 ml of 0.5N cold HCL, followed by 50 ml of cold 0.5N sodium bicarbonate. Finally, 2 0 the organic phase was dried over anhydrous sodium sul f ate and evaporated under vacuum on a rotary evaporator. The product was dissolved in 45 ml of absolute ethanol and crystallized at -20° C. Pure long needles of oleylmethanesulfonate were obtained in 90% yield.
Step (b): 1,2-O-dioleyl-3-dimethylaminopropylglycerol Racemic 3-(dimethylamino)-1,2 propanediol (Aldrich Chemical, Milwaukee, Wisconsin), 1.5 g, 8.3 mmoles, and potassium hydroxide, 3.7g in 100 ml of freshly distilled dry benzene was refluxed for 2 hours in a 300 ml, three-necked, round bottom flask fitted with a Soxhlet apparatus containing molecular sieves. Oleyl methanesulfonate, 5.78 g, dissolved in 100 ml of dry benzene, was dropped slowly into the reaction mixture and refluxing was continued for another 4 hours. At the end of the reaction period, cold water and diethylether were added. The organic phase was washed with acid and bicarbonate successively as described above. The crude yellow product gave three spots on thin layer SUBSTfTUTE SHEET
chromatography on silica gel G plates, developed with chloroform/acetone/methanol/acetic acid/water, (50/15/5/5/2) by volume. The required compound was purified by silicic acid column chromatography as follows: Approximately 3.Og of the above material was loaded on the silica CC 7, 3ioRad (40.Og) column and sequentially eluted with chloroform (200 ml), chloroform/methanol 5%, (200 ml), 10% (250 :-:1) and finally with methanol (500 ml). The pure compound was eluted with 10% methanol fractions and gave an Rf value of 0..~5 when chromatographed on the silica gel G plates developed n the above system.
Step (c): 1,2-0-dioleyl-3-dimethylamino prc~_~1-3-hydroxyethylammonium acetate Racemic 1,2-0-dioleyl-3-dimethylaminopropylglycerol, 2.1 g, (3.4 mmol) and 4 ml of 2-bromoethanol (Aldrich Che.:~ical, Milwaukee, Wisconsin) in 18 ml of dimethylformamide was added in a 100 ml round bottom flask and stirred for 36h at ~5'C.
At the end of the reaction period, the mixture was concentrated under reduced pressure, and the produc;. was purified by passing through the silica gel colu.::n. The compound was dissolved in a small amount of chloroF~~:-.; and loaded on to 30 gms of silica gel 60, 70-270 mesh, pac::ed in a 1x18 column. The pure compound was eluted with o" o .:.etanol in chloroform and gave an Rf value of 0.21 on silica gel G
plates developed in the above system. Finally, the bromide salt was converted to acetate by passing the product through a Whatman DE-52 cellulose (acetate form) column. The product was obtained in 50/50 chloroform/methanol eluate. The compound was crystallized in acetonitrile at -20° C.
EXAMPLE 2: Synthesis of DL 1,2-0-dipalmityl-3-dimethylamino propyl-B-hydroxyethylammonium acetate (DPRI diether) This compound was synthesized by substituti;,g palmityl alcohol for oleyl alcohol in the above procedure.
S~!BSTIT~TE SHEET
EXAMPLE 3: Synthesis of DL-1,2-dioleoyl-3-dimethylaminopropyl-B-hydroxyethylammonium acetate (DORI diester) To 10 g. of oleoyl chloride in 21 ml of dry dimethylformamide were added 1.6 g of Rac-3-(dimethylamino)-1,2 propanediol and 5 ml of tributyl. The mixture was heated to 60-65°C for 48 hours. After the mixture was cooled to room temperature, 50 ml of freshly distilled diisopropylether was added and the mixture was heated to boiling. The reaction mixture was again cooled to room temperature and filtered.
Filtrate was evaporated under vacuum and the produc~ was crystallized with acetonitrile. The pure dioleovl-3-dimethylaminopropylglycerol was further subjec~ed. to quaternization by treatment with 2-bromoethanol in dimethylformamide as described in Example 1 above.
EXAMPLE 4: Synthesis of DL-1,2-dipal.~.,itcyl-3-dimethylaminopropyl-f3-hydroxyethylammonium (DPRI diester) This compound was synthesized by using pal:~itoyl chloride instead of oleoyl chloride in the above procedure.
EXAMPLE 5: Synthesis of DL-1,2-dioleoyl-3-propyl-trimethylammonium chloride (DOTAP).
To 2.0 g of 3-(dimethylamino)-1,2-propanediol, dissolved in 15 ml of freshly distilled chloroform and 10 ml of anhydrous pyridine, chilled to 4'C, was added dropwise 12.6 g of oleoylchloride, dissolved in 50 ml of chloroform, over a period of one hour. The reaction was allowed to stir overnight and then stopped by the addition of 5o ml of cold water and ether. The organic phase was washed twice with 0.5N
HCL and 0.5N sodium bicarbonate, and after drying over anhydrous sodium sulfate, evaporated under vacuum. The product was purified by silicic acid column chromatography as described in Example ~. T!:e pure compound was next quaternized with methyl chlorine as follows:
SUBSTI~ gHEET
2~798I4 500 mg of the pure compound was added into the protein hydrolysis tube and the methyl chloride (Aldrich Chemical, Milwaukee, Wisconsin) was condensed into the tube by repeated cooling of the tube in liquid nitrogen until filled with 5 ml S of methyl chloride. The tube was once again thawed, frozen and evacuated with oil pump to remove any residual air.
Finally, the tube was sealed and placed in the heated metal block maintained at 70'C for 72 hours. After the reaction period, the tube was cooled to 0'C and then opened to evaporate unreacted methyl chloride. The yellow wax was crystallized from acetonitrile at -20 C. Further purification of the compound was done on the silica gel 60 column. The pure compound was eluted with 200 ml or 10%
methanol in chloroform and gave an Rf value of .23 on a silica gel G plates, when developed in the above solvent system.
EXAMPLE 6: Synthesis of DL 1,2-dipalmitoyl-3-propyl-trimethylammonium chloride (DPTMA diester).
.
This compound was synthesized by using palmitoyl chloride instead of oleoyl chloride in the above procedure.
EXAMPLE 7: Synthesis of Mixed Acyl/Ether Derivatives The alkyl, acyl and mixture of acyl/alkyl derivatives with the same or different aliphatic carbon chain lengths of the above compounds can be synthesized by using known procedures of blocking the primary and or secondary alcohol of the starting materials.
For example, the 1-acyl, 2-alkyl analogue of the above compound was synthesized by benzylation of the primary hydroxyl group of 3-(dimethylamino)-1,2-propanediol (1.0) mol) with 0.9 mol of benzyl chloride to obtain a lvso compound which, on condensation with palmitic or oleic methansulfonate gave 1-O-alkyl, 2-O-benzyl-3-dimethylaminopropyl glycerol. Debenzylaticn followed by acylation of the resulting compound with palmitic acid SUBSTITUTE SHEET
_4g-chloride and quaternization under similar conditions as described above gave the required compound. The synthesis of alkyl/acyl analogues was achieved by two routes:
(a) 3-(dimethylamino)-1,2-propanediol (1.0 mol) was reacted with 0.7 mol of palmitic methanesulfonate to obtain 1-O-palmityl-2-lyso-3-dimethylaminopropyl glycerol. Acylation of the above lyso compound with oleic anhydride gave the alkyl/acyl derivative.
(b) The primary alcohol group of batyl alcohol (Serdary Research Laboratory) is protected with ts-C1 and NaI and the secondary hydroxyl group is then acylated with oleic anhydride to obtain alkyl/acyl iodohydrin derivative.
Further treatment of the iodohydrin derivative with di:aethyl amine gave the required product. These compounds are t!~.en quaternized by using the procedures described above.
EXAMPLE 8: 3,5-(N,N-di-lysyl)-diaminobenzoyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-!3-hydroxyethylamine) (DLYS-DABA-DPRI diester) Step 1: Di-t-Butyloxycarbonyl-3,5-di-aminobenzoic acid (Bis-Boc-DABA) A quantity of 3,5-Di-aminobenzoic acid (1.52 g; 10 ..~:ol), triethylamine (2.8 ml, 10 mmol) and di-t-butyl-di-carbonate (4.5 g; 22 mmol) (Aldrich Chemical Co, Milwaukee, WI), were dissolved in DMF (10 ml) and stirred for 24 hours at room temperature. The solvent was evaporated under vacuum and the product was chromatographed on silica gel using chloroform as eluent to obtain the title compound.
Step 2: Bis-Boc-DABA-DPRI diester Bis-Boc DABA (3.52 g, 10 mmol) and DPRI (10 mmol) were coupled following the procedure described in procedures 7.3 and 7.4 above.
Step 3: 3,5-(NN-Di-lysyl)-DABA-DPRI diester S~8STt1'tITE SH~e~
Compound #6 (2 mmol) was treated with TFA (10 ml) for 30 min at room temperature to remove the BOC protecting groups.
After evaporating the solvent, the product was reacted with Bis-Boc-lysine (5 mmol) using DCC as condensing agent. The product isolated after evaporating the solvent was de-protected using TFA and purified as described in 7.4 above.
EXAMPLE 9: 3,5-(N,N-di-lysyl)-diaminobenzoyl-glycyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-B-hydroxyethylamine) (DLYS-DABA-GLY-DPRI diester) Step 1: Di-t-Butyloxycarbonyl-3,5-di-aminobenzoic acid (Bis-Boc-DABA) As in Example 7 above.
Step 2: Boc-glycyl-DPRI diester:
Boc-glycine (1.75g, 10 mmol) and DPRI (10 mmcl) were coupled following the procedure described in Steps 3 and 4 of Example 8.
Step 3: Bis-Boc-DABA-glycyl-DPRI diester:
Bis-Boc-DABA (3.52 g, 10 mmol) of the compound from Step 2 above was treated with TFA (10 ml) doe 30 min. at room temperature to remove the Boc protecting group. TFA was evaporated and the product was coupled with Bis-Boc-DABS. °rcm Step 1 above as described in Example 8.
Step 4: 3,5-(NN-Di-lysyl)-DABA-glycyl-DPRI diester The compound from Step 3 above (2 mmol) was treated with TFA (10 ml) for 30 min. at room temperature to remove the BOC
protecting groups. After evaporating the solvent, the product was reacted with Bis-Boc-lysine (5 mmol) using DCC as condensing agent. The product isolated after evaporating the solvent was deprotected using TFA and purified as described in Step 4 of Example 8.
Various DORI derivatives corresponding to the DPRI
derivatives described in Examples 8 and 9 can be synthesized ~0 by substituting DORI in the coupling procedures.
SUBSTITUTE SHEEP
~o~9g14 EXAMPLE 10: Synthesis of L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-f3-hydroxyethylamine) (SPC-DPRI diester) L-5-carboxytetrabutyloxycarbonylspermine (tetra-BOC-Sper-COOH) (664 mg; 1 mmol) prepared according to published procedures (J.-P. Behr et. al. Proc. Natl. Acad. Sci USA, 86, pp 6982-6986, 1989) was coupled to DPRI (1 ., ol) as described in 8.3. The product was de-protected and purified l0 by chromatography to prepare SPC-DPRI diester.
EXAMPLE 11: PREPARAT~I~N OF LIPOSOME-FORMING DOTAP
The cationic liposome-forming material ' 2 bis oleo lox -3 trimeth lammonio ro ane DOTAP ma ''be ( Y Y) -( Y )P P ( ) Y
also prepared as reported by L. Stamatatos, et al.
Biochemistry 27:3917-3925 (1988) or H. Eibl et al., Biophysical Chemistry 10:261-271 (1979).
Briefly, Stamatatos et al. report that 1' ~.mol of 3-bromo-1,2-propanediol (Aldrich, Milwaukee, WI) was acylated for 48 hours at 20°C with 3 mmol of oleoyl chloride (freshly prepared from oleic acid and oxalyl chloride) in dry, alcohol-free diethyl ether (20 ml) containing S mmol of dry pyridine. The precipitate of pyridinium hydrcchlcride was filtered off, and the filtrate was concentrated under nitrogen and redissolved in 10 ml of hexane. The hexane solution was washed 3 times with an equal volume of 1:1 methanol/0.1 N aqueous HCOONa, pH 3.0, 3 times with 1:1 methanol/0.1 N aqueous NaOH, and 1 time with 1% aqueous NaCl.
The crude 3-bromo-1,2-bis-(oleoyloxy)propane was then stirred for 72 hours in a sealed tube with a solution of 15%
trimethylamine in dry dimethyl sulfoxide (30 ml) at 25°C.
The products of this reaction were dissolved in chlorofor~
(200 ml), which was repeatedly washed with 1:1 methanol/IOOmM
aqueous HCOONa, pH 3.0, and then evaporated in vacuo to yield a light yellow oil. The material was purified on a column cf silicic acid (Bio-Sil A, Bio-Rad Laboratories), eluting with SUBSTltUSE SHEET
-S, -a 0-15% gradient of methanol in chloroform to give the desired product in pure form at 9-10% methanol.
This purified product was a colorless, viscous oil that migrates with an R. of 0.4 on thin layer chromatography plates (Silica Gel G) that were developed with 50:15:5:5:2 CHC13/acetone/CH30H/CH3COOH/H.
EXAMPLE 12: LIPID VESICLE PREPARATION
Dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG) and dioleoylphosphatidylethanolamine (DOPE)-were purchased from Avanti Polar Lipids, (Pelham, Alabama). DOT:y'~. was synthesized according to U.S. Patent No. 4,897,355 to Epstein, D. et al. or Felgner, P.L. et al., PNAS 84: 7413-7417 (1987) and DOTAP was synthesized according to Example 10. DOPG/DOPC vesicles were prepared by drying 50 mg of DOPG
and 50 mg of DOPC under a stream of nitrogen gas into a sonication vial. The sample was. placed on a vacuum pump overnight and was hydrated the following day with deionized water to a concentration of 10 mg/ml total lipid. The sample was sonicated for 2 hours in the capped vial, using the cleat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting and the bath was circulated at 15°C. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles (MLV) or by extrusicn through nuclepore membranes to produce unilamellar vesicles of a discrete size. Other methods are also available and are known to those familiar with the art. DOTMA or DOTAP
vesicles were prepared in an exactly analogous manner.
EXAMPLE 13: POLYNUCLEOTIDE/CATIONIC LIPID COMPLEX FORI~.ATION
Polynucleotide complexes were prepared by mixing 0.5 ml of a 10 ug/ml polynucleotide solution with 0.5m1 of sonicated DOTMA/PE or DOTAP/PE liposomes at 40-100 ug/ml by slow suBSmutE sH~Er 20'~9~14 addition through a syringe with constant gentle vortexing.
The diluted polynucleotide and liposome solutions are prepared from concentrated stock solutions by dilutions into Opti-MEM Reduced Serum Media obtained from Gibco/BRL, Gaithersburg Maryland, at room temperature. This procedure results in positively charged complexes which will spontaneously deliver polynucleotide into cells in tissue culture. Different ratios of positively charged liposomes to polynucleotides cane.be used to suit the need. These methods _, are essentially as_'described in Felgner, P.L. et al., PNAS
,.~~>
84: 7413-7417 (1987), and Felgner, P. and M. Holm, Focus 11(2) Spring, 1989.
I5 EXAMPLE 14: TRANSFECTION PROTOCOLS
A: General Protocol:
Transfections of RNA according to Examples 15-19 were carried out as follows:
Plates (10 cm) of rapidly dividing adherent cells near confluency, or 1 x 10' suspension cells, were transfected as follows unless otherwise noted. Cells were washed once in Opti-MEM Reduced Serum Medium (Gibco) and then returned to the incubator covered in Opti-MEM. Aliquots (4 nl) of Opti-MEM Medium were placed in 12 x 75 mm polystyrene snap cap tubes, and 50 ug of Lipofectin Reagent were added. A mixture of capped mRNA and uncapped carrier RNA transcribed from EcoR
V-linearized pIBI31 (according to Malone, R. et al., Proc.
Nat'1 Acad. Sci. USA 86:6077-6081 (1989)) was then added to the media/lipid mixture to a total of 20 ug of RNA. The mixture was immediately vortexed. Cells were removed from the incubator, the medium removed, and the Opti-MEM/lipid/RNA
mixture added. Cells were then returned to the incubator for 8 h, unless otherwise noted, and harvested as described.
Murine fibroblasts (NIH 3T3, clone 2B) cells were maintained in Dulbecco's Modified Eagles Medium, (DMEM) + 10~
(v/v) calf serum (CS) prior to transfection.
SUBS'TITUT'E SHEET
B: 96-well microwell plate procedure:
The RNA transfection according to Example 20 and the DNA transfections according to Examples 20-23 were carried out in 96-well plates, as follows:
(1) The wells of a 96-well microtiter plate were seeded with 20,000 to 40,000 cells per well;
(2) Dilutions of cationic lipid preparations and polynucleotide preparations from stock solutions were carried out by 2-dimensional serial dilutions in two separate 96-well plates according to the scheme set form in the Table below entitled "Transfection Protocol in vitro";
(3) Corresponding dilutions of lipid and polynucleotide were mixed by transferring an equal volume of polynucleotide to a corresponding lipid microwell;
(4) The serum-containing media was evaporated from the wells containing the cells;
(5) A quantity of about 100 ~,1 of the cationic lipid/DNA complexes were added to cells in each well of the microtiter plate. Final dilutions and molar ratios of lipid and polynucleotide in each well are indicated in the Table below entitled "Mix Plate";
(6) The plates were incubated at 37°C (5~ COZ). At 4-24 hours post transfection, an aliquot of 10~ serum in Optimem~ was added to each well;
Various techniques for introducing the DNA or mRNA
precursors of bioactive peptides into cells include the use of viral vectors, including recombinant vectors and retroviruses, which have the inherent ability to penetrate cell membranes. However, the use of such viral agents to integrate exogenous DNA into the chromosomal material of the cell carries a risk of damage to the genome and the possibility of inducing malignant transformation. Another aspect of this approach which restricts its use in vivo is that the integration of DNA into the genome accomplished by these methods implies a loss of control over the expression of the peptide it codes for, so that transitory therapy is difficult to achieve and potential unwanted side effects of the treatment could be difficult or impossible to reverse or halt.
Liposomes have been discussed as possible in vivo delivery vehicles and some encouraging results using this approach'to the intracellular expression cf DNA have been obtained (Mannino, R.J. Fould-Fogerite, S., Biotechnia~ues 6, 682-690 (1988); Itani, T., Ariga, H., Yamaguchi, N., Tadakuma, T. & Yasuda, T. Gene 56 267-276 (1987); Nicolau, C. , Legrand, A. & Grosse, G.E. Meth. Enz. 149 157-176 (1987) ;
Straubinger, R.M. & Papahadjopoulos, D. Meth. Enz. 101 512-527 X1983); Wang, C.Y. & Huang, L. Proc Natl. Acad. Sci. USA
84 7851-7855 (1987)); however, the methodology has fundamental problems. Chief among the difficulties is the failure of liposomes to fuse with the target cell surface, but to be taken up phagocytically instead. Phagocytized liposomes are delivered to the lysosomal compartment, where polynucleotides are subjected to the action of digestive SUBSTITUTE gHE~
20'79814 enzymes and degraded, leading to low efficiency of expression.
A major advance in this area was the discovery that a positively charged synthetic cationic lipid, N-fl-(2,3 dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), in the form of liposomes, or small vesicles, could interact spontaneously with DNA to form lipid-DNA complexes whi=h are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in both uptake and expression of the DNA (Felgner, P.L. et al. Proc.
Natl. Acad. Sci.. USA 84:7413-7417 (1987) and U.S. Patent No.
4,897,355 to Eppstein, D. et al.). Others have successfully used a DOTMA analogue, 1,2-bis(oleoyloxy)-3-(trimethylammonio)propane (DOTAP) in combination with a phospholipid to form DNA-complexing vesicles. The Lipofectin~' reagent (Bethesda Research Laboratories, Gaithersburg, Maryland), an effective agent for the delivery of highly anionic polynucleotides into living tissue culture cells comprises positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged co.;,plexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional polynucleotide into, for example, tissue culture cells.
Although the use of known cationic lipids overcomes many problems associated with conventional liposome technology for polynucleotide delivery in vitro, several problems related to both in vitro and in vivo applications remain. First, although the efficiency of cationic lipid mediated delivery is relatively high compared to other methods, the absolute level of gene product produced is typically only several hundred copies per cell on average. Thus it would be desirable to improve delivery and expression by a factor of ~~ me-mT~ 1TC cueeT
-S-to 1000-fold to achieve useful methodologies. Secondly, m known cationic lipids such as DOTMA are toxic to tissue culture cells: thus, any improvements that reduce in vitro toxicity would strengthen the methodology.
A significant body of information is emerging regarding the use of other cationic lipids for the delivery of macromolecules into cells. . Loyter prepared vesicles containing a quaternary ammonium surfactant that are capable of transferring functional tobacco mosaic virus into alant l0 protoplasts. (Ballas, N., Zakai, N., Sela, I. and Loyter, A.
Biochim. Biovhys Acta 939 8-18 (1988)). Huang used cetyl-trimethylammonium bromide to obtain functional expression from the chloramphenicol acetyl transferase gene transfected into mouse fibroblasts (Pinnaduwage, P., Schmitt, L. and Huang, L. Biochim. Biophys Acta 985 33-37 (1989)). Behr has shown that a novel lipophilic derivative of spermine can transfect primary pituitary cells (Behr, J-P, Demeneix, B., Loeffler, J-P and Perez-Mutul, J. Proc. Natl. Acad. Sci. USA
86 6982-6986 (1989)). Finally, John Silvius has shown that a cationic lipid (DOTAP), originally synthesized by Eibl (Eibl, H. and Woolley, P. Hiophys. Chem. 10 261-271 (1979)) forms liposomes which can fuse with negatively charged liposomes and can deliver functional DNA and RNA into '-~ssue culture fibroblasts (Stamatatos, L., Leventis, R., Zuckermann, M.J. & Silvius, J.R. Biochemistry 27 3917-3925 (1988)). Other laboratories have studied the physical properties of vesicles formed from synthetic cationic amphophiles (Rupert, L.A.M., Hoekstra, D. and Engberts, J.B.F.N. Am. Chem. Soc. 108: 2628-2631 (1985); Carmona-Ribeiro, A.M., Yoshida, L.S. and Chaimovich, H. J. Phys Chew 39 2928-2933 (1985); Rupert, L.A.M., Engberts, J.B.F.N. and Hoekstra, D. J. Amer. Chem. Soc. 108:3920-3925 (1986)).
It is not feasible to extend in vitro transfection technology to in vivo applications directly. In vivo, the diether lipids; such as DOTMA or Lipofectin the current commercial standard, would be expected to accumulate in the SUaST~TUTE SH~~ s body due to the poorly metabolized ether bonds. And finally, it has been reported that the cationic lipid transfection methodology is inhibited by serum; for in viva applications conditions must be identified which allow transfection to occur in a complex biological milieu such as 100% serum.
Therefore, while the known lipofection technique of transfection described is more efficient and satisfactory than previously known procedures, and permits transient as well as stable trapsfection and peptide expression, it is not understood what-factors regulate the efficiency of the transfection process and how it may be optimized. It would be desirable ~o determine these factors in order to develop an intracellular delivery system having the advantages of the above-described systems but without their inherent limitations.
Accordingly, it is an object of the invention to provide cationic lipids which carry out both stable and transient transfections of polynucleotides such as DNA and mRNA into cells more effectively.
It is also an object of the invention to provide cationic lipids which deliver other molecules of therapeutic interest, including proteins, peptides and small crganic molecules, into cells more effectively.
Further, it is an object of the invention to provide cationic lipids that are not only more effective in accomplishing intracellular delivery but are also metabolizable so as to have reduced in vivo and in vitro toxicity.
It is another object of the invention to provide transfection formulation, comprising novel cationic lipids, that are optimally effective in both in vivo and in vitro transfection.
Brief Description of the FiQUres Figure 1 presents data showing the effect the presence of serum during lipid complex formation on subsequent R21A
transfection.
susST~TU'f~ ~~EET
'~~ ~~814 _,_ Figure 2 demonstrates the effect of serum on the effectiveness of RNA transfection.
Figure 3 demonstrates the effect of cationic lipid concentration on the effectiveness of RNA transfection using DOTAP and DOTMA as cationic lipids.
Figure 4 demonstrates the effect of neutral lipids on the comparative effectiveness of a series cationic lipids in promoting RNA transfection.
Figure 5 demonstrates the comparative effectiveness of DPTMA, DOTMA and corresponding derivatives of the Rosenthal Inhibitor in RNA transfection.
Figures 6a-6d demonstrate the effect of increasing relative concentrations of lysophosphatidylcholine in lipid formulations on DNA transfection efficiency as der.:onstrated by expression of gene product in cell culture.
Figures 7a-7c demonstrate the comparative DNA
transfection activity of various cationic lipid analogs.
Figures 8a-8d demonstrate the effect of neutral phospholipids in the transfection lipid formulation on the efficiency of DNA transfection.
Figures 9a-9c demonstrate the effect of cholesterol in the transfection lipid formulation on the efficiency o~ DNA
transfection.
Summarv of the Invention The present invention provides compositions of novel cationic lipids, suitable for use in the intracellular delivery of bioactive agents, comprising polynucleotides, proteins, small organic molecules and drugs, in both in vivo and in vitro applications, and into the cells of plants and animals.
These compositions have the general structure SUBSTITUTE ~H~~T
0'~ 981 _8_ HZ C - Y 1 - Rl i i3 (I) ( CH2 ) n - N' - R° X_ Rs _ O _ Rs _ R~
wherein Y' and Y2 are the same or different and are -O-CHZ-, -O-C(0)-, or -p-;
R1 and RZ are the same yr different and are H, or C, to Cz3 alkyl or alkenyl; and R', R', Rs, R6, and ~' are as defined below.
Preferred embodiments are compositions wherein R' and R' are individually C: to CZ, alkyl groups, Rs is - ( CH, ) a-, R' is absent, R' is H, and R1 and RZ individually have from 0 to 6 sites of unsaturation, and have the structure CH3- ( CH2 ) a- ( CH=CH-CHZ ) b- ( CHZ ) wherein the sum of a and c is from 1 to 23; and b is 0 to 6.
Particularly preferred embodiments are compositions wherein the long chain alkyl groups are fatty acids, that is, wherein Y1 and YZ are alike and are -O-C(O)-. These co.:,pcunds are easily metabolized by cells and therefore 1ac?: ~he toxicity of presently known transfection agents.
A specific example of this class of compounds is DL-1,2 dioleoyl-3-dimethylaminopropyl-B-hydroxyethylammonium and its salts.
Other particularly preferred embodiments are those compounds wherein Y1 and Y~ are alike and are -O-CH2-. These compounds, having ether-linked alkyl groups, have been found to be superior in transfective properties to presently b:nown cationic lipids. A specific example of a compound cf t::is class is 1, 2-O-dioleyl-3-dimethylaminopropyl-f3-hydroxyethylam.:,cr.iu::~
and its salts. Useful cationic lipids for intracellular delivery also comprise compounds wherein Y' and '~' are SUBSTITUTE SHEEt diffe~rent and are either -O-CH2- or -O-C(0)-. These compounds, having alkyl groups attached by both ether and ester linkages, will have combined properties of low toxicity and improved transfective properties. A particularly preferred composition of this class is 1-O-oleyl-2-oleoyl-3-dimethylaminopropyl-b-hydroxyethylammonium and its salts.
Additional novel cationic lipids provided by the invention are adducts of the general structure comprising additional cationic groups attached at the hydroxyl of the B
hydroxyethanolamine moiety. In preferred embodiments of this class of compounds, the additional cationic groups are provided by lysyl groups attached to the hydroxyl group through a diaminocarboxylic acid linker. A glycyl spacer may connect the linker to the hydroxyl group. Particularly preferred compositions of this class are 3,5-(N,N-dilysyl)-diaminobenzoyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-t3-hydroxyethylamine) and 3,5-(N,N-dilysyl)diaminobenzoyl-glycyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-B-hydroxy-ethylamine).
Alternatively, the additional cationic groups of the adduct can be provided by attaching cationic amine-containing groups such as, for example, spermine, spern,idine, histcnes, or other molecules known to bind DNA. Preferred e:nbodi-:en~s of this class of compositions are L-spermine-5-carboxyl-3-(DL-I,2-dioleoyl-dimethylaminopropyl-f3-hydroxyethylamine).
These cationic groups can in turn provide further hydrophobic regions to the cationic lipid composition through alkyl quaternizing groups on the attached lysine, spermine, or other amine-containing groups.
Also included within the scope of the invention are analogues of known cationic lipids having ester linkages substituted for ether linkages between alkyl substituents and the glycerol moiety of the structure to provide less toxic, more easily metabolized compositions suitable for use in 3~ vivo. These analogues have the general structure s~8sr~rurE sHEET
2079$14 -, o-H2C - Y1 - Ri HC - YZ - RZ
~ R3 (II) HZC - NY - R' X-Rs or an optical isomer thereof, wherein Y1 and YZ are different and are either -O-CH2-, -O-C(O)- or -O-' R1 and R2 are':.individually C~ to C~~ alkyl or alkenyl, or H;
and R', R', Rs and X are as defined below.
According to yet another aspect of the invention there are provided lipid formulations for transfection comprising a cationic lipid and an effective transfection-promoting amount of a lysophosphatide, having the structure HZC - Y - R ~ HZC - OH
HC - OH or HC - Y - R
O ~ 0 H,C--O- P-Z HZC-~-P- Z
wherein Y is selected from the group consisting c° -O-CH2-and -O-C(O)-;
R is Cio to Cz3 alkyl or alkenyl ; and Z is a headgroup.
Preferred formulations for transfection of polynucleotides and peptides into cells comprise novel cationic compounds of the invention having the structure set forth herein, together with an effective transfection promoting amount of a lysophosphatide. The lysophosphatide may have a neutral or a negative hea~3group. Lysophos phatidylcholine and lysophosphatidylethanolamine are preferred, and 1-oleoyl lysophosphatidylcholine is suesTt~~ sHE~
WO 91 / 16024 PtrT/US91 /02691 -"
particularly preferred. Lysophosphatide lipids are advantageously present in the formulation in a molar ratio of 0.5 lyso lipid to cationic lipid.
Lyso forms of cationic lipids, selected from the novel cationic lipids of the invention, DOTMA, or DOTAP can also be used to increase the effectiveness of the transfection.
These lyso forms are advantageously present in effective amounts up to about one-third of the total cationic lipid in the formulations.
According to another aspect of the invention, there is provided a liposomal formulation, comprising a cationic lipid of the invention, wherein the cationic lipid is ir, the fc;-m of vesicles in an aqueous media. The lipids of the liposomal formulation can further comprise a neutral lipid species selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, or cholesterol. A
preferred molar ratio of cationic to neutral lipid species in these formulations is from about 9/1 to 1/9; a molar ratio of about. 5/5 is particularly preferred. The liposomal formulation can further comprise a lyso lipid selected from the group consisting of lysophosphatidylcholine, lyscphos-phatidylethanolamine, or a lyso form of a cationic lipid species.
According to yet another aspect of the invention, there are provided pharmaceutical products comprising the cationic lipids of the invention having any of the structures disclosed herein together with a pharmacologically effective amount of a therapeutic agent. Cationic lipids present in these compositions facilitate the intracellular delivery of 3o the active therapeutic agent. Products are provided for topical, enteral and parenteral uses. In one phar:aceutical product the therapeutic agent is a steroid; in another, the therapeutic agent is a non-steroidal anti-inflammatory agent.
In other pharmaceutical products of the.invention, the therapeutic agent is an antiviral nucleoside analogue or preferably a lipid derivative of an antiviral nucleoside CI tQQTtTI ITi= CLtCtT
20'~9g~
analogue, which is a phosphatidyl derivative, or a diphosphate diglyceride derivative. The aritiviral nucleoside can be a dideoxynucleoside, a didehydronucleoside, a halogenated or azido- derivative of a nucleoside, or an S acyclic nucleoside. In preferred embodiments, the lipid derivatives of antiviral nucleosides are (3'-azido-3'-deoxy)thymidine-5'-diphospho-3-diacylglycerol (AZT
diphosphate diglyceride) and dideoxythymidine diphosphate diglyceride. In particularly preferred embodiments, the lipid derivative of an antiviral nucleoside is an acyclovir or gancyclovir diphosphate diglyceride or diphosphate diglyceride derivatives of 1-(2-deoxy-2'-fluoro-1-f3-D-arabinofuranosyl)-5-iodocytosine (FIAC) or 1(2'-deoxy-2'-fluoro-1-B-D-arabinofuranosyl)5-iodouracil (FIAU).
In other pharmaceutical products of the invention the therapeutic agent is a polynucleotide. In one of these embodiments, the therapeutic polynucleotide is a ribozyme, or an antisense RNA or DNA. In preferred embodiments, the formulation comprises an antisense DNA or RNA or a ribozya~e directed against HIV. In a particularly preferred embodiment, the therapeutic polynucleotide is an antisense DNA or RNA or a ribozyme directed against the rev transactivator of HIV. An example of such an agent is the 28-mer phosphorothioate antisense polynucleotide.
Alternatively, the therapeutic polynucleotide can be one coding for an immunogen, a natural hormone, or a synthetic analogue of a natural hormone; or it can be a polynucleotide sequence coding for a gene product that is deficient or absent in a disease state, and administration of said product to a human in need of therapy relating to said gene product has a therapeutic effect.
The pharmaceutical products disclosed may also comprise a therapeutic protein or polypeptide corresponding to those coded for by the therapeutic polynucleotides described above.
In a preferred embodiment, the invention provides pharmaceutical preparations for topical use comprising a sues~murF s~~r novel cationic lipid of the invention, having any of the structures disclosed herein together with a pharmacologically effective amount of a therapeutic agent in a pha .~aceutically acceptable vehicle. Preferred therapeutic agents are steroids, non-steroidal anti-inflammatory agents, antiviral nucleosides or phospholipid derivatives of these antiviral nucleosides, a therapeutic polynucleotide which is a ribozyme or an antisense RNA or DNA sequence, a polynucleotide coding for a therapeutic protein or polypeptide, or a therapeutic l0 protein or polypeptide itself. The therapeutic protein or polypeptide may be, for example, one that is absent or deficient in a genetic disease, an immunogen, a natural hormone, or a synthetic analogue of a natural hormone.
Included among the particularly preferred embodiments according to this aspect of the invention are topical formulations for the treatment of herpes simplex, comprising a cationic lipid of the invention together with a pharmacologically effective concentration of acyclovir, gancyclovir,l-(2-deoxy-2'-fluoro-1-B-D-arabinofuranosyl)-5 iodocytosine (FIAC) or 1(2'-deoxy-2'-fluoro-1-B-D-arabinofuranosyl)5-iodouracil (FIAU) in an pha .,ace~,aically acceptable vehicle. In preferred embodiments, the preparation comprises phosphoglyceride deriva~ines of acyclovir, gancyclovir, FIAC or FIAU.
According to another aspect of the invention, there is provided a method for introducing a biologically active agent into a cell, either plant or animal, comprising the steps of preparing lipid vesicles comprising a cationic lipid of the invention, and using these lipid vesicles to facilitate the transfection or transport of bioactive agents into the cells.
The intracellular transport may be accomplished by incorporating or encapsulating the bioactive agent in the lipid vesicle and contacting the cell with the lipid vesicles, as in conventional liposome methodology; or alternatively, by contacting the cells simultaneously with empty lipid vesicles, comprising the cationic lipids together svssri~rvrE sHE~r 20"9814 with the bioactive agent, according to conventional transfection methodology. In the process of either strategy, the bioactive agent is taken up by the cell. In preferred embodiments of the method, the bioactive agent is a protein, polynucleotide, antiviral nucleoside or a drug. In particularly preferred embodiments, the bioactive agent is an antisense RNA or DNA sequence or a ribozyme. According to one embodiment of the method, the contacting step occurs in vitro. The method may be applied in the treatment of disease in a vertebrate, comprising the step of administering a pharmaceutical preparation comprising any one of the cationic lipids having the structure set forth above together with a pharmacologically effective amount of a therapeutic agent specific for the treatment of the disease to the vertebrate and permitting the therapeutic agent to be incorporated into a cell, whereby the disease is effectively treated. The bioactive agent is delivered to the cells of the animal in vivo or in vitro. The in vitro delivery of a bioactive agent may be carried out on cells that have been removed from an animal. The cells are returned to the animal body whereby the animal is treated.
The methods according to other embodiments cf the invention include the topical application of a preparation to the skin; the injection of a preparation into a body cavity or into the tissues of said vertebrate; or the oral administration of said preparation. The biologically active agent can be a polynucleotide, such as, for example, DNA or mRNA coding for a polypeptide, and said polypeptide is expressed after said DNA or said mRNA is taken up into said cell. In yet other embodiments, the biologically active agent is a drug.
The cationic lipids of the invention provide more . effective intracellular delivery than the use of presently available agents for the purpose. Further these lipids include species that are less toxic to cells ~ahen used in in vivo and in l~itro procedures .
-14a-An object of the present invention is to provide cationic lipids for intracellular delivery of biologically active molecules. In accordance with an aspect of the present invention, there is provided a composition having the structure Hz C - Y i - Rl HC - Yz - Rz R' ( I ) (CHz) n - 1'T' - R~ X
Rs _ O - Rs _ R~
wherein Yl and Yz are the same or different and are -O-CHz-, -O-C(O)-, or -O-;
R1 and R2 are the same or different and are H, or C: to Cz3 alkyl or alkenyl:
R' and R' are the same or dif ferent and are C1 to Cz alkyl, or H; ' Rs is C1 to Cz' alkyl straight chain or branched chain:
R6 is -C(O)-(CHz)m NH-, a diaminocarboxylic acid which is alkyl, aryl, or aralkyl, or -C(O)-(CHz)m-NH- linked to said diaminocarboxylic acid, or is absent;
R' is H, spermine, spermidine, a histone, or a protein with DNA-binding specificity, or the same groups wherein the amines of the R' moiety are quaternized with R', R', or Rs groups; or R' is an L- or D-alpha amino acid having a positively charged group on the side chain, said amino acids comprising arginine, histidine, lysine or ornithine or analogues thereof, or wherein the amine of the R' moiety is quaternized with R', R' or RS groups; or R' is a polypeptide selected from the group consisting of L-or D-alpha amino acids, wherein at least one of the amino acids residues comprises arginine, histidine, lysine, ornithine, or analogues thereof;
n is 1 to 8 ;
m is 1 to 18 ; and X is a non-toxic anion.
-14b-In accordance with another aspect of the invention, there is provided 3,5-(N,N-dilysyl)-diaminobenzoyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-t3-hydroxyethylamine).
In accordance with another aspect of the invention, there is provided 3,5-(N,N-dilysyl)-diaminobenzoylglycyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-B-hydroxyethylamine).
In accordance with another aspect of the invention, there is provided L-spermine-5-carboxyl-3-(DL-1,2-dioleoyl dimethylaminopropyl-t3-hydroxyethylamine).
In accordance with another aspect of the invention, there is provided a composition having the structure H~ C - Y1 - g,l HC - yz - R2 R3 (II) H~ C - N' - R' X-or an optical isomer thereof, wherein Y1 and YZ are different and are either -O-CH2-, -O-C(O)- or -o-;
R1 and RZ are individually Cl to C23 alkyl or alkenyl, or H;
R3, R' and RS are the same or different and are H, C1 to C1' alkyl , C7 to C11 aryl or alkaryl , or at least two of R' , R' and RS are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino:
n is 1 to 22; and X is a non-toxic anion.
In accordance with another aspect of the invention, there is provided a formulation for transfection of polynucleotides into cells, comprising a cationic lipid and an effective transfection-promoting amount of a lysophosphatide, having the structure -14c-HZ C - Y - R HZ C - OH
HC - OH or HC - Y - R
O O
a H2 C----O P- Z ~ HZ C--O---P- Z
O' O' wherein Y is selected from the group consisting of -O-CH2-and -O-C(O)-;
R is Clo to C2, alkyl or alkenyl; and Z is a headgroup.
1~
These and other advantages and features of the present invention will become more fully apparent from the following description and appended claims.
Detailed Description of the Invention The cationic lipids (CLs) of the invention, comprising compositions having an ammonium group together with hydrophobic alkyl groups, as well as adducts of these cationic lipids, are advantageously used in formulations to prepare lipid vesicles or liposomes to be used in transfection procedures, or to similarly facilitate the intracellular delivery of proteins, polypeptides, small organic molecules, and drugs of therapeutic interest. The adducts further comprise additional cationic and hydrophobic groups that enhance the effectiveness of the lipids in interacting with cell membranes.
We have discovered that certain derivatives and adducts of a compound having the structure l~
H=C--OC ( O ) -R
HC-OC(O)-R
(CHx)" - N' ' CHI
I _ _ CHx CHx OH
wherein R is a long chain fatty acid, are highly effective compounds for use in lipid formulations for transfection and other intracellular delivery procedures. A
single species of a compound of this type, comprising C,g (stearoyl) fatty acids was described by Rosenthal, A. F. and R. P. Geyer, J. Biol. Chem. 235(8):2202-2206 (1960). The Rosenthal compound, which is an inhibitor of phospholipase A
(Rosenthal Inhibitor, RI), is itself ineffective as a promoter of transfection or intracellular delivery. :Modifications to the RI molecule that we have discovered to be most effective in conferring 20'~ 9814 transfective properties are substitution of preferred long chain aliphatic groups, selection of preferred acyl (ester) or alkyl (ether) links between the glycerol moiety of RI and the aliphatic groups, and the addition of groups to the hydroxyl moiety which promote interaction with cell membranes. These compounds have proved to be superior in transfective performance to any presently known, including the cationic lipids described in European Application No. 0 187 702 (1986).
Nomenclature To simplify description, compounds are referred to herein by acronyms, as follows:
RI: The Rosenthal Inhibitor DORI: Dioleoyl derivatives of RI having two C,9 unsaturated (18:1) aliphatic groups, comprising:
DORI diester: DL-1,2-dioleoyl-3-dimethylaminopropyl-s3-hydroxyethylammonium DORIE diether: DL-1,2-0-dioleyl-3-dimethylaminopropyl -B-hydroxyethylammonium DORI ester/ether: DL-1-O-oleyl-2-oleoyl-3-dimethyl-aminopropyl-B-hydroxyethylam~monium OR
DL-1-oleoyl-2-0-oleyl-3-di:~ethyl-aminopropyl-f3-hydroxyethylar"moni ~::"
DPRI: Derivatives of RI having C16 (16:0) aliphatic groups, comprising:
DPRI diester:DL 1,2-dipalmitoyl-3-dimethylaminopropyl-f3-hydroxyethylammonium ~5 DPRI diether:DL 1,2-0-dipalmityl-3-dimethylaminopropyl-B-hydroxyethylammonium DOTMA: N-[1-(2,3-dioleyloxy)propylJ-N,N,N-trimethylammonium DOTAP: DL-1,2-dioleoyl-3-propyl-N,N,N-trimethylammonium DPTMA: DL-(2,3-dipalmityl)-3-propyl-N,N,N-trimethylammonium DLYS-DABA-DORI diesters, diethers, or ester/ethers: Lysine-containing adducts of DORI, having lysine groups attached at SUBSTITUTE ,SHE~r the hydroxyl group of the B-hydroxyethyl moiety through a diaminobenzoic acid linker, which is optionally joined to DORI through a glycyl spacer.
DLYS-DABA-DPRI diesters, diethers, or ester/ethers: analogues of above DORI compounds, but comprising DPRI.
SPC-DORI diesters, diethers, or ester/ethers: Sper:,:ine-containing adducts of DORI, having spermine attached at the hydroxyl group of the B-hydroxyethyl moiety.
SPC-DPRI diesters, diethers, or ester/ethers: analogues of DORI compounds above, but comprising DPRI.
SPC-DABA-DORI diesters, diethers; or ester/ethers: Spernine-containing adducts of DORI, having spermine groups attached at the hydroxyl group of the B-hydroxyethyl moiety through a diaminobenzoic acid linker, which is optionally joined to DORI through a glycyl spacer.
Cationic lipids according to one aspect of the inve.~.tion have the general formula HZC _ yi _ Ri HC - YZ - RZ , R3 (I) 3 0 ( CHZ ) n - N' - R° X_ Rs _ 0 _ R~ _ R~
wherein Y' and YZ are the same or different and are -0-CHI- -, -O-C(0)-, or -O-;
R1 and Rz are the same or different and are H, or C. to Cz3 alkyl or alkenyl;
R3 and R° are the same or different and are C, to alkyl, or H;
R5 is C1 to C2~ alkyl straight chain or branched chain;
R6 is -C (O) - (CHZ) m-NH-, a diaminocarboxylic acid ~~hic:, is alkyl, aryl, or aralkyl, or -C(O)-(CH~)~-NH- linked to said diaminocarboxylic acid, or is absent;
SUgSTiTUTE SHEET
2p'~9814 -, 8-R' is H, spermine, spermidine, a histone, or a protein with DNA-binding specificity, or wherein the amines of the R' moiety are quaternized with R3, R', or RS groups; or R' is an L- or D-alpha amino acids having a positively charged group on the side chain, such amino acids comprising arginine, histidine, lysine or ornithine or analogues thereof, or the same amino acids wherein the amine of the R' moiety is quaternize.d with R', R' or RS groups; or R' is a polypeptide selected from the group comprising L- or l0 D-alpha amino acids, wherein at least one of the amino acids residues comprises arginine, histidine, lysine, ornithine, or analogues thereof;
n is 1 to 8;
m is 1 to 18; and X is a non-toxic anion.
We have determined structure-transfection activity relationships within classes of cationic lipids having a quaternary ammonium group and have, found these relationships to be useful in predicting efficient transfection. We accordingly provide synthetic cationic lipids of this class suitable for use in transfection formulations. CLs having long chain aliphatic (R' and RZ) groups cor""prising ether linkages are preferred to those having ester linkages; CLs having unsaturated R1 and RZ groups are pre~erred to CLs having corresponding saturated groups; and CLs such as analogues of RI, having polar hydroxyethyl group substituents on the quaternary ammonium group are more effective than those substituted with alkyl groups, for example, the methyl substituent of DOTMA.
Therefore, in particularly preferred embodiments, the cationic lipids of the invention are derivatives of RI having a structure comprising at least one alkyl ether group. A
specific memeber of this class of cationic lipids is a DORI
diether (DORIE) having long chain alkyl groups with one site of unsaturation, and having the structure:
S~~E SHE~r 2~'~9814 _19_ H2 i - O - ( CH2 ) a - CH = CH - ( CHZ ) ~ . - CH3 HC - 0 - ( CHZ ) 8 - CH = CH - ( CH2 ) ~ - CH3 HZ C - N' - CH3 X-For applications demanding metabolizable, less toxic compounds, CLs having long chain R1 and RZ aliphatic groups attached by acyl bonds are preferred. Therefore, in other preferred embodiments, the cationic lipids of the invention comprise derivatives of RI having the structural characteristics of Formula I, but comprising at least one acyl group, as, for example, a DORI diester having the structure:
HZ i - O - C ( 0 ) - ( CHZ ) ~ - CH = CH - ( CHI ) . - CH3 HC - O - C ( O ) - ( CH2 ) , - CH = CH - ( CHI ) , - CH3 2 5 ~ CH3 H~ C - N+ - CH3 X-CHI - CH= - OH _ In yet other preferred embodiments, cationic lipids of the invention are substituted at the hydroxyl group of an ethanolamine moiety with various species which act to enhance binding to cell membranes. In preferred embodiments the amine group of ethanolamine is quaternized.
Preferred species for this purpose are 'compounds such as spermines and spermidines, or other compounds having nultiple amino groups, or histones, or similar proteins rich in basic amino acids such as arginine and histidine. Caticnic substances such as the histones, spermines, and spermidines are known to bind and modulate negatively charged cell membrane surfaces. For example, lipid-derivatized soermine-SUBSTITUTE SHEET
like structures are reported to efficiently modulate gene transfer into mammalian 5 endocrine cells (Behr, J.-P. et al. Proc. Natl. Acad. Sci. USA 86:6982-6986 (1989).
We have designed a series of molecules which combine advantageous properties of both cationic lipids and cationic structures derived from amino acids arid spermines.
These molecules are prepared by coupling spermine, through a carboxylic acid group, to the hydroxyl moiety of the ethanolamine group of a lipid such as DORI, DORIE or 10 DPRI.
One such series of compounds, is represented by L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethylaininopropyl-~3-hydethylamine, designated SPC-DPRI-diester, which has the structure 15 ~ Hz -0-C(0)-(CHz ),4-CH3 Hz-0-C(0)-. (CHz), 4-CH3 CHz - +-CM3 CHz-CHz-0-C(0)-~H-(CHz)3-NH-(CHz)3-NHz 20 NH-(CHz)3-NHz In an example of another lipid of this type, the basic amino acid lysine is linked to the same hydroxyl moiety of the lipid through a linker molecule. The linker molecule can be any diaminocarboxylic acid, either alkyl, aryl or aralkyl, having two amino sites by which lysine is anchored as a pendant in a branched molecule that can bind to multiple binding sites simultaneously. In preferred embodiments, the linker molecule is joined to the hydroxyl group of the hydroxy lipid through a spacer arm which can be any alkyl amino acid. Glycine is a preferred spacer arm. A
representative cationic lipid of this type comprises lysine linked to the hydroxyl moiety of DPRI through diaminobenzoic acid and a glycine spacer, to form 3,5-(N,N-di-Ivs~~l)-diaminobenzoyl-V Ivcyl- 3-I DL-1.2-dipalnlit~~w~ -dimethylaminopropyl-B-hydroxyethylamine).. This lipid, designated DLYS-DABA-GLY-DPRI-diester, has the structure CHz-O-C ( O ) - ( CHZ ) 1,,-CH3 CHZ-O-C ( O ) - ( CHZ ) 14 -CHI
CHZ - N''-CH3 CHI-CHZ-O-C ( 0 ) -CHZ-NH-C ( 0 ) -C5H3- ~ NH-C ( 0 ) -CH-NHS 1 ( CHI ) ;, -NH, Particularly preferred compounds of this class are DLYS-DABA-GLY-DORI-diester, having the structure CHI-O-C ( O ) - ( CHZ ) ~-CH = CH- ( CHZ ) ~-CH3 CHZ-O-C ( O ) -CHZ ) ~-CH = CH- ( CHI ) ~-CH3 CHZ -N' - CH3 3 0 CHZ-CH,-O-C ( O ) -CHZ-NH-C ( O ) -CSH~- NH-C ( O ) -CH-NH~
! C ~, ) 4-tli:=
and DLYS-DABA-GLY-DORI-diether, having the struc~~.:re CHZ-O- ( CHZ ) s-CH = CH- ( CHZ ) 7-CH3 4 0 CHZ-O- ( CH2 ) 3-CH = CH- ( CHZ ) ~-CH3 CHZ -N' - CH3 CHz-CHZ-O-C ( O ) -CH2-NH-C ( O ) -CSH3- f NH-C ( O ) -CH-NHS
(CHI) 4-NHS
Other molecules of this type can comprise linkers or spacer arms to which are joined other basic ami:.o acids, such as V~' histidine and arginine or analogues or derivatives or these basic amino acids comprising related molecules, which are structurally modified, for example by having substituent groups, such as 1-methyl histidine or 3-methyl histidine. Polymers of these amino acids or their analogues can be attached to the linker in the same manner.
Amine-containing groups added to the cationic lipids of the invention through spacers and linkers at the (3-hydroxyethylammonium moiety can in turn provide further hydrophobic regions to the lipid structure by quaternization of the amine with the alkyl, alkenyl, aryl and aralkyl groups of R3, R4, and R'. Thus, the assembled lipid adducts, comprising additional cationic groups, and in some cases additional hydrophobic groups as well, incorporate additional sites capable of interaction with the cell membrane, thereby increasing the intracellular delivery potency of the cationic lipid.
For some applications it is important that cationic lipids used are metabolizable and therefore non-toxic, both for in vitro applications and especially when used in vivo, and yet retain the substantial transfective properties associated with lipid species having an ether-linked alkyl group. Accordingly, we have synthesized cationic lipids according to another aspect of the invention having the formula HZC - Y1 - Rl R' (II) H,_C - N' - R' X-Rs 2> or an optical isomer thereof, wherein Y' and Yz are different and are either -)-CH2-, -)-C())-, or OH;
Rl and Rz are individually absent or are C, to C23 alkyl or alkenyl;
R3, R4 and RS are the same or different and are H, C, to C.,~ alkyl, C~ to Cl ~ aryl. or aralkyl, or at least two of R3, R4, and RS are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino;
X is a non-toxic anion.
According to one aspect of the invention, the CLs are combined with other lipids in formulations for the preparation of lipid vesicles or liposomes for use in intracellular delivery systems. The formulations preferably are prepared from a mixture of positively charged lipids, negatively charged lipids, neutral lipids and cholesterol or a similar sterol. The positively charged lipid can be one of the cationic lipids of the invention alone, a mixture of these, or one of the cationic lipids of the invention in combination with the cationic lipids DOTMA, DOTAP, or analogues thereof. Neutral and negatively charged lipids can be any of the natural or synthetic phospholipids or mono-, di-, or triacylglycerols. The natural phospholipids are typically those from animal and plant sources, such as phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, phosphatidylserine, or phosphatidylinositol. Synthetic phospholipids typically are those having identical fatty acid groups, including, but not limited to, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine and the corresponding synthetic phosphatidylethanolainines and phosphatidylglycerols. The neutral lipid can be phosphatidylcholine, cardiolipin, phosphatidylethanolamine, mono-, di- or triacylglycerols, or analogues thereof. The negatively charged lipid can be -24=
phosphatidylglycerol, phosphatidic acid or a similar phospholipid analog. Other additives such as cholesterol, glycolipids, fatty acids, sphingolipids, prostaglandins, gangliosides, neobee, niosomes, or any other natural or synthetic amphophiles can also be used in liposome formulations, as is conventionally known for the preparation of liposomes.
In a formulation for preparing cationic lipid vesicles, the cationic lipid can be present at a concentration of between about 0.1 mole% and 100 mole%, preferably 5 to 100 mole%, and most preferably between 20 and 100 mole%. The neutral lipid can be present in a concentration of between about 0 and 99.9 mole%, preferably 0 to 95 mole%, and ~:ost preferably 0 to 80 mole%. In order to produce lipid vesicles or liposomes having a net positive charge, the quantity of the positively charged component must exceed that of the negatively charged component. The negatively charged lipid can be present at between about 0 to 49 mole% and preferably 0 to 40 mole%. Cholesterol or a similar sterol can be present at 0 to 80 mole%, and preferably 0 to 50 hole%.
Lipid formulations comprising at least one a..~..ahiDathic lipid can spontaneously assemble to form pri:~ary l.iposc.:,es, heterogeneous in size. Therefore, according to a ~re~erred method, the lipid reagents of the invention, comprising at least one cationic lipid species, are prepared as liposomes according to the procedure of Example 12. The component lipids are dissolved in a solvent such as chlorofor:a and the mixture evaporated to dryness as a film on the inner surface of a glass vessel. On suspension in an aqueous solvent, the amphipathic lipid molecules assemble themselves into prinary liposomes. If other molecules are present in the a~_:eous solvent, such as, for example, a bioactive substance, these will be captured within the liposomes. Otherwise, empty liposomes will be formed.
A bioactive substance in the form of its lipid derivative, may be added to the component lipids of the liocso:~e SUBSTITUTE SHEET
20'9814 formulation, to be incorporated into the wall of the liposomes on hydration.
These primary liposomes are reduced to a selected mean diameter by means of the freeze-thaw procedure referred to S above. The CLs of the invention are formed into vesicles of uniform size prior to transfection procedures, according to methods for vesicle production published in the literature and known to those in the art, for example, the sonication of spontaneously formed liposomes comprised of the lipids in aqueous solution described by Felgner, P.L. et al., Proc.
Natl. Acad. Sci.. USA 84:7413-7417 (1987) or the reverse-phase evaporation procedure of J. Wilschut et al.
Biochemistry 19:6011-6021(1980) or freeze-thaw and extrusion (Mayer, L. et al., Biochim. Biophys. Acta 858:161-168 (1986).
To prepare liposomes suitable for physiological in vivo use, having a unilamellar structure and a uniform size of from about 50 to about 200 ~m in diameter, the primary liposomes are preferably processed by the freeze-thaw and extrusion processes.
Other suitable conventional methods of preparation include, but are not limited to, those disclosed by Bangham, A. et al., J. Mol. Biol. 23: 238-252 (1965); Olson, _. et al., Biochim. Biophys. Acta 557: 9-23 (1979), Szoka _. et al., Proc. Natl. Acad. Sci. OSA 75: 4194-4198 (1978), Mayhew, E. et al. Biochim. Bioph~rs. Acta 775: 169-175 (1984), Kim, S.
et al. Hiochim. Biophys. Acta 728:339-348), and Fukunaga, M.
et al. Endocrinol. 115:757-761 (1984).
Transfection Parameters We have discovered that several factors affect the efficiency of cationic lipid-mediated transfection as determined by the level of gene product produced.
1. Cationic Lipid Formulations Lyso lipid compounds Incorporation of a ruantity of a single chaff.~.
phosphatide into the lipid fornulation for transfecticn :gas the effect of increasing the efficiency of transfecticn.
SUBSTITUTE SHEET
2p79814 As demonstrated in Example 20, the addition of monooleoyl lysophosphatidylcholine to~ a transfection formulation comprising DOTMA and DOPE (Lipofectin~'), in amounts up to a molar ratio of lysophosphatide to DOTMA of 0.5, can increase the efficiency of transfecting DNA coding for B-galactosidase into cells by an amount greater than 100%.
According to current theories of self-assembling lipid structures, the combined thermodynamic forces of packing constraints and the~.interactive free energies of lipid polar headgroups with an.~aqueous media determine the geometry and structure of lipid vesicles. Entropy favors small structures, and packing constraints oppose close packing.
Accordingly, in an aqueous media, the entropically favored structures for homogenous systems of single-chain lipids are single layer micelle structures having a relatively small radius of about 15-20 Angstrom units, while those for corresponding systems of double-chain lipids, whose lipid chains cannot be so tightly packed, are double layered structures having aqueous interiors with wall thicknesses of about 50 Angstroms (Israelachvili, J. N. et al., Biochim.
Bioohvs. Acta 470:185-201 (1977).
At high concentrations of lipids, vesicles interact with one another to aggregate, fusing together the outer lipid membranes of each. Membrane fusion is a phenomenon that occurs broadly in biological processes. It is this phenomenon which causes lipid vesicles to fuse with the lipid bilayer of cell membranes whereby the contents of the lipid vesicle are delivered into the cell cytoplasm. However, when the fusogenic properties of lipid vesicles causes their aggregation with each other, their diameter can increase to beyond that of the effective range for transfecticn.
Fusogenic behavior of cationic lipid vesicles resulting in aggregation of the vesicles is induced by the presence of anions in the aqueous media which interact with the cationic SU~~~ SH
polar headgroups of the lipid formulations (Duzgunes, N. et al., Biochemistry 29:9179-9184 (1989).
It is believed that the presence of effective concentrations of single chain lipids in the lipid S formulation opposes fusogenic behavior leading to aggregation, while preserving the fusogenic behavior that allows vesicle contents to be delivered into cells. Single chain lipids can shift the thermodynamic equilibria of lipid systems to allow closer packing and to favor the stability of formed lipid vesicles so as to resist aggregation. As levels of single-chain lipids increase, however, the efficiency of transfection no longer is improved, but decli.~.es. This effect may be due to an increase in the resistance cf the lipid vesicles to fusion which inhibits fusion with cell membranes or to toxic properties of the single-chair. (lyso) lipids, or to both effects.
Accordingly, improved transfection formulations contain amphipathic lipids comprising a polar headgroup and having a single lipid chain in amounts capable of pre:~oting transfection while preserving the ability of the lipid vesicles assembled from the formulation to achieve r~~sion with cell membranes.
Suitable lyso lipids comprise lysophosphat~es of phospholipids having a neutral, positively c::ar~ed, or negatively charged headgroup. Phospholipids having a neutral headgroup are preferred. Particularly preferred lysophosphatide species are lysophosphatidylcholine and lysophosphatidylethanolamine. Other suitable single chain lyso lipids comprise any of the cationic lipid compounds of formula I or formula II wherein either Y1 and R' together or YZ and RZ together are -OH. Preferred cationic li~i~s for this purpose comprise Rosenthal Inhibitor ester and ether derivatives disclosed herein as well as lyso fonas of SOT.~.A, DOTAP, and similar saturated analogues, and co:,~aini.~,a typically C_4, C:S, and C:e alkyl chains.
SU~~.ITE l~W~~r =28-The single chain lyso lipid compounds have been found to be effective in molar ratio concentrations of up to 0.5 relative to the concentration of the double lipid chain cationic lipids of the transfection formulations.
Presence of a neutral lipid Under some conditions, the presence of a neutral lipid in the transfection lipid formulation appears to reduce the efficiency of transfection. The presence of DOPE c_- DOPC
reduced the effectiveness of DOTMA in RNA transfection, while l0 cholesterol was less inhibitory (Examples 17 and 18; FiQUres 3-4). However, DORI was most effective in DNA transfection when combined with DOPE in a molar ratio of 5/S (Exa.~..ple 22;
Figure 8). The effect may be related to the physical structure of the transfected polynucleotide.
2. Transfection Conditions Presence of serum Although the presence of serum appears to i.~.hi:,i~ the formation of cationic lipid/RNA complexes, the presence of serum in the transfection procedure itself, that is, after the addition of cationic lipid/polynucleotide co:~plexes formed in the absence of serum, is only slightl:~ ini~;tcrv (Examples 15 and 22 ) . Previous results seem to indica ~.s the t serum inhibits transfection; however, these evcer_.-..ents (Figures 1-5) shows comparatively good activity even ~.. to 2 ~ presence of seru:a .
Cell density Cationic lipid-mediated transfections can be effec~ivelw carried out over a range of cell densities. Transfecticn o~
pSV2-lacZ into COS.7 cells was carried out accordinc t~ the procedure of Example 14B at cell densities fro:.-. ~,OOC
cells/well to highly confluent cells at 40, 000 cells wel '.
The successful transfection of highly conflue;;~ cells indicates tha t cell division is not rec~;ired f or e; t:~er expression or functional delivery of DNA ; however , cc ti:~al expression was observed at 20,000 cells;Twe''; (°Ov confluency). Further decreasing cell density to S,CC:;
SUBSTITUTE SHEET
_ 2079814 10,000 cells/well led to a shift of optimal expression to lower lipid concentration. This result may be due to higher toxicity (greater amount of cationic lipid per cell) and in general a lower expression corresponding to the lower number of cells.
Choice of cell line for transfection Transfection of pSV2-lacZ using a DORI/DOPE 5/5 lipid formulation under the protocol of Example 14B was carried out for a number of different cell lines. A wide range of Q-l0 galactosidase activity, from 50 pg/well to 20, 000 pg/well was determined among these cells, as follows:
L-M 50 pg L-929 g0 pg CV-1 (ATCC CCL70) 900 pg COS.7 (ATCC CRL 1651) 1000-2000 pg BHK (ATCC 20,000 pg The enormous variation in the level o° expression is probably caused by differences in both DNA uptake as well as intracellular metabolic factors. It is a factor to consider when the yield of gene product isla priority.
ADTJ1 ications The cationic lipids of the invention can be advantageously used, either alone or in combination pith other known cationic lipids such as for example, DOT:~.A or DOTAP, in any procedure comprising the use of liposomes or lipid vesicles to deliver substances intracellularly either in vitro or in vivo. Those lipids having metabolizable ester bonds are preferred for in vivo use.
1. Production of Gene Product Contemplated uses comprise transfection procedures corresponding to those presently known and using amphipathic lipids, including commercial cationic lipid preparations, such as LipofectinT~, and using conventional cationic lipid technology and methods. Accordingly, the lipid compositions disclosed herein can be used to facilitate t~:e intercel?ular delivery of DNA or mRNA sequences coding for therapeutically active polypeptides, as described in detail in ti. S. Patent SUBSTITUTE SHEET
No. 5,703,055. They can be similarly used for the liposomal delivery of the expressed 5 gene product, the polypeptide or protein itself. Thus cationic lipid mediated delivery of DNA and mRNA polynucleotides or proteins can provide therapy for genetic disease by supplying deficient or absent gene products to treat any genetic disease in which the defective gene or its product has been identified, such as Duchenne's dystrophy (Kunkel, L. and Hoffman, E. Brit. Med. Bull. 45(3) : 630-643 (1989) or 10 cystic fibrosis (Goodfellow, P. Nature, 341(6238):102-3 (Sept. 14, 1989).
The cationic lipid-mediated intracellular delivery described above can also provide immunizing polypeptides to the cell, either by delivering a polynucleotide coding for the immunogen, or the immunogen itself.
The transfection procedures described above may be applied by direct 15 injection of cationic lipids together with DNA, RNA or proteins into cells of an animal in vivo. However, it has been recently shown that cationic lipids are particularly effective at facilitating in vitro transfection of cells.
Therefore the above therapies can be alternatively carried out by in vitro transfection of some of the cells of an animal using cationic lipid delivery methods, and reintroduction of the cells into 20 the animal. The ability to transfect cells at high efficiency with cationic lipids thus provides an alternate method for immunization. The gene for an antigen is introduced, by means of cationic lipid-mediated delivery, into cells which have been removed from an animal. The transfected cells, now expressing the antigen, are reinjected into the animal where the immune system can now respond to the (now) 25 endogenous antigen. The process can be enhanced by co-injection of either an adjuvant or lymphokines, or a gene coding for such lymphokines, to further stimulate the lymphoid cells.
Cationic lipid methodology is preferred over other methods: it is more convenient and efficient than calcium phosphate, DEAF dextran or electroporation methods.
Other therapeutically important polynucleotides suitable for cationic lipid mediated delivery are negatively charged novel oligonucleotides of various technologies, including antisense polynucleotide sequences, useful in eliminating or reducing the production of a gene product, as described by Ts'o, P. et al. Annals New York Acad. Sci. 570:220-241 (1987). Many of these oligonucleotide species, which are scarce and expensive to synthesize, are inefficiently captured by encapsulation into liposomes of negatively charged lipids, according to ordinary current methods. We have experimental studies showing that these oligonucleotides are captured within cationic lipvsomes with efficiencies approaching 100%. Also within the scope of the invention is the delivery, by means of the cationic lipids disclosed, of ribozymes, or catalytic RNA species, either of the "hairpin"
type as described by Hampel et al. Nucleic Acids Research 18(2):299-304 (1990); or the "hammerhead" type described by Cech, T. and Bass, H. Annual Rev. Biochem. 55:599-629 (1986) .
Particularly preferred contemplated uses of the invention are deliveries of either an antisense polynucleotide or ribozyme as described above, and having as its target the rev site of the HIV genome Matsukura, M. et al.
Proc. Nat'1. Acad. Sci. 86:4244-4248 (1989 ) describe a 28-mer phosphorothioate compound anti-HIV (anti-rev transactivator) specific for the site.
Other therapeutic uses of cationic lipids herein disclosed include the liposomal delivery of nucleoside or nucleotide analogues having an antiviral effect, such as dideoxynucleotides, didehydronucleotides, nucleoside or nucleotide analogues having halo-substituted purine or pyrimidine rings such as S-trifluoromethyl-2'-deoxyuridine or y 5-flurouracil: nucleoside or nucleotide analogues having , -32-halo- and azido-substituted ribose moieties, such as 3'-azido-3'deoxythymidine (AZT), nucleoside analogues having carbon substituted for oxygen in the ribose moiety (carbocyclic nucleosides), or nucleotide analogues having an acyclic pentose such as acyclovir or gancyclovir (DFiPG) .
The antiviral potency of these analogues is found to be increased when they are presented to the cells as phospholipid derivatives. These derivatives may be incorporated into the liposomal structure for administration to cells thereby forming a more stable liposomal complex which can deliver greater amounts of drugs to target cells with less toxicity. Effective antiviral lipid derivatives of nucleoside analogues comprise phosphatidyl 2',3'-dideoxynucleosides, 2'3'-didehydro-nucleosides, 3'-azido-2'-deoxynucleosides, 3'-fluoro-deoxynucleosides and 3'-fluorodideoxynucleosides, 9-p-D-arabinofuranosyladenine (araA), 1-p-D-arabino-2o furanosylcytidine (araC), nucleosides such as acyclovir and gancyclovir having an acyclic ribose group, or the same nucleoside analogues as diphosphate diglyceride derivatives.
Preferred species of lipid derivatives of antiviral or antiretroviral nucleoside analogues for the treatment of HIV
infection using cationic lipid mediated liposomal delivery are phospholipid derivatives of 3'-azido-2',3'-dideoxypyrimidine, 3'-halopyrimidine dideoxynucleoside, or a 2',3'-didehydro-2',3'-dideoxynucleoside, for example, phosphatidyl 3'-azido-3'deoxythymidine (pAZT) or phosphatidyl 2-chlorodeoxyadenosine. Certain viral infections, comprising herpes, cytomegalovirus, and hepatitis B infections are effectively treated with nucleoside analogues comprising acyclovir, gancyclovir, 1-(2-deoxy-2'-fluoro-1-f3-D-arabinofuranosyl)-5-iodocytosine (FIAC) or 1(2'-deoxy-2'- ' fluoro-i-t3-D-arabinofuranosyl)5-iodouracil (FIAU).
Phospholipid derivatives of these agents, preferably the ' phosphatidyl and diphosphate diglyceride derivatives can be administered in these diseases using cationic lipid liposomal delivery systems, according to the invention. Details of the structures, synthesis and liposomal delivery of lipid derivatives of antiviral nucleosides are presented in U.S.
Patent No. 5,223,263.
Among other therapeutically important agents that can be thus delivered are peptides comprising physiologic species such as interleukin-2, tumor necrosis factor, tissue plasminogen activator, factor VIII, erythropoietin, growth factors such as epidermal growth factor, growth hormone releasing factor, neural growth factor, and hormones such as tissue insulin, calcitonin, and human growth hormone as well as toxic peptides such as ricin, diphtheria toxin, or cobra venom factor, capable of eliminating diseased or malignant cells.
Use of the disclosed lipids is also contemplated for the encapsulation of various other agents to be delivered intracellularly according to methods known to those skilled in the art, and as described in Duzgunes, N., Subcellular Biochemistry 11:195-286 (1985). Materials to be delivered can be proteins or polypeptides, especially negatively charged molecules, monoc14na1 antibodies, RNA-stabilizing factors and other transcription and translation regulating factors, antisense oligonucleotides, ribozymes,and any molecule possessing intracellular activity. Such encapsulation further protects the described agents from non-productive sequestration by substances of the extracellular environment.
Pharmaceutical formulations The cationic lipids of the invention can be used in pharmaceutical formulations to deliver therapeutic agents by various routes and to various sites in the animal body to achieve a desired therapeutic effect. Local or systemic delivery of the therapeutic agent can be achieved by 20'~9g14 administration comprising application or insertion of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, intradermal, peritoneal, subcutaneous and topical administration. The effect of the cationic lipids in these formulations is to enhance the potency and efficiency of -the therapeutic agent contained therein by facilitating its intracellular delivery.
Topical formulations are those advantageously applied to the skin or mucosa. Target mucosa can be that of the gastrointestinal tract, comprising the mouth, naso-pharynx and stomach, or the vaginal or anorectal ~~ucosa. Otter target tissues can be the accessible surfaces and canal of the ear and the ocular tissues. Cationic lipids present in topical formulations can act to facilitate introduction of bioactive molecules into the target tissue, such as the stratum corneum of the skin, by perturbing the barrier properties of the protective membrane, or by introducing perturbing agents or penetration enhancers such as Azone~' or by promoting the activity of these penetration enhancers.
Several classes of drugs consisting of small organic molecules can be delivered in the formulations as described above. One such class comprises steroidal anti-=nflam.-~atory agents which may be prepared in liposomal formulations for topical application. Drugs of this class co:,iprise hydrocortisone, fluocinolone acetonide, available as Synalar"
(Syntex, Palo Alto, California 94303); fluocinonide, available as Lidex~" (Syntex, Palo Alto, California 94303 ) ;
and dexamethasone, available as Decaderm~" (Merck, Sharpe and Dohme, West Point, Pennsylvania 19486).
Other topical formulations comprising the cationic lipids are preparations comprising topical antibiotics such as clindamycin, tobramycin, neomycin, gentamycin, tetracycline, erythromycin; oxidants such as benzoyl peroxide; antifungal agents, such as clotrinazole, miconazole, nystatin, lactoconazole, econazole, and SUBSTtTt~TE SHEET
tolnaftate; retinoic acid for the treatment of acne; and agents for the treatment of herpes simplex and comprising antiviral nucleoside analogues such as acyclovir and gancyclovir. These nucleoside analogue formulations preferably comprise 5 lipid derivatives of the antiviral agents, particularly the phosphatidylglycerol derivatives as disclosed in U.S. Patent No. 5,223,263 and as such may be incorporated into liposomes comprising one or more cationic lipids of the invention.
Other pharmaceutical formulations comprising the cationic lipids of the 10 invention are topical preparations containing an anesthetic or cytostatic agent, immunomodulators, bioactive peptides or oligonucleotides, sunscreens or cosmetics. Preparations for topical use are conveniently prepared with hydrophilic and hydrophobic bases in the form of creams, lotions, ointments or gels;
alternatively, the preparation may be in the form of a liquid that is sprayed on the 15 skin. The effect of the cationic lipids is to facilitate the penetration of the active antiviral agent through the stratum corneum of the dermis.
Similar preparations for opthalmic use are those in which the pharmacologically effective agent is timolol, betaxolol, levobunalol, pilocarpine, and the antibiotics and corticosteroids disclosed for topical applications.
20 Another group of drugs can be delivered orally, topically, or systemically with the cationic lipid materials according to formulations of the invention are non-steroidal anti-inflammatory agents, such as, for example, 1-acetylsalicylic acid (aspirin; Bayer); piroxicam, available as Feldene~ (Pfizere, New York, New York 10017);
(Z)-5-fluoro-2-methyl-1-[[p-alcohol(methylsulfinyl)-phenyl]methylene]1-H-indene-3-acetic acid (sulindac), available as Clinoril~' (Merck, Sharpe and Dohme, West Point, Pennsylvania 19486); 2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid, monosodium salt (diclofenac), available as Voltaren~' (Ciba-Geigy, Summit, New Jersey); 2~
4~-, difluoro-4-hydroxy-3-biphenylcarboxylic acid (diflunisal), available as Dolobid~', (Merck, Sharpe and Dohme); 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid (indomethacin), available as Indocin~' (Merck, Sharpe and Dohme); ()-2-(p-isobutylphenyl)propionic acid (ibuprofen), available as Advil~' (Whitehall Laboratories, Inc., New York , NY 10017); N-(2), 6-dichloro-m-tolyl) anthranilic acid (meclophenomate), available as Meclomen~'(Parke-Davis, Morris Plains, New Jersey 07950; fenoprofen, an arylacetic acic derivative, available as Nalfon~' (Dista Produces Co., Indianapolis, Indiana 46285; 2-naphthaleneacetic acid, 6-methoxy-alpha-methyl-,(+) (naproxyn), available as :daprosyn~' (Syntex, Palo Alto, California 94303); 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetate dihydrate (tolmetin), available as Tolectin~' (McNeil Pharmaceutical, Spring House, Pennsylvania 19477); and derivatives and congeners thereof.
The composition and form of pharmaceutical preparations comprising the cationic lipids disclosed, in combination with SUBSTITUTE SHEET
a drug or other therapeutic agent, can vary according to the intended route of administration.
Orally administered preparations may be in the form of solids, liquids, emulsions, suspensions, or gels, or preferably in dosage unit form, for example as tablets or capsules. Tablets may be compounded in combination with other ingredients customarily used, such as talc, vegetable oils, polyols, gums, gelatin, starch, and other carriers.
The lipid vesicles may be dispersed in or combined wi th a suitable liquid carrier in solutions, suspensions, or emulsions.
Parenteral compositions intended for injection, either subcutaneously, intramuscularly, or intravenously, can be prepared either as liquids or solid forms for solution in liquid prior to injection, or as emulsions. Such preparations are sterile, and liquids to be injected intravenously should be isotonic. Suitable excipients are, for example, water, dextrose, saline, and glycerol.
The cationic lipids of the invention may also be present in liquids, emulsions, or suspensions for delivery of active therapeutic agents in aerosol form to cavities of the body such as the nose, throat, or bronchial passages. The ratio of active ingredient to the cationic lipid and the other compounding agents in these preparations will vary as the dosage form requires.
e~~ ~ocTtT1 ITS CHFF't Preparation of Cationic Lipid Compounds A. Derivatives of the Rosenthal Inhibitor Cationic lipids of the invention which are analogues of the Rosenthal inhibitor may be synthesized by acyl and alkyl substitution of a 3-dimethylaminopropane diol, followed by quaternization of the amino group as described in Examples through 5. Alkyl substitution of the primary and secondary alcohol groups of the diol to from a diether derivative is accomplished by treating the 3-dimethylamino-1,2-propanediol l0 with an alkyl or alkenyl methanesulfonate in a neutral solvent, such as benzene, as described in Exanple ~ ~cr the synthesis of 1,2-0-dioleoyl-3-dimethylamino propyl-B-hydroxyethylammonium acetate. Acyl substitution or the primary and secondary alcohol groups to form a diester derivative is accomplished by treating 3-dimethylaminopropanediol with an acyl halide in a sui~able solvent at an elevated temperature for an exte::ded ti-e, as described in Example 3 for the synthesis of DL-1,2-dicleoyl-3-dimethylaminopropyl-B-hydroxyethylammonium acetate. The synthesis of mixed acyl/alkyl derivatives is accomplished by blocking the primary or secondary alcohol groups of the starting diol, for example by benzylation, to form a lyso compound, which, on condensation with an alkyl or alkenyl methanesulfonate, yields a 1-O-benzyl-, 2-O-alkyl glycerol derivative. Debenzylation, followed by acylation wi~h an acyl halide yields a 1-acyl, 2-O-alkyl deriva~ive.
Alternatively, the diol can be alkylated with an alkyl SUBSTITUTE SNE~.
' -39-methanesulfonate, and the 1-alkyl, 2-lyso derivative isolated and acylated with an acyl anhydride as described in Example 6, part A.
~ Quaternization of the thus-substituted diol is carried out by treatment with a quaternizing group in the form of a halo derivative, and in the presence of a basic catalyst, such as 4-dimethylaminopyridine.
B. Synthesis of Rosenthal Inhibitor adducts comprising additional cationic and hydrophobic moieties One type of cationic lipid composition having multiple amino groups present is prepared by attaching a molecule which is basic in nature and of the type known to bind to DNA, such as for example a histone, spermine or spermidine through a carboxyl group attached to the basic molecule (J.-P. Behr et al., Proc. Natl. Acad. Sci. USA 86:6982-6986 (1989)) to the available hydroxyl group of a DORI or DPRI
diester, diether, or ester/ether using a condensing reagent, as for example, dicyclohexylcarbodiimide (DCC).
Another approach, comprising the attachment of pendant lysine groups, uses a linker molecule capable of bonding to the available hydroxyl group of an hydroxylipid and having at least two sites capable of bonding to lysine. This approach is exemplified by attaching two lysine groups to DPRI-diester through diamino benzoic acid.
C. Synthesis of ester/ether derivatives of DOTMA, DOTAP
and their analogues Cationic lipids corresponding to Formula IT_ and having both an acyl and alkyl group attached thereto are synthesized essentially as described in U.S_ Patent No. 4,897,355, except that 3-(dialkylamino)-1,2-propane diols (designated Formula 3 therein) are converted to mixed acyl/ether derivatives according to the procedure of Example 6.
Any of the cationic lipid molecules of the invention can be synthesized to contain alkyl chains which are linked to the glycerol moiety by either ester linkages or by ether linkages. Accordingly, the molecules may be either diester, diether, 1-ether-2-ester or 1-ester-2-ether. The structure-transfection activity relationships indicate that for optimal polynucleotide delivery the molecules should be ~f the diether type; however, these molecules are difficult to metabolize in vivo and would be expected to result in toxic effects due to accumulation of the lipids in the body. The diester compounds should be readily metabolized; however, these compounds are less active at delivering polynucleotide than the corresponding diether cationic lipids. The ether-ester molecules will have transfection activity that is intermediate between diether and diester molecules, but unlike the diether molecules, ether-ester molecules can be metabolized and excreted by the body. Analogous phospholipids, for example the platelet aggregating factor, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, are metabolized by several cell types, including epithelial cells of the lung and skin fibroblasts (Kumar, R. et al. Biochim.
Bioohvs. Acta 917:33-41 (1987). This feature of the ester/ether species of cationic lipids is sign-ificant ir. view of studies indicating liposome mediated transfection can occur with significant efficiency in vivo, for example in infusion into the trachea (Brigham, K.L. et al. Amer. J. of the Medical Sciences 298(4):278-281 (1989). Due to improved transfection activity and metabolizability of ether/ester molecules, these agents will have particular advantages both in vitro and in vivo.
Non-toxic salts of the compounds described herein are included within the scope of the invention. Such salts may be prepared from pharmaceutically non-toxic acids including inorganic acids and organic acids. Such acids inc'_ude hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, benzoic, citric, glutamic, lactic acid and the like. For the SU8ETITUTE SHEET' preparation of pharmaceutically acceptable salts, see S. M.
Berge et al., Journal of Pharmaceutical Sciences, 66:1-19(I977) which is incorporated herein by reference. Cationic lipid reagents of the invention may be prepared and stored in aqueous solution as empty liposomes, or may be stored dry after formulation to be later used as encapsulating agents for selected bioactive substances.
Optimal transfection and intracellular delivery parameters Accurate evaluation of the effectiveness of cationic lipid species in achieving intracellular delivery requires that structure-activity relationships be determined using an optimized standard formulation and procedure.
we have investigated the optimal conditions using DOTMA, a cationic lipid known to be an effective transfection agent, according to the experiments as follows.
A. Characteristics of the Media The critical procedural issue in cationic lipid mediated transfection relates to how serum is introduced into the transfection procedure. The studies of Examples 15 and 16 show that the presence of serum in a first step, wherein the lipid vesicles form complexes with polynucleotide molecules, is inhibitory to transfection. However, when the complexes are first allowed to form in the absence cf serum, these complexes can be added into tissue culture media containing low concentrations (5 to 15%) of serum without such inhibition. Note that in Figure 2 a dramatic increase in the functional delivery and expression of mRNA occurs in comparison,to Figure 1.
Moreover, cells transfected by the methodology represented in Figure 2 not only express the gene product more efficiently, but they also look visibly healthier under the microscope. Toxicity studies using trypan blue exclusion indicate that cells can withstand higher cationic lipid concentration in the presence of serum.
J
SUBSTITUTE SHEET
2p'~9814 B. Characteristics of the Lipid Formulation The critical formulation features for optimal activity were identified by comparing the effectiveness of 24 cationic lipid formulations in transfecting cells with messenger RNA
containing a luciferase message. Figure 3 shows results from transfections using Lipofectin~' (DOTMA:DOPE 50:50) showing cationic lipid dose-response and serum effects. aigher lipid concentrations are required for the maximum response in the presence of serum.
Since formulations containing increasing ~:antities of a neutral lipid appear to be increasingly less active, some alternative formulations, lacking the neutral p'.~.cspholipid component, were tested. Transfection fo ~,ulations were prepared both with and without a neutral phospholipid component according to the procedures of Examples ~, 3 and 9.
The cationic lipid DOTMA was corlbined in formula=ions either alone or combined with cholesterol and compared :pith similar formulations comprising the neutral lipid DOPE as indicated in the table of Example 18 below. The highest activity occurs in formulations lacking the phospholipid component, particularly in the presence of cholesterol. Figure 4 taken from the same set of transfections, indicates that tZe newly defined cationic lipid composition (DOTMA/DOPE/Cholesterol 70/0/30), containing no phospholipid, gives rise to much higher levels of mRNA expression (compare the scales on the y-axis of the two Figures 3 and 4) and that this reagent has similar activity in the presence and absence of serum.
Comparison of More Polar Species of CorresDOnd~nct Cationic Lipids The transfection effectiveness of a group of cationic lipids was evaluated under optimal transfection conditions determined as described; that is using lipid formulations in the ratio CL/cholesterol of 70/30 with no phospholipid component, and allowing the fist stage associaticn of lipid vesicles and mRNA to occur in the absence of ser~,::~. As in ~, ~ ~ s=~ W- -t-y ., v ~i~~~~E E ~ ~ L. ~~!tF"' 2~ 79814 the previous examples, tissue culture 3T3 mouse cells were transfected with RNA coding for the luciferase enzyme. The commercially available Rosenthal Inhibitor (RI), DL-2,3-distearoyloxypropyl(dimethyl)-8-hydroxyethylammoniumbromide (Sigma, St. Louis, M0.), was prepared as lipid vesicles according to Example 11 and was found to have very weak activity as a cationic lipid for use in transfections. T_he DPRI diester (dipalmitoyl), and DORI diester (dioleoyl) derivatives of RI were synthesized. We also synthesized (2,3-dipalmitoyl)-prop-1-yl-N,N,N-trimethylammonium (DPTMA)), an analogue of DOTMA, a cationic lipid known to be an effective agent. The synthesized lipids as well as DOT:~.A
itself,N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium were evaluated for their ability to transfect the tissue culture cells with luciferase RNA. Data are presented in Figure 5. The primary finding is that the hydroxyethyl moiety present at the hydrophilic site in the Rosenthal inhibitor increases the transfective effectiveness of cationic lipids as compared to corresponding cationic lipids lacking this group. Further, the representative cationic lipid of the invention, DORI, is a more effective transfective agent than DOTMA, even though it lacks the ether groups shown in previous examples, to confer super~cr transfective activity. It should be noted that DOTM.A, under the optimized transfective conditions of these experiments, has greatly enhanced transfective properties as compared to commercial Lipofectin~". Further, the superior transfective agent DORI is superior as a metabolizable, non-toxic transfective agent.
In summary, these studies indicate that effective transfection of cells using CLs requires selecting the most effective cationic lipid for the application, the optimal transfection formulation, and the use of an opti:~al transfection procedure.
The invention can be better understood by way cf ~he following examples which are representative of the preferred ~I ~RSTITUTE SHEET
_2p79814 embodiments thereof, but which are not to be construed as limiting the scope of the invention.
EXAMPLE 1: Synthesis of 1,2-0-dioleyl-3-dimethylamino propyl-B-hydroxyethylammonium acetate (DORI diether) Step (a): Oleylmethanesulfonate In a 500 ml three-necked flask equipped with a dropping funnel, 5.0 g (18.7 mmoles) of oleyl alcohol (Nu Check Prep, Elysian, MN 56028) was dissolved in 6.67 ml of dry pyridine and 100 ml of freshly distilled chloroform. The solution was chilled in an i'ce bath and 3.22 g (28.14 mmoles) of methanesulfonyl chloride (Nu Check Prep) dissolved in 50 ml of dry chloroform was added dropwise during one hour. The reaction mixture was allowed to stir for another 4 hours at room temperature. At the end of the reaction period, 30 ml of ice cold water and 50 ml of diethylether was added. The organic layer was washed twice with 50 ml of 0.5N cold HCL, followed by 50 ml of cold 0.5N sodium bicarbonate. Finally, 2 0 the organic phase was dried over anhydrous sodium sul f ate and evaporated under vacuum on a rotary evaporator. The product was dissolved in 45 ml of absolute ethanol and crystallized at -20° C. Pure long needles of oleylmethanesulfonate were obtained in 90% yield.
Step (b): 1,2-O-dioleyl-3-dimethylaminopropylglycerol Racemic 3-(dimethylamino)-1,2 propanediol (Aldrich Chemical, Milwaukee, Wisconsin), 1.5 g, 8.3 mmoles, and potassium hydroxide, 3.7g in 100 ml of freshly distilled dry benzene was refluxed for 2 hours in a 300 ml, three-necked, round bottom flask fitted with a Soxhlet apparatus containing molecular sieves. Oleyl methanesulfonate, 5.78 g, dissolved in 100 ml of dry benzene, was dropped slowly into the reaction mixture and refluxing was continued for another 4 hours. At the end of the reaction period, cold water and diethylether were added. The organic phase was washed with acid and bicarbonate successively as described above. The crude yellow product gave three spots on thin layer SUBSTfTUTE SHEET
chromatography on silica gel G plates, developed with chloroform/acetone/methanol/acetic acid/water, (50/15/5/5/2) by volume. The required compound was purified by silicic acid column chromatography as follows: Approximately 3.Og of the above material was loaded on the silica CC 7, 3ioRad (40.Og) column and sequentially eluted with chloroform (200 ml), chloroform/methanol 5%, (200 ml), 10% (250 :-:1) and finally with methanol (500 ml). The pure compound was eluted with 10% methanol fractions and gave an Rf value of 0..~5 when chromatographed on the silica gel G plates developed n the above system.
Step (c): 1,2-0-dioleyl-3-dimethylamino prc~_~1-3-hydroxyethylammonium acetate Racemic 1,2-0-dioleyl-3-dimethylaminopropylglycerol, 2.1 g, (3.4 mmol) and 4 ml of 2-bromoethanol (Aldrich Che.:~ical, Milwaukee, Wisconsin) in 18 ml of dimethylformamide was added in a 100 ml round bottom flask and stirred for 36h at ~5'C.
At the end of the reaction period, the mixture was concentrated under reduced pressure, and the produc;. was purified by passing through the silica gel colu.::n. The compound was dissolved in a small amount of chloroF~~:-.; and loaded on to 30 gms of silica gel 60, 70-270 mesh, pac::ed in a 1x18 column. The pure compound was eluted with o" o .:.etanol in chloroform and gave an Rf value of 0.21 on silica gel G
plates developed in the above system. Finally, the bromide salt was converted to acetate by passing the product through a Whatman DE-52 cellulose (acetate form) column. The product was obtained in 50/50 chloroform/methanol eluate. The compound was crystallized in acetonitrile at -20° C.
EXAMPLE 2: Synthesis of DL 1,2-0-dipalmityl-3-dimethylamino propyl-B-hydroxyethylammonium acetate (DPRI diether) This compound was synthesized by substituti;,g palmityl alcohol for oleyl alcohol in the above procedure.
S~!BSTIT~TE SHEET
EXAMPLE 3: Synthesis of DL-1,2-dioleoyl-3-dimethylaminopropyl-B-hydroxyethylammonium acetate (DORI diester) To 10 g. of oleoyl chloride in 21 ml of dry dimethylformamide were added 1.6 g of Rac-3-(dimethylamino)-1,2 propanediol and 5 ml of tributyl. The mixture was heated to 60-65°C for 48 hours. After the mixture was cooled to room temperature, 50 ml of freshly distilled diisopropylether was added and the mixture was heated to boiling. The reaction mixture was again cooled to room temperature and filtered.
Filtrate was evaporated under vacuum and the produc~ was crystallized with acetonitrile. The pure dioleovl-3-dimethylaminopropylglycerol was further subjec~ed. to quaternization by treatment with 2-bromoethanol in dimethylformamide as described in Example 1 above.
EXAMPLE 4: Synthesis of DL-1,2-dipal.~.,itcyl-3-dimethylaminopropyl-f3-hydroxyethylammonium (DPRI diester) This compound was synthesized by using pal:~itoyl chloride instead of oleoyl chloride in the above procedure.
EXAMPLE 5: Synthesis of DL-1,2-dioleoyl-3-propyl-trimethylammonium chloride (DOTAP).
To 2.0 g of 3-(dimethylamino)-1,2-propanediol, dissolved in 15 ml of freshly distilled chloroform and 10 ml of anhydrous pyridine, chilled to 4'C, was added dropwise 12.6 g of oleoylchloride, dissolved in 50 ml of chloroform, over a period of one hour. The reaction was allowed to stir overnight and then stopped by the addition of 5o ml of cold water and ether. The organic phase was washed twice with 0.5N
HCL and 0.5N sodium bicarbonate, and after drying over anhydrous sodium sulfate, evaporated under vacuum. The product was purified by silicic acid column chromatography as described in Example ~. T!:e pure compound was next quaternized with methyl chlorine as follows:
SUBSTI~ gHEET
2~798I4 500 mg of the pure compound was added into the protein hydrolysis tube and the methyl chloride (Aldrich Chemical, Milwaukee, Wisconsin) was condensed into the tube by repeated cooling of the tube in liquid nitrogen until filled with 5 ml S of methyl chloride. The tube was once again thawed, frozen and evacuated with oil pump to remove any residual air.
Finally, the tube was sealed and placed in the heated metal block maintained at 70'C for 72 hours. After the reaction period, the tube was cooled to 0'C and then opened to evaporate unreacted methyl chloride. The yellow wax was crystallized from acetonitrile at -20 C. Further purification of the compound was done on the silica gel 60 column. The pure compound was eluted with 200 ml or 10%
methanol in chloroform and gave an Rf value of .23 on a silica gel G plates, when developed in the above solvent system.
EXAMPLE 6: Synthesis of DL 1,2-dipalmitoyl-3-propyl-trimethylammonium chloride (DPTMA diester).
.
This compound was synthesized by using palmitoyl chloride instead of oleoyl chloride in the above procedure.
EXAMPLE 7: Synthesis of Mixed Acyl/Ether Derivatives The alkyl, acyl and mixture of acyl/alkyl derivatives with the same or different aliphatic carbon chain lengths of the above compounds can be synthesized by using known procedures of blocking the primary and or secondary alcohol of the starting materials.
For example, the 1-acyl, 2-alkyl analogue of the above compound was synthesized by benzylation of the primary hydroxyl group of 3-(dimethylamino)-1,2-propanediol (1.0) mol) with 0.9 mol of benzyl chloride to obtain a lvso compound which, on condensation with palmitic or oleic methansulfonate gave 1-O-alkyl, 2-O-benzyl-3-dimethylaminopropyl glycerol. Debenzylaticn followed by acylation of the resulting compound with palmitic acid SUBSTITUTE SHEET
_4g-chloride and quaternization under similar conditions as described above gave the required compound. The synthesis of alkyl/acyl analogues was achieved by two routes:
(a) 3-(dimethylamino)-1,2-propanediol (1.0 mol) was reacted with 0.7 mol of palmitic methanesulfonate to obtain 1-O-palmityl-2-lyso-3-dimethylaminopropyl glycerol. Acylation of the above lyso compound with oleic anhydride gave the alkyl/acyl derivative.
(b) The primary alcohol group of batyl alcohol (Serdary Research Laboratory) is protected with ts-C1 and NaI and the secondary hydroxyl group is then acylated with oleic anhydride to obtain alkyl/acyl iodohydrin derivative.
Further treatment of the iodohydrin derivative with di:aethyl amine gave the required product. These compounds are t!~.en quaternized by using the procedures described above.
EXAMPLE 8: 3,5-(N,N-di-lysyl)-diaminobenzoyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-!3-hydroxyethylamine) (DLYS-DABA-DPRI diester) Step 1: Di-t-Butyloxycarbonyl-3,5-di-aminobenzoic acid (Bis-Boc-DABA) A quantity of 3,5-Di-aminobenzoic acid (1.52 g; 10 ..~:ol), triethylamine (2.8 ml, 10 mmol) and di-t-butyl-di-carbonate (4.5 g; 22 mmol) (Aldrich Chemical Co, Milwaukee, WI), were dissolved in DMF (10 ml) and stirred for 24 hours at room temperature. The solvent was evaporated under vacuum and the product was chromatographed on silica gel using chloroform as eluent to obtain the title compound.
Step 2: Bis-Boc-DABA-DPRI diester Bis-Boc DABA (3.52 g, 10 mmol) and DPRI (10 mmol) were coupled following the procedure described in procedures 7.3 and 7.4 above.
Step 3: 3,5-(NN-Di-lysyl)-DABA-DPRI diester S~8STt1'tITE SH~e~
Compound #6 (2 mmol) was treated with TFA (10 ml) for 30 min at room temperature to remove the BOC protecting groups.
After evaporating the solvent, the product was reacted with Bis-Boc-lysine (5 mmol) using DCC as condensing agent. The product isolated after evaporating the solvent was de-protected using TFA and purified as described in 7.4 above.
EXAMPLE 9: 3,5-(N,N-di-lysyl)-diaminobenzoyl-glycyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-B-hydroxyethylamine) (DLYS-DABA-GLY-DPRI diester) Step 1: Di-t-Butyloxycarbonyl-3,5-di-aminobenzoic acid (Bis-Boc-DABA) As in Example 7 above.
Step 2: Boc-glycyl-DPRI diester:
Boc-glycine (1.75g, 10 mmol) and DPRI (10 mmcl) were coupled following the procedure described in Steps 3 and 4 of Example 8.
Step 3: Bis-Boc-DABA-glycyl-DPRI diester:
Bis-Boc-DABA (3.52 g, 10 mmol) of the compound from Step 2 above was treated with TFA (10 ml) doe 30 min. at room temperature to remove the Boc protecting group. TFA was evaporated and the product was coupled with Bis-Boc-DABS. °rcm Step 1 above as described in Example 8.
Step 4: 3,5-(NN-Di-lysyl)-DABA-glycyl-DPRI diester The compound from Step 3 above (2 mmol) was treated with TFA (10 ml) for 30 min. at room temperature to remove the BOC
protecting groups. After evaporating the solvent, the product was reacted with Bis-Boc-lysine (5 mmol) using DCC as condensing agent. The product isolated after evaporating the solvent was deprotected using TFA and purified as described in Step 4 of Example 8.
Various DORI derivatives corresponding to the DPRI
derivatives described in Examples 8 and 9 can be synthesized ~0 by substituting DORI in the coupling procedures.
SUBSTITUTE SHEEP
~o~9g14 EXAMPLE 10: Synthesis of L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-f3-hydroxyethylamine) (SPC-DPRI diester) L-5-carboxytetrabutyloxycarbonylspermine (tetra-BOC-Sper-COOH) (664 mg; 1 mmol) prepared according to published procedures (J.-P. Behr et. al. Proc. Natl. Acad. Sci USA, 86, pp 6982-6986, 1989) was coupled to DPRI (1 ., ol) as described in 8.3. The product was de-protected and purified l0 by chromatography to prepare SPC-DPRI diester.
EXAMPLE 11: PREPARAT~I~N OF LIPOSOME-FORMING DOTAP
The cationic liposome-forming material ' 2 bis oleo lox -3 trimeth lammonio ro ane DOTAP ma ''be ( Y Y) -( Y )P P ( ) Y
also prepared as reported by L. Stamatatos, et al.
Biochemistry 27:3917-3925 (1988) or H. Eibl et al., Biophysical Chemistry 10:261-271 (1979).
Briefly, Stamatatos et al. report that 1' ~.mol of 3-bromo-1,2-propanediol (Aldrich, Milwaukee, WI) was acylated for 48 hours at 20°C with 3 mmol of oleoyl chloride (freshly prepared from oleic acid and oxalyl chloride) in dry, alcohol-free diethyl ether (20 ml) containing S mmol of dry pyridine. The precipitate of pyridinium hydrcchlcride was filtered off, and the filtrate was concentrated under nitrogen and redissolved in 10 ml of hexane. The hexane solution was washed 3 times with an equal volume of 1:1 methanol/0.1 N aqueous HCOONa, pH 3.0, 3 times with 1:1 methanol/0.1 N aqueous NaOH, and 1 time with 1% aqueous NaCl.
The crude 3-bromo-1,2-bis-(oleoyloxy)propane was then stirred for 72 hours in a sealed tube with a solution of 15%
trimethylamine in dry dimethyl sulfoxide (30 ml) at 25°C.
The products of this reaction were dissolved in chlorofor~
(200 ml), which was repeatedly washed with 1:1 methanol/IOOmM
aqueous HCOONa, pH 3.0, and then evaporated in vacuo to yield a light yellow oil. The material was purified on a column cf silicic acid (Bio-Sil A, Bio-Rad Laboratories), eluting with SUBSTltUSE SHEET
-S, -a 0-15% gradient of methanol in chloroform to give the desired product in pure form at 9-10% methanol.
This purified product was a colorless, viscous oil that migrates with an R. of 0.4 on thin layer chromatography plates (Silica Gel G) that were developed with 50:15:5:5:2 CHC13/acetone/CH30H/CH3COOH/H.
EXAMPLE 12: LIPID VESICLE PREPARATION
Dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG) and dioleoylphosphatidylethanolamine (DOPE)-were purchased from Avanti Polar Lipids, (Pelham, Alabama). DOT:y'~. was synthesized according to U.S. Patent No. 4,897,355 to Epstein, D. et al. or Felgner, P.L. et al., PNAS 84: 7413-7417 (1987) and DOTAP was synthesized according to Example 10. DOPG/DOPC vesicles were prepared by drying 50 mg of DOPG
and 50 mg of DOPC under a stream of nitrogen gas into a sonication vial. The sample was. placed on a vacuum pump overnight and was hydrated the following day with deionized water to a concentration of 10 mg/ml total lipid. The sample was sonicated for 2 hours in the capped vial, using the cleat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting and the bath was circulated at 15°C. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles (MLV) or by extrusicn through nuclepore membranes to produce unilamellar vesicles of a discrete size. Other methods are also available and are known to those familiar with the art. DOTMA or DOTAP
vesicles were prepared in an exactly analogous manner.
EXAMPLE 13: POLYNUCLEOTIDE/CATIONIC LIPID COMPLEX FORI~.ATION
Polynucleotide complexes were prepared by mixing 0.5 ml of a 10 ug/ml polynucleotide solution with 0.5m1 of sonicated DOTMA/PE or DOTAP/PE liposomes at 40-100 ug/ml by slow suBSmutE sH~Er 20'~9~14 addition through a syringe with constant gentle vortexing.
The diluted polynucleotide and liposome solutions are prepared from concentrated stock solutions by dilutions into Opti-MEM Reduced Serum Media obtained from Gibco/BRL, Gaithersburg Maryland, at room temperature. This procedure results in positively charged complexes which will spontaneously deliver polynucleotide into cells in tissue culture. Different ratios of positively charged liposomes to polynucleotides cane.be used to suit the need. These methods _, are essentially as_'described in Felgner, P.L. et al., PNAS
,.~~>
84: 7413-7417 (1987), and Felgner, P. and M. Holm, Focus 11(2) Spring, 1989.
I5 EXAMPLE 14: TRANSFECTION PROTOCOLS
A: General Protocol:
Transfections of RNA according to Examples 15-19 were carried out as follows:
Plates (10 cm) of rapidly dividing adherent cells near confluency, or 1 x 10' suspension cells, were transfected as follows unless otherwise noted. Cells were washed once in Opti-MEM Reduced Serum Medium (Gibco) and then returned to the incubator covered in Opti-MEM. Aliquots (4 nl) of Opti-MEM Medium were placed in 12 x 75 mm polystyrene snap cap tubes, and 50 ug of Lipofectin Reagent were added. A mixture of capped mRNA and uncapped carrier RNA transcribed from EcoR
V-linearized pIBI31 (according to Malone, R. et al., Proc.
Nat'1 Acad. Sci. USA 86:6077-6081 (1989)) was then added to the media/lipid mixture to a total of 20 ug of RNA. The mixture was immediately vortexed. Cells were removed from the incubator, the medium removed, and the Opti-MEM/lipid/RNA
mixture added. Cells were then returned to the incubator for 8 h, unless otherwise noted, and harvested as described.
Murine fibroblasts (NIH 3T3, clone 2B) cells were maintained in Dulbecco's Modified Eagles Medium, (DMEM) + 10~
(v/v) calf serum (CS) prior to transfection.
SUBS'TITUT'E SHEET
B: 96-well microwell plate procedure:
The RNA transfection according to Example 20 and the DNA transfections according to Examples 20-23 were carried out in 96-well plates, as follows:
(1) The wells of a 96-well microtiter plate were seeded with 20,000 to 40,000 cells per well;
(2) Dilutions of cationic lipid preparations and polynucleotide preparations from stock solutions were carried out by 2-dimensional serial dilutions in two separate 96-well plates according to the scheme set form in the Table below entitled "Transfection Protocol in vitro";
(3) Corresponding dilutions of lipid and polynucleotide were mixed by transferring an equal volume of polynucleotide to a corresponding lipid microwell;
(4) The serum-containing media was evaporated from the wells containing the cells;
(5) A quantity of about 100 ~,1 of the cationic lipid/DNA complexes were added to cells in each well of the microtiter plate. Final dilutions and molar ratios of lipid and polynucleotide in each well are indicated in the Table below entitled "Mix Plate";
(6) The plates were incubated at 37°C (5~ COZ). At 4-24 hours post transfection, an aliquot of 10~ serum in Optimem~ was added to each well;
(7) At the end of the incubation, the assay media of the cells or a whole cell lysate was assayed for expression activity.
Tnlhere beta-galactoside was the reporter gene, the expression was monitored colorimetrically, using 2-nitrophenyl-~i-D-galactopyranoside (ONPG) or clorophenyl red-~i-D-galactopyranoside (CPRG) as a substrate, reading the plates with a microtiter reader at 405 nm.
-54a-Transfection Protocol in vitro Cationic Lipid Plate Cationic livid (nmolelnl° s!!) 2X serial dilation in eierotiter elate .
1 2 3 ~ 5 6 7 d A 672.1 336.07168.0483.9 41.97 21.06 10.6 5.Z3 B 672.1 336.07168.0 83.9 X1.97 21.06 10.16 5.23 C 672.1 336.07168.0483.9 X1.97 21.06 lO.i6 5.23 D 672.14 335.07168.0 83.9 X1.97 21.06 10.6 5.23 E 672.14 336.07168.Oa83.9 X1.97 21.06 10.16 5.23 F 672.1a 336.07168.0483.94 X1.97 21.06 10.6 5.23 G 672.14 336.07168.0483.9 41.97 21.06 10.46 5.23 H 672.14 336.07168.0 83.94 11.97 21.06 10.46 5.23 Polynucleoti de Plate Pohnueleotlde /mlwti)ZX serialdilution <nmole in eicrotiter vlste 1 2 3 ~ 5 6 7 8 A 2v2.42 2~2.~22~2.v22~2.~2 242.2 22.42 242.42 22.42 B 121.21 121.21121.21121.21 121.21 121.21121.21 121.21 C 60.61 60.E1 60.61 60.61 60.61 60.61 60.61 60.61 D 30.30 30.30 30.30 30.30 30.30 30.30 30.30 30.30 F 15.15 15.15 15.15 15.15 15.15 15.15 15.15 15.15 F 7.58 7.5E 7.58 7.58 7.58 7.58 7.58 7.58 G 3.79 3.79 3.79 3.79 3.79 3.79 3.79 3.79 H 1.B9 1.89 1.69 1.89 1.89 1.89 1.89 1.89 .
A
WO 91 / 16024 PC'1'/US91 /02691 -54b-2~. ~~~'/
Mix Plate (by tranferina ecrual volume of Polynucleotide to Lipid) +/- serum (by adding opti-mem or serum containing opti-mem) Final Concentrations of Cationic Lipid and Polynucleotide prior transfection: and their Molar Ratio 'Cationic molslel)?~
Lipid ( ssrisl dilation eolsaawrise 1 2 3 ~ 5 6 ~ 8 00 00 00 21.00 10.50 5.2s 2.63 1.32 (Lipid](ut'!) 158 8x x2 . . . 60.50 60.60 60.60 60.6060.60 tNAI(ur!) 60 60.60 60.60 . 1.39 0.69 0.35 0.17 0.09 0.0~ 0.02 L/N ratio 2.77 B 158.00 8x.00 42.00 21.00 10.50 5.25 2.63 1.32 tLipid)(u!'J) 30 30.30 30.30 30.30 30.30 30.30 30.3030.30 tNA1(u!!) . 2.77 1.39 0.69 0.35 0.17 0.09 0.0a L/N ratio 5. s5 C 158.00 81.00 x2.00 21.00 10.50 5.25 2.63 1.32 (Lipid](uM) 15.15 15.15 ls.l5 15.15 15.15 l5.ls l5.ls15.15 tNAI(~) 11.09 s.55 2.77 1.39 0.69 0.35 0.17 0.09 L/1i ratio D 158.00 8x.00 42.00 21.00 10. 5.25 2.63 1.32 (Lipid](uH) s0 7.s7 7.s7 7.s7 7.s7 7.s7 7.s7 7.s7 7.s7 t~](yt'!) 22.19 11.09 5. 2.77 1.39 0.69 0.35 0.17 L/N ratio s5 E 158.00 82.00 X2.00 21.00 10.50 5.25 2.63 1.32 tLipidl(uM) 3.79 3.79 3.79 3.75 3.79 3.79 3.79 3.79 tNA](uM) 0.33 22.19 11.09 ,.55 2.77 1.39 0.69 0.35 LJN ratio F 158.00 8.00 X2.00 21.00 10.50 5.25 2.63 1.32 (lipid]tuH) 1.90 1.90 1.90 1.90 1.90 1.90 1.90 1.90 INA)(u!'1) 88.x2 w .33 22.19 11.09 5.55 2.77 1.39 0.69 L/N ratio G 168.00 8a.00 x2.00 21.00 10.50 5.25 2.63 1.32 ILipid)(u!!) 95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 tNA](uH) . 88.12 aa.33 22.19 11.05 5.55 2.77 1.39 L/N ratio 176.8 H 168.00 8x.00 x2.00 21.00 10.50 5.25 2.63 1.32 ILipid)(uM) 0.48 0. a8 O.aB O.aB O.aB O.aB O.aB O.aB INA](u!!) 353.68 176.8a 8B. .33 22.19 11.09 5.55 2.77 L/N ratio a2 . Pol)mucleotide(tsnole/ml): 2X serialdil ave ro~wrise nucleotide l~1330;
Add Lipid/Polynucleotide ixture to late containing Cells M P
SUBSTITUTE SHEET
2 0 ~ 9 814 EXAMPLE 15 : DEMONSTRATION OF THE SERUM INHIBITORY EFFECT
Luciferase RNA expression was determined in 3T3 cells following cationic lipid mediated transfection, according to the procedure described in Example 14, in the presence of increasing concentrations of fetal bovine serum. The transfection formulation consisted of luciferase mRNA
(HYCLONE) in a lipid mixture comprising 80% DOTMA and 20%
DOPE. In carrying out the transfections, serum was added to both the cationic lipid solution and the RNA stock solutions prior to mixing the'lFipid and the RNA.
The data beltiw, plotted as Figure 1, shows the marked inhibitory effect of serum on transfection.
Percent Serum Luciferase Activity 5 71.1 10 47.0 15 35.6 20 29.9 Control 13.9 EXAMPLE 16: TWO-STAGE PROTOCOL TO OPPOSE THE SERUM
INHIBITORY EFFECT
In an experiment subsequent to that described in Exa.~.,ole 15, the procedure was identical except that DOTMA:DOPE 80:20 was mixed with the mRNA solution before the addition of serum. The data below and in Figure 2 show a marked transfection-enhancing effect at low serum concentrations.
Note the difference in y-axis scales in Figures 1 and 2.
Incubation Serum: None 5% 15% 20%
(minutes) suss~ru~. sHF~r 2~79~.~ ~
EXAMPL~ 17: OPTIMIZATION OF CATIONIC LIPID MEDIATED
TRANSFECTION
A total of 24 cationic lipid vesicle formulations were prepared using either DOTMA or DOTAP as the cationic lipid species (CL). The effect of charge density was evaluated by increasing the mole% of the cationic lipid species relative to a neutral phospholipid, either dioleoyl phosphatidyl ethanolamine (DOPE) or dioleoyl phosphatidyl choline (DOPC).
Each formulation was prepared with and without 33 mole%
cholesterol. Four different levels of lipid were tested: 50, 75, 100, and 125 ~cg; at a fixed RNA level of 20 ~g total, comprised of 5~g luciferase message and 15~:g ribosomal RNA.
The levels of expression, including the peak level at the optimum lipid concentration, are listed below and plotted in Figure 3.
Luciferase light units Molepercent CL-CL + phospholiDid 20% 500 80~
DOTAP ' 1 536 1066 DOTMA:Cholesterol 7:3 127 1102 1568 DOTAP:Cholesterol 7:3 2 77 784 DOTMA:Cholesterol 7:3 48 522 501 DOTAP:Cholesterol 7:3 0 88 256 These data identify several critical formulation issues 3o that are important for optimal activity:
(1) The inclusion of neutral phospholipids in CL vesicle formulations reduce functional activity and expression of mRNA.
(2) DOPC has a greater inhibitory effect than DOPE.
(3) DOTMA (a diether compound) is more active than DOTAP
(the corresponding diester compound).
(4) Cholesterol does not have a dramatic inhibitory effect in these formulations.
~~~~ ntlAr EXAMPLE 18: EFFECTIVENESS OF TRANSFECTION FORMULATIONS
LACKING NEUTRAL PHOSPHOLIPIDS
Since the data of Example 17 indicated that formulations containing increasing quantities of a neutral phospholipid (DOPE or DOPC) are increasingly less active, some alternative formulations lacking the neutral phospholipid component were tested. Four different.levels of Lipid were tested: 50, 75, 100, and 125 ~cg; at a fixed RNA level of 20 ug total, comprised of 5~g luciferase message and l5ug ribosomal RNA.
The levels of expression, including the peak level at the optimum lipid concentration, are listed below and plotted in Figure 4.
The data indicates that formulations consisting of either 100 mole% DOTMA or 70 mole% DOTMA and 30 mole% cholesterol give rise to the highest activity in the absence of serum. Data below indicate that the best activity in the presence of serum occurs with the formulations containing cholesterol.
For example, the replacement of 30% of the DOTMA in 100/0/0 by cholesterol in the formulation 70/0/30 demonstrates marked enhancement of activity due to the presence of cholesterol.
Formulation Total Luciferase Light Units DOTMA/PL/CHOL Lipid(uQ) 10% Serum Oct~-MFri so/5o/o so 1217 56a 75 1309 1~6 100 1047 g6 100 1491 ?:~0 125 1421 .60 S~O.QTh'I !TC QLIGt'~
. 20~981~
100 323 7g4 EXAMPLE 19: STRUCTURE-TRANSFECTION ACTIVITY OF
CATIONIC LIPIDS
To compare the effect of various structural modifications on the transfection activity demonstrated by cationic lipids, formulations containing DOTMA, DPTMA, DPRI
diester and DORI diester were prepared as described in the preceding examples and used in the transfection cf tissue culture cells with RNA coding for the luciferase enzyme as described in Example 14A. DOTMA is the cationic libid found in Lipofectin~'. However, in this experiment, all lipid formulations were prepared with 70 moleo cationic lipid and 30 moles cholesterol, a ratio which is shown to make the DOTMA formulation used herein 3-4 fold more active than the Lipofectin~' reagent (See Example 17 and Figure .~). A range of lipid from 0. 012 to 0. 300ug were used to transfect a f i xed amount of RNA, comprising 5~cg luciferase message and l5ug ribosomal RNA. The results are indicated in the data below and also in Figure 5.
uM Lipid DORI DOTMA DPRI DpmM.A
0.012 30 26 54 16 0.025 62 91 284 17 0.050 248 554 467 24 0.075 640 1555 404 36 0.100 1541 3901 160 53 0.125 2933 4662 272 65 0.150 5906 6368 413 11.~
0.175 9216 6772 899 145 0.200 12115 6757 1959 190 0.225 11705 6491 2124 210 0.250 10230 6572 2329 209 0.275 9885 5616 2339 336 0.300 7947 3651 1995 SUBSTITUTE SHEET
y The relative activities of the analogues is shown to be DORI>DOTMA>DPRI>DPTMA. The commercially available Rosenthal Inhibitor (RI) was tested and found to have very weak activity (data not shown); however, the dipalmitoyl derivative (DPRI diester) was several times more active than the corresponding dipalmitoyl derivative of DOTMA (DPTMA).
It was for this reason the dioleoyl derivative of the Rosenthal inhibitor was synthesized, and it was found to be more active than DOTMA. Based on this analysis, quaternization of the DOTMA derivatives with the hydroxyethyl moiety present in RI ,will further improve the activity of the cationic lipids.
The structure activity relationships indicated by this data are:
(1) Ether>Est~r aliphatic group linkages (2) Unsaturated>Saturated aliphatic groups (3) Hydroxyethyl>Methyl quaternizing groups These data indicate that cationic lipids can be made that differ substantially with .respect to transfection activity and that some analogs are more active than DOTMA.
Note particularly that the DOTMA formulation here and shown on Figure 5 is much more active than the commercial Lipofectin~' standard.
EXAMPLE 20: Effect of Lyso Lipids in Increasing the Effectiveness of Transfection Formulations The in vitro transfection efficiency of lipid formulations containing lysophosphatidylcholine (1-oleoyl lysophosphatidylcholine) in DOTMA/DOPE (Lipofectin~' ) was evaluated by the gene expression of beta-galactosidase from pSV2-lac2 plasmid in COS.7 cells.
Transfection Protocol:
A population of 20,000 cells was transfected in microwell plate wells using the cruantities of lipid and DNA indicated in Example 14A and in the absence of serum.
SUBSTITUTE SHEET
W
DNA (B-galactosidase; pSV2LacZ) and transfection lipid formulations of Lipofectin~' and Lipofectin~" and lysophosphatidylcholine were prepared as serial dilutions from stock solutions (DNA: 160 ~cg/ml; Lipids: 0.747 rlM) in S Optimem~' in 96-well plates, and the corresponding dilutions mixed together. A quantity of 100 ml of the DNA-lipid mixture was added to each microtiter well containing about 20,000 COS.7 cells aspirated free of fluid. The plate was incubated at 37'C (5% C02) for 4 hours, at which time 50 ml of 30 % bovine serum in OptimemT" was added to each well to yield a serum concentration of 10%. After an additional 24 hours of incubation at 37°C, a volume of 100 ml of loo bovine calf serum in Optimem~' was added to each well and the incubation continued for another 24 hours at 37°C. After :~3 hours, the transfection reagent was aspirated and 50,1 of lysis buffer (0.1% triton-X100 in 250 mM Tris, pH 8) was added to each well. The plate was frozen at -70' C and subj ected to 3 freeze-thaw cycles between -70 ° C and room temperature. A quantity of 50.1 of PBS (containing 0.5%
BSA) was added to each well, followed by an addition of 150u1 of a f3-galactosidase substrate ONPG at a concentration of 2 mg/ml. Absorbance at 405nm was read from a standard curve.
To compare the effect of various structural modifications on the transfection activity demonstrated by cationic lipids, formulations containing DOTMA, DPTMA, DPRI diester and DORI
diester were prepared as described in the preceding examples and used in the transfection of tissue culture cells with RNA
coding for the luciferase enzyme as described in Example 14A.
DOTMA is the cationic lipid found in Lipofectin'~. The following four formulations were tested:
Composition Molar Ratios DOTMA/DOPE/LysoPC 5/5/0 (1/1/0) DOTMA/DOPE/LysoPC 5/5/1.25 (1/1/.25) DOTMA/DOPE/LysoPC 5/5/2.5 (1/1/.5) DOTMA/DOPE/ LysoPC 5/5/5 (1/1/1) SUBSTITUTE SHEET
RESULTS:
Experimental results are summarized in the following tables. Data represent pg expression of B-galactosidase.
DOTHA/DOPE/LysoPC 1/1/0 (5/5/0) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 -56.9 211.7 778.7 1171.9 1098.6 667.2 433.8 255.4 3030 -63.3 32.9 351:.1 1390.6 1175.7 776.1 386.3 167.2 1515 -67.1 -49.3 6,T9.4 734.6 1265.1 738.0 346.9 168.1 758 -66.2 -49.7 ,23.0 519.4 437.6 635.5 352.8 130.8 379 -73.0 -52.2 -45.9 265.6 163.0 300.7 316.4 140.6 189 -75.6 -49.7 -57.8 133.3 58.3 177.8 252.0 174.4 95 -76.0 -73.4 -57.3 18.5 30.0 68.1 97.3 152.0 47 -72.6 -69.2 -54.4 -20.9 8.8 27.0 68.1 81.
DOTMA/DOPE/Lyso PC 1/1/0.25 (5/5/1.25) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 -111.7 -22.4 1039.5 1678.2 1801.4 1202.0 445.7 160.0 3030 -122.9 -66.9 244.0 1602.5 2101.1 1658.6 493.3 611.0 1515 -134.1 -122.9 129.2 787.4 1801.4 1563.3 711.8 571.7 758 -128.5 -111.7 -103.3 529.7 809.8 1588.5 793.0 468.1 379 -122.9 -125.7 -117.3 230.0 440.1 611.0 711.8 196.4 189 -142.5 -145.4 -131.3 89.9 188.0 213.2 314.0 120.8 95 -125.7 -153.8 -128.5 -47.3 78.7 426.1 179.6 126.4 47.4 -139.7 -145.4 -103.3 -64.1 358.9 123.6 78.7 89.9 DOTMA/DOPE/Lyso PC 1/1/0.5 (5/5/2.5) Cationic (pmole) lipid DNA<pmole)16800 8400 4200 2100 1050 525 262.5 131 6060 -10.2 53.4 446.6 237.4 355.8 765.0 593.0 269.0 3030 -53.8 4.6 211.0 1025.8 374.6 613.4 394.6 273.4 1515 -58.2 -36.2 281.8 772.2 877.0 672.6 679.8 282.2 758 -65.4 -55.4 121.8 505.0 728.2 1284.2 667.8 371.0 379 -68.2 -71.8 32.2 320.2 185.4 544.2 1002.2 325.0 189 -69.0 -73.0 -23.0 179.0 228.2 221.8 375.4 284.2 95 -71.0 -73.0 -42.6 68.6 45.4 157.3 219.4 84.6 47.4 -70.6 -70.6 -21.4 33.0 69.4 41.8 75.8 75.8 w v o Mrrt 1TG t N~
20'9814 DOTHA/DOPE/LysoPC 1/1/1 (5/5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 55.6 190.0 381.7 156.0 64.7 9.0 95.5 152.1 3030 -47.2 98.7 341.4 752.8 114.9 67.5 250.9187.2 1515 -59.4 44.9 267.9 652.8 468.3 50.5 115.3170.2 758 -65.7 -30.9 199.9 537.8 765.5 169.8 130.3208.6 1'~9 -62.6 -39.6 110.2 466.7 275.0 544.5 219.6271.0 189 -72.8 -51.1 19.2 306.2 199.5 352.1 483.3273.0 95 -74.0 -65.7 -13.6 123.6 168.7 166.3 158.4218.1 47.4 -75.2 -57.8 -32.1 77:0 95.1 69.4 155.2143.4 Inclusion of Lyso PC (monooleoyl PC) in DOTMA/DOPE
enhances the transfection efficiency when the molar ratio is appropriate.
40 DOTMA/DOPE/lyso pc at 1/1/0.25 (or 5/5/1.25) appears to be optimal. -Detailed transfection efficiency of each cationic lipid formulation is shown in the 3 dimensional plots of Figure 6a 45 6d.
EXAMPLE 21: COMPARATIVE TRANSFECTION EFFICIENCY OF CATIONIC
SO LIPID ANALOGS
Cationic lipid formulations comprising DOTMA/DOPE 5/S, DORI/DOPE 5/5, and DORIE/DOPE 5/5 were used to transfect COS.7 cells at a density of 40,000 cells per well according to the procedure of Example 14B. As indicated Figure and 55 in the Table below, DORI and DORIE analogs show superior transfection activity compared to DOTMA. No significant difference in effectiveness was seen between cationic lipid having ester linkages and ether linkages (DORI compared to DORIE). However, the hydroxyethyl moiety linked to the 60 nitrogen of quaternary ammonium (DORI and DORIE) appears to improve activity as compared to the methyl group of DOTM.A.
c~~ ~ee~r~~ ~~ cup WO 9l / 16024 PCT/US91 /02691 2p'~9$14 DOTHA/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 -200.0 326.1 1764.1 1450.3 571.2 375.2 22.2 -20.3 3030 -291.5 -332.7 1012.4 744.4 509.2 139.9 28.8 -23.5 1515 -304.6 48.4 702.0 398.0 499.3 215.0 58.2 48.4 758 -275.2 -186.9 577.8 385.0 293.5 110.5 45.1 28.8 379 -317.6 -262.1 120.3 221.6 286.9 123.5 45.1 45.1 189 -324.2 -294.8 28.8 179.1 139.9 -66.0 68.0 19.0 95 -327.5 -298.0 -141.2 205.2 130.1 136.6 19.0 -0.7 47.4 -311.1 -324.2 -26.8 126.8 -26.8 126.8 -13.7 28.8 ' ~ORI/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 1321.4 1289.1 2111.7 1611.7 906.0 466.5 285.1 87.5 3030 853.6 1289.1 1958.5 1559.3 1079.4 502.8 321.4 293.1 1515 906.0 1781.0 1773.0 1724.6 680.2 252.8 184.3 139.9 758 563.3 708.5 833.5 1281.0 700.4 418.1 248.8 220.6 379 410.1 942.3 139.9 329.4 635.9 256.9 309.3 297.2 189 -190.7 510.9 180.2 139.9 277.0 87.5 111.7 14.9 95 -198.8 -37.5 107.7 91.5 63.3 252.8 14.9 152.0 47.4 -279.4 -33.5 144.0 35.1 35.1 107.7 87.5 27.0 DORIE/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 -67.3 1134.1 2040.3 1682.7 1352.8 415.3 92.4 290.3 3030 -209.7 1349.4 1752.2 1856.3 981.3 380.6 148.0 61.2 1515 -174.9 293.8 1904.9 2123.7 1321.6 387.6 328.5 106.3 758 -178.4 151.5 700.1 1175.8 1526.5 516.0 120.2 68.1 379 -174.9 -60.3 179.2 196.6 453.5 339.0 193.1 -15.2 189 -265.2 -147.2 -39.5 -29.1 325.1 134.1 50.8 -4.8 95 -147.2 -105.5 -112.4 144.5 -4.8 266.0 71.6 -46.5 47.4 -109.0 -251.3 -49.9 245.2 -60.3 -46.5 -63.8 -29.1 SUBSTITUTE SHEET
20 EXAMPLE 22: EFFECT OF NEUTRAL LIPIDS IN THE TRANSFECTION
FORMULATION ON EFFICIENCY OF TRANSFECTION
A. Neutral Phospholipid Increasing concentrations of dioleoylphosphatidyl ethanolamine (DOPE) were added to DORI and the lipid 25 formulation used to transfect COS.7 cells at a density of 20,000 cells/well with pSV2-lacZ according to the procedure of Example 14B. The formulation were evaluated for their comparative transfective efficiency by the expression of Q
galactosidase activity as indicated in Figure o and the 30 Tables below:
DORI/DOPE (10/0) Cationic lipid (pmole) DNA(pcaole) 16800 8400 4200 2100 1050 525 262.5 131 6060 240.8 496.5 905.5 558.7 197.4 80.3 35.5 22.5 3030 -45.4 600.6 1389.6 954.6 239.3 133.8 44.2 22.5 1515 -109.0 232.1 947.4 888.2 253.8 19.7 39.9 50.0 758 -123.4 -85.8 376.6 229.2 323.1 112.1 156.9 24.0 379 -101.7 -81.5 44.2 96.2 219.1 130.9 38.4 31.2 189 -126.3 -94.5 -6.4 45.7 139.6 133.8 29.8 31.2 95 -100.3 -101.7 -55.5 73.1 52.9 44.2 6.6 6.6 47 -113.3 -114.7 -15.0 -38.2 15.3 -4.9 -6.4 5.2 SUBSTITUTE SHEET
20'9$14 DORI/DOPE (8/2) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 51.2 202.8 216.0 144.8 84.7 77.4 66.1 39.9 3030 107.3 287.1 88.6 81.1 107.3 53.0 49.3 47.4 1515 30.6 429.4 139.2 109.2 39.9 62.4 45.5 77.4 758 51.2 408.8 245.9 313.3 105.5 60.5 30.6 47.4 379 79.3 180.4 171.0w" 195.4 75.5 215.1 86.7 64.3 189 28.7 3.1 36.2 182.2 64.3 38.1 75.5 103.6 95 -46.2 -20.0 0:6 30.6 -29.4 21.2 51.2 6.2 47 13.7 24.9 -38.7 30.6 -16.3 -25.6 34.3 -3.I
DORI/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 341.5 876.6 1095.7 1543.8 1470.2 854.8 518.7 234.4 .
3030 -63.2 640.8 819.7 1497.0 1640.8 908.4 490.3 425.1 1515 -105.0 378.3 1075.6 1890.0 1189.3 741 505 232 758 -111.7 112.4 572.2 1478.6 1515.4 . . .
637.5 591.0 247.8 379 -110.0 -3.0 336.5 766.2 744.5 998.7 667.6 239.5 189 -106.7 -41.5 134.1 366.6 293.0 384.9 369.9 192.6 95 -105.0 -63.2 42.1 155.9 130.8 219.4 289.6 276.3 47 -110.0 -13.0 -11.4 150.8 77.3 122.4 67.2 35.5 SUBSTITUTE SHEET
DORI/DOPE (2/8) Cationic lipid (pmole) DNA<pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 235.3 1102.5 1307.2 742.2 566.6 166.3 31.8 52 3030 -63.0 788.7 1821.5 1274.9 623.2 145.6 68.0 .
1515 -107.8 18.0 1078.4 1407.7 749.1 190.4 88.7 .
758 -125.1 -94.0 206.0 737.0 680.1 206.0 95.6 .
379 -123.3 -83.7 68.0 497.3 245.6 193.9 66.3 .
189 -125.1 -95.8 -61.3 247.3 169.8 130.1 95.6 .
Tnlhere beta-galactoside was the reporter gene, the expression was monitored colorimetrically, using 2-nitrophenyl-~i-D-galactopyranoside (ONPG) or clorophenyl red-~i-D-galactopyranoside (CPRG) as a substrate, reading the plates with a microtiter reader at 405 nm.
-54a-Transfection Protocol in vitro Cationic Lipid Plate Cationic livid (nmolelnl° s!!) 2X serial dilation in eierotiter elate .
1 2 3 ~ 5 6 7 d A 672.1 336.07168.0483.9 41.97 21.06 10.6 5.Z3 B 672.1 336.07168.0 83.9 X1.97 21.06 10.16 5.23 C 672.1 336.07168.0483.9 X1.97 21.06 lO.i6 5.23 D 672.14 335.07168.0 83.9 X1.97 21.06 10.6 5.23 E 672.14 336.07168.Oa83.9 X1.97 21.06 10.16 5.23 F 672.1a 336.07168.0483.94 X1.97 21.06 10.6 5.23 G 672.14 336.07168.0483.9 41.97 21.06 10.46 5.23 H 672.14 336.07168.0 83.94 11.97 21.06 10.46 5.23 Polynucleoti de Plate Pohnueleotlde /mlwti)ZX serialdilution <nmole in eicrotiter vlste 1 2 3 ~ 5 6 7 8 A 2v2.42 2~2.~22~2.v22~2.~2 242.2 22.42 242.42 22.42 B 121.21 121.21121.21121.21 121.21 121.21121.21 121.21 C 60.61 60.E1 60.61 60.61 60.61 60.61 60.61 60.61 D 30.30 30.30 30.30 30.30 30.30 30.30 30.30 30.30 F 15.15 15.15 15.15 15.15 15.15 15.15 15.15 15.15 F 7.58 7.5E 7.58 7.58 7.58 7.58 7.58 7.58 G 3.79 3.79 3.79 3.79 3.79 3.79 3.79 3.79 H 1.B9 1.89 1.69 1.89 1.89 1.89 1.89 1.89 .
A
WO 91 / 16024 PC'1'/US91 /02691 -54b-2~. ~~~'/
Mix Plate (by tranferina ecrual volume of Polynucleotide to Lipid) +/- serum (by adding opti-mem or serum containing opti-mem) Final Concentrations of Cationic Lipid and Polynucleotide prior transfection: and their Molar Ratio 'Cationic molslel)?~
Lipid ( ssrisl dilation eolsaawrise 1 2 3 ~ 5 6 ~ 8 00 00 00 21.00 10.50 5.2s 2.63 1.32 (Lipid](ut'!) 158 8x x2 . . . 60.50 60.60 60.60 60.6060.60 tNAI(ur!) 60 60.60 60.60 . 1.39 0.69 0.35 0.17 0.09 0.0~ 0.02 L/N ratio 2.77 B 158.00 8x.00 42.00 21.00 10.50 5.25 2.63 1.32 tLipid)(u!'J) 30 30.30 30.30 30.30 30.30 30.30 30.3030.30 tNA1(u!!) . 2.77 1.39 0.69 0.35 0.17 0.09 0.0a L/N ratio 5. s5 C 158.00 81.00 x2.00 21.00 10.50 5.25 2.63 1.32 (Lipid](uM) 15.15 15.15 ls.l5 15.15 15.15 l5.ls l5.ls15.15 tNAI(~) 11.09 s.55 2.77 1.39 0.69 0.35 0.17 0.09 L/1i ratio D 158.00 8x.00 42.00 21.00 10. 5.25 2.63 1.32 (Lipid](uH) s0 7.s7 7.s7 7.s7 7.s7 7.s7 7.s7 7.s7 7.s7 t~](yt'!) 22.19 11.09 5. 2.77 1.39 0.69 0.35 0.17 L/N ratio s5 E 158.00 82.00 X2.00 21.00 10.50 5.25 2.63 1.32 tLipidl(uM) 3.79 3.79 3.79 3.75 3.79 3.79 3.79 3.79 tNA](uM) 0.33 22.19 11.09 ,.55 2.77 1.39 0.69 0.35 LJN ratio F 158.00 8.00 X2.00 21.00 10.50 5.25 2.63 1.32 (lipid]tuH) 1.90 1.90 1.90 1.90 1.90 1.90 1.90 1.90 INA)(u!'1) 88.x2 w .33 22.19 11.09 5.55 2.77 1.39 0.69 L/N ratio G 168.00 8a.00 x2.00 21.00 10.50 5.25 2.63 1.32 ILipid)(u!!) 95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 tNA](uH) . 88.12 aa.33 22.19 11.05 5.55 2.77 1.39 L/N ratio 176.8 H 168.00 8x.00 x2.00 21.00 10.50 5.25 2.63 1.32 ILipid)(uM) 0.48 0. a8 O.aB O.aB O.aB O.aB O.aB O.aB INA](u!!) 353.68 176.8a 8B. .33 22.19 11.09 5.55 2.77 L/N ratio a2 . Pol)mucleotide(tsnole/ml): 2X serialdil ave ro~wrise nucleotide l~1330;
Add Lipid/Polynucleotide ixture to late containing Cells M P
SUBSTITUTE SHEET
2 0 ~ 9 814 EXAMPLE 15 : DEMONSTRATION OF THE SERUM INHIBITORY EFFECT
Luciferase RNA expression was determined in 3T3 cells following cationic lipid mediated transfection, according to the procedure described in Example 14, in the presence of increasing concentrations of fetal bovine serum. The transfection formulation consisted of luciferase mRNA
(HYCLONE) in a lipid mixture comprising 80% DOTMA and 20%
DOPE. In carrying out the transfections, serum was added to both the cationic lipid solution and the RNA stock solutions prior to mixing the'lFipid and the RNA.
The data beltiw, plotted as Figure 1, shows the marked inhibitory effect of serum on transfection.
Percent Serum Luciferase Activity 5 71.1 10 47.0 15 35.6 20 29.9 Control 13.9 EXAMPLE 16: TWO-STAGE PROTOCOL TO OPPOSE THE SERUM
INHIBITORY EFFECT
In an experiment subsequent to that described in Exa.~.,ole 15, the procedure was identical except that DOTMA:DOPE 80:20 was mixed with the mRNA solution before the addition of serum. The data below and in Figure 2 show a marked transfection-enhancing effect at low serum concentrations.
Note the difference in y-axis scales in Figures 1 and 2.
Incubation Serum: None 5% 15% 20%
(minutes) suss~ru~. sHF~r 2~79~.~ ~
EXAMPL~ 17: OPTIMIZATION OF CATIONIC LIPID MEDIATED
TRANSFECTION
A total of 24 cationic lipid vesicle formulations were prepared using either DOTMA or DOTAP as the cationic lipid species (CL). The effect of charge density was evaluated by increasing the mole% of the cationic lipid species relative to a neutral phospholipid, either dioleoyl phosphatidyl ethanolamine (DOPE) or dioleoyl phosphatidyl choline (DOPC).
Each formulation was prepared with and without 33 mole%
cholesterol. Four different levels of lipid were tested: 50, 75, 100, and 125 ~cg; at a fixed RNA level of 20 ~g total, comprised of 5~g luciferase message and 15~:g ribosomal RNA.
The levels of expression, including the peak level at the optimum lipid concentration, are listed below and plotted in Figure 3.
Luciferase light units Molepercent CL-CL + phospholiDid 20% 500 80~
DOTAP ' 1 536 1066 DOTMA:Cholesterol 7:3 127 1102 1568 DOTAP:Cholesterol 7:3 2 77 784 DOTMA:Cholesterol 7:3 48 522 501 DOTAP:Cholesterol 7:3 0 88 256 These data identify several critical formulation issues 3o that are important for optimal activity:
(1) The inclusion of neutral phospholipids in CL vesicle formulations reduce functional activity and expression of mRNA.
(2) DOPC has a greater inhibitory effect than DOPE.
(3) DOTMA (a diether compound) is more active than DOTAP
(the corresponding diester compound).
(4) Cholesterol does not have a dramatic inhibitory effect in these formulations.
~~~~ ntlAr EXAMPLE 18: EFFECTIVENESS OF TRANSFECTION FORMULATIONS
LACKING NEUTRAL PHOSPHOLIPIDS
Since the data of Example 17 indicated that formulations containing increasing quantities of a neutral phospholipid (DOPE or DOPC) are increasingly less active, some alternative formulations lacking the neutral phospholipid component were tested. Four different.levels of Lipid were tested: 50, 75, 100, and 125 ~cg; at a fixed RNA level of 20 ug total, comprised of 5~g luciferase message and l5ug ribosomal RNA.
The levels of expression, including the peak level at the optimum lipid concentration, are listed below and plotted in Figure 4.
The data indicates that formulations consisting of either 100 mole% DOTMA or 70 mole% DOTMA and 30 mole% cholesterol give rise to the highest activity in the absence of serum. Data below indicate that the best activity in the presence of serum occurs with the formulations containing cholesterol.
For example, the replacement of 30% of the DOTMA in 100/0/0 by cholesterol in the formulation 70/0/30 demonstrates marked enhancement of activity due to the presence of cholesterol.
Formulation Total Luciferase Light Units DOTMA/PL/CHOL Lipid(uQ) 10% Serum Oct~-MFri so/5o/o so 1217 56a 75 1309 1~6 100 1047 g6 100 1491 ?:~0 125 1421 .60 S~O.QTh'I !TC QLIGt'~
. 20~981~
100 323 7g4 EXAMPLE 19: STRUCTURE-TRANSFECTION ACTIVITY OF
CATIONIC LIPIDS
To compare the effect of various structural modifications on the transfection activity demonstrated by cationic lipids, formulations containing DOTMA, DPTMA, DPRI
diester and DORI diester were prepared as described in the preceding examples and used in the transfection cf tissue culture cells with RNA coding for the luciferase enzyme as described in Example 14A. DOTMA is the cationic libid found in Lipofectin~'. However, in this experiment, all lipid formulations were prepared with 70 moleo cationic lipid and 30 moles cholesterol, a ratio which is shown to make the DOTMA formulation used herein 3-4 fold more active than the Lipofectin~' reagent (See Example 17 and Figure .~). A range of lipid from 0. 012 to 0. 300ug were used to transfect a f i xed amount of RNA, comprising 5~cg luciferase message and l5ug ribosomal RNA. The results are indicated in the data below and also in Figure 5.
uM Lipid DORI DOTMA DPRI DpmM.A
0.012 30 26 54 16 0.025 62 91 284 17 0.050 248 554 467 24 0.075 640 1555 404 36 0.100 1541 3901 160 53 0.125 2933 4662 272 65 0.150 5906 6368 413 11.~
0.175 9216 6772 899 145 0.200 12115 6757 1959 190 0.225 11705 6491 2124 210 0.250 10230 6572 2329 209 0.275 9885 5616 2339 336 0.300 7947 3651 1995 SUBSTITUTE SHEET
y The relative activities of the analogues is shown to be DORI>DOTMA>DPRI>DPTMA. The commercially available Rosenthal Inhibitor (RI) was tested and found to have very weak activity (data not shown); however, the dipalmitoyl derivative (DPRI diester) was several times more active than the corresponding dipalmitoyl derivative of DOTMA (DPTMA).
It was for this reason the dioleoyl derivative of the Rosenthal inhibitor was synthesized, and it was found to be more active than DOTMA. Based on this analysis, quaternization of the DOTMA derivatives with the hydroxyethyl moiety present in RI ,will further improve the activity of the cationic lipids.
The structure activity relationships indicated by this data are:
(1) Ether>Est~r aliphatic group linkages (2) Unsaturated>Saturated aliphatic groups (3) Hydroxyethyl>Methyl quaternizing groups These data indicate that cationic lipids can be made that differ substantially with .respect to transfection activity and that some analogs are more active than DOTMA.
Note particularly that the DOTMA formulation here and shown on Figure 5 is much more active than the commercial Lipofectin~' standard.
EXAMPLE 20: Effect of Lyso Lipids in Increasing the Effectiveness of Transfection Formulations The in vitro transfection efficiency of lipid formulations containing lysophosphatidylcholine (1-oleoyl lysophosphatidylcholine) in DOTMA/DOPE (Lipofectin~' ) was evaluated by the gene expression of beta-galactosidase from pSV2-lac2 plasmid in COS.7 cells.
Transfection Protocol:
A population of 20,000 cells was transfected in microwell plate wells using the cruantities of lipid and DNA indicated in Example 14A and in the absence of serum.
SUBSTITUTE SHEET
W
DNA (B-galactosidase; pSV2LacZ) and transfection lipid formulations of Lipofectin~' and Lipofectin~" and lysophosphatidylcholine were prepared as serial dilutions from stock solutions (DNA: 160 ~cg/ml; Lipids: 0.747 rlM) in S Optimem~' in 96-well plates, and the corresponding dilutions mixed together. A quantity of 100 ml of the DNA-lipid mixture was added to each microtiter well containing about 20,000 COS.7 cells aspirated free of fluid. The plate was incubated at 37'C (5% C02) for 4 hours, at which time 50 ml of 30 % bovine serum in OptimemT" was added to each well to yield a serum concentration of 10%. After an additional 24 hours of incubation at 37°C, a volume of 100 ml of loo bovine calf serum in Optimem~' was added to each well and the incubation continued for another 24 hours at 37°C. After :~3 hours, the transfection reagent was aspirated and 50,1 of lysis buffer (0.1% triton-X100 in 250 mM Tris, pH 8) was added to each well. The plate was frozen at -70' C and subj ected to 3 freeze-thaw cycles between -70 ° C and room temperature. A quantity of 50.1 of PBS (containing 0.5%
BSA) was added to each well, followed by an addition of 150u1 of a f3-galactosidase substrate ONPG at a concentration of 2 mg/ml. Absorbance at 405nm was read from a standard curve.
To compare the effect of various structural modifications on the transfection activity demonstrated by cationic lipids, formulations containing DOTMA, DPTMA, DPRI diester and DORI
diester were prepared as described in the preceding examples and used in the transfection of tissue culture cells with RNA
coding for the luciferase enzyme as described in Example 14A.
DOTMA is the cationic lipid found in Lipofectin'~. The following four formulations were tested:
Composition Molar Ratios DOTMA/DOPE/LysoPC 5/5/0 (1/1/0) DOTMA/DOPE/LysoPC 5/5/1.25 (1/1/.25) DOTMA/DOPE/LysoPC 5/5/2.5 (1/1/.5) DOTMA/DOPE/ LysoPC 5/5/5 (1/1/1) SUBSTITUTE SHEET
RESULTS:
Experimental results are summarized in the following tables. Data represent pg expression of B-galactosidase.
DOTHA/DOPE/LysoPC 1/1/0 (5/5/0) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 -56.9 211.7 778.7 1171.9 1098.6 667.2 433.8 255.4 3030 -63.3 32.9 351:.1 1390.6 1175.7 776.1 386.3 167.2 1515 -67.1 -49.3 6,T9.4 734.6 1265.1 738.0 346.9 168.1 758 -66.2 -49.7 ,23.0 519.4 437.6 635.5 352.8 130.8 379 -73.0 -52.2 -45.9 265.6 163.0 300.7 316.4 140.6 189 -75.6 -49.7 -57.8 133.3 58.3 177.8 252.0 174.4 95 -76.0 -73.4 -57.3 18.5 30.0 68.1 97.3 152.0 47 -72.6 -69.2 -54.4 -20.9 8.8 27.0 68.1 81.
DOTMA/DOPE/Lyso PC 1/1/0.25 (5/5/1.25) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 -111.7 -22.4 1039.5 1678.2 1801.4 1202.0 445.7 160.0 3030 -122.9 -66.9 244.0 1602.5 2101.1 1658.6 493.3 611.0 1515 -134.1 -122.9 129.2 787.4 1801.4 1563.3 711.8 571.7 758 -128.5 -111.7 -103.3 529.7 809.8 1588.5 793.0 468.1 379 -122.9 -125.7 -117.3 230.0 440.1 611.0 711.8 196.4 189 -142.5 -145.4 -131.3 89.9 188.0 213.2 314.0 120.8 95 -125.7 -153.8 -128.5 -47.3 78.7 426.1 179.6 126.4 47.4 -139.7 -145.4 -103.3 -64.1 358.9 123.6 78.7 89.9 DOTMA/DOPE/Lyso PC 1/1/0.5 (5/5/2.5) Cationic (pmole) lipid DNA<pmole)16800 8400 4200 2100 1050 525 262.5 131 6060 -10.2 53.4 446.6 237.4 355.8 765.0 593.0 269.0 3030 -53.8 4.6 211.0 1025.8 374.6 613.4 394.6 273.4 1515 -58.2 -36.2 281.8 772.2 877.0 672.6 679.8 282.2 758 -65.4 -55.4 121.8 505.0 728.2 1284.2 667.8 371.0 379 -68.2 -71.8 32.2 320.2 185.4 544.2 1002.2 325.0 189 -69.0 -73.0 -23.0 179.0 228.2 221.8 375.4 284.2 95 -71.0 -73.0 -42.6 68.6 45.4 157.3 219.4 84.6 47.4 -70.6 -70.6 -21.4 33.0 69.4 41.8 75.8 75.8 w v o Mrrt 1TG t N~
20'9814 DOTHA/DOPE/LysoPC 1/1/1 (5/5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 55.6 190.0 381.7 156.0 64.7 9.0 95.5 152.1 3030 -47.2 98.7 341.4 752.8 114.9 67.5 250.9187.2 1515 -59.4 44.9 267.9 652.8 468.3 50.5 115.3170.2 758 -65.7 -30.9 199.9 537.8 765.5 169.8 130.3208.6 1'~9 -62.6 -39.6 110.2 466.7 275.0 544.5 219.6271.0 189 -72.8 -51.1 19.2 306.2 199.5 352.1 483.3273.0 95 -74.0 -65.7 -13.6 123.6 168.7 166.3 158.4218.1 47.4 -75.2 -57.8 -32.1 77:0 95.1 69.4 155.2143.4 Inclusion of Lyso PC (monooleoyl PC) in DOTMA/DOPE
enhances the transfection efficiency when the molar ratio is appropriate.
40 DOTMA/DOPE/lyso pc at 1/1/0.25 (or 5/5/1.25) appears to be optimal. -Detailed transfection efficiency of each cationic lipid formulation is shown in the 3 dimensional plots of Figure 6a 45 6d.
EXAMPLE 21: COMPARATIVE TRANSFECTION EFFICIENCY OF CATIONIC
SO LIPID ANALOGS
Cationic lipid formulations comprising DOTMA/DOPE 5/S, DORI/DOPE 5/5, and DORIE/DOPE 5/5 were used to transfect COS.7 cells at a density of 40,000 cells per well according to the procedure of Example 14B. As indicated Figure and 55 in the Table below, DORI and DORIE analogs show superior transfection activity compared to DOTMA. No significant difference in effectiveness was seen between cationic lipid having ester linkages and ether linkages (DORI compared to DORIE). However, the hydroxyethyl moiety linked to the 60 nitrogen of quaternary ammonium (DORI and DORIE) appears to improve activity as compared to the methyl group of DOTM.A.
c~~ ~ee~r~~ ~~ cup WO 9l / 16024 PCT/US91 /02691 2p'~9$14 DOTHA/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 -200.0 326.1 1764.1 1450.3 571.2 375.2 22.2 -20.3 3030 -291.5 -332.7 1012.4 744.4 509.2 139.9 28.8 -23.5 1515 -304.6 48.4 702.0 398.0 499.3 215.0 58.2 48.4 758 -275.2 -186.9 577.8 385.0 293.5 110.5 45.1 28.8 379 -317.6 -262.1 120.3 221.6 286.9 123.5 45.1 45.1 189 -324.2 -294.8 28.8 179.1 139.9 -66.0 68.0 19.0 95 -327.5 -298.0 -141.2 205.2 130.1 136.6 19.0 -0.7 47.4 -311.1 -324.2 -26.8 126.8 -26.8 126.8 -13.7 28.8 ' ~ORI/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 1321.4 1289.1 2111.7 1611.7 906.0 466.5 285.1 87.5 3030 853.6 1289.1 1958.5 1559.3 1079.4 502.8 321.4 293.1 1515 906.0 1781.0 1773.0 1724.6 680.2 252.8 184.3 139.9 758 563.3 708.5 833.5 1281.0 700.4 418.1 248.8 220.6 379 410.1 942.3 139.9 329.4 635.9 256.9 309.3 297.2 189 -190.7 510.9 180.2 139.9 277.0 87.5 111.7 14.9 95 -198.8 -37.5 107.7 91.5 63.3 252.8 14.9 152.0 47.4 -279.4 -33.5 144.0 35.1 35.1 107.7 87.5 27.0 DORIE/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 -67.3 1134.1 2040.3 1682.7 1352.8 415.3 92.4 290.3 3030 -209.7 1349.4 1752.2 1856.3 981.3 380.6 148.0 61.2 1515 -174.9 293.8 1904.9 2123.7 1321.6 387.6 328.5 106.3 758 -178.4 151.5 700.1 1175.8 1526.5 516.0 120.2 68.1 379 -174.9 -60.3 179.2 196.6 453.5 339.0 193.1 -15.2 189 -265.2 -147.2 -39.5 -29.1 325.1 134.1 50.8 -4.8 95 -147.2 -105.5 -112.4 144.5 -4.8 266.0 71.6 -46.5 47.4 -109.0 -251.3 -49.9 245.2 -60.3 -46.5 -63.8 -29.1 SUBSTITUTE SHEET
20 EXAMPLE 22: EFFECT OF NEUTRAL LIPIDS IN THE TRANSFECTION
FORMULATION ON EFFICIENCY OF TRANSFECTION
A. Neutral Phospholipid Increasing concentrations of dioleoylphosphatidyl ethanolamine (DOPE) were added to DORI and the lipid 25 formulation used to transfect COS.7 cells at a density of 20,000 cells/well with pSV2-lacZ according to the procedure of Example 14B. The formulation were evaluated for their comparative transfective efficiency by the expression of Q
galactosidase activity as indicated in Figure o and the 30 Tables below:
DORI/DOPE (10/0) Cationic lipid (pmole) DNA(pcaole) 16800 8400 4200 2100 1050 525 262.5 131 6060 240.8 496.5 905.5 558.7 197.4 80.3 35.5 22.5 3030 -45.4 600.6 1389.6 954.6 239.3 133.8 44.2 22.5 1515 -109.0 232.1 947.4 888.2 253.8 19.7 39.9 50.0 758 -123.4 -85.8 376.6 229.2 323.1 112.1 156.9 24.0 379 -101.7 -81.5 44.2 96.2 219.1 130.9 38.4 31.2 189 -126.3 -94.5 -6.4 45.7 139.6 133.8 29.8 31.2 95 -100.3 -101.7 -55.5 73.1 52.9 44.2 6.6 6.6 47 -113.3 -114.7 -15.0 -38.2 15.3 -4.9 -6.4 5.2 SUBSTITUTE SHEET
20'9$14 DORI/DOPE (8/2) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 51.2 202.8 216.0 144.8 84.7 77.4 66.1 39.9 3030 107.3 287.1 88.6 81.1 107.3 53.0 49.3 47.4 1515 30.6 429.4 139.2 109.2 39.9 62.4 45.5 77.4 758 51.2 408.8 245.9 313.3 105.5 60.5 30.6 47.4 379 79.3 180.4 171.0w" 195.4 75.5 215.1 86.7 64.3 189 28.7 3.1 36.2 182.2 64.3 38.1 75.5 103.6 95 -46.2 -20.0 0:6 30.6 -29.4 21.2 51.2 6.2 47 13.7 24.9 -38.7 30.6 -16.3 -25.6 34.3 -3.I
DORI/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 341.5 876.6 1095.7 1543.8 1470.2 854.8 518.7 234.4 .
3030 -63.2 640.8 819.7 1497.0 1640.8 908.4 490.3 425.1 1515 -105.0 378.3 1075.6 1890.0 1189.3 741 505 232 758 -111.7 112.4 572.2 1478.6 1515.4 . . .
637.5 591.0 247.8 379 -110.0 -3.0 336.5 766.2 744.5 998.7 667.6 239.5 189 -106.7 -41.5 134.1 366.6 293.0 384.9 369.9 192.6 95 -105.0 -63.2 42.1 155.9 130.8 219.4 289.6 276.3 47 -110.0 -13.0 -11.4 150.8 77.3 122.4 67.2 35.5 SUBSTITUTE SHEET
DORI/DOPE (2/8) Cationic lipid (pmole) DNA<pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 235.3 1102.5 1307.2 742.2 566.6 166.3 31.8 52 3030 -63.0 788.7 1821.5 1274.9 623.2 145.6 68.0 .
1515 -107.8 18.0 1078.4 1407.7 749.1 190.4 88.7 .
758 -125.1 -94.0 206.0 737.0 680.1 206.0 95.6 .
379 -123.3 -83.7 68.0 497.3 245.6 193.9 66.3 .
189 -125.1 -95.8 -61.3 247.3 169.8 130.1 95.6 .
95 -125.1 -118.2 -95.8 137.0 73.2 52.5 45.6 .
47 -128.5 -123.3 -82.0 -14.7 228.4 24.9 62.9 .
21.5 20 B: Cholesterol Cholesterol (CHOL) was added to DORI at a molar ratio of DORI/CHOL 7/3 and the lipid formulation used to transfect COS.7 cells at a density of 40,000 cells/well with pSV2-lacZ
according to the procedure of Example 14B. The same cells 25 were transfected using DORI/DOPE_for a comparative value.
The formulation were evaluated for their comparative transfective efficiency by the expression of p-galactosidase activity as indicated in Figure 9 and the Tables below:
SUBSTITUTE SHEET
20'~9$1~
DORI/CHOL (10/0) Cationic lipid (pmole) DNA(pmole) 16.8 8.4 4.2 2.1 1.05 0.53 0.26 0.13 6.06 864.2 622.2 1243.8 447.6 116.4 166.1 13.2 69.3 3.03 721.5 1121.5 1527.9 703.7 lOl.I -39.0 -26.2 91.0 1.52 173.8 1073.1 939.4 577.6 194.1 12.0 38.7 89.7 0.76 -30.1 484.6 613.2 162.3 148.3 27.3 -3.3 -27.5 0.38 -45.4 180.1 327.9 175.0 116.4 17.1 47.6 19.6 0.19 -70.8 40.0 130.4 201.8 536.8 -33.9 23.4 19.6 0.095 -51.7 -39.0 55.3 54.0 243.8 -3.3 -32.6 -28.8 0.047 -109.0 -75.9 20.9 10.7 186.5 15.8 23.4 -37.7 DORI/CHOL (7/3) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 669.0 1445.1 1810.3 680.5 55.6 0.0 0.0 0.0 3030 5.7 1232.5 1784.6 723.3 89.9 0.0 0.0 0.0 1515 0.0 626.2 1437.9 720.4 131.2 0.0 38.5 0.0 758 0.0 164.1 1047.1 547.8 14T.2 0.0 0.0 0.0 379 0.0 0.0 319.5 342.4 101.3 0.0 0.0 0.0 189 0.0 0.0 71.3 138.4 302.4 0.0 0.0 0.0 95 0.0 0.0 37.1 0.0 117.0 0.0 0.0 0.0 47 0.0 0.0 0.0 0.0 64.2 0.0 0.0 0.0 DORZ/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 13I
6060 596.9 1858.9 2010.5 1917.0 1283.9 445.3 273.9 0.6 3030 162.0 1914.2 1936.8 1921.2 965.2 265.4 271.1 30.3 1515 109.6 1624.0 1646.5 1775.4 1109.6 462.3 91.2 34.6 758 11.9 598.3 722.9 1064.3 1432.6 218.7 99.7 21.8 379 -19.3 441.1 385.8 837.7 1077.1 486.4 237.1 20.4 189 -85.8 145.0 356.1 333.4 582.7 391.5 85.6 150.7 95 -151.0 40.2 78.5 21.8 210.2 54.4 33.1 170.5 47 -173.7 -26.3 10.5 -34.8 292.4 79.9 11.9 -67.4 SUBSTITUi'E SHEE'~' ~:);17 2~79g14 There will be various modifications, improvements, and applications of the disclosed invention that will be apparent to those skilled in the art, and the present application is intended to cover such embodiments. Although the present invention has been described in the context of cer~ain preferred embodiments, it is intended that the full scone of the disclosure be measured by reference to the following claims.
SUBSTITUTE eus=e~.
21.5 20 B: Cholesterol Cholesterol (CHOL) was added to DORI at a molar ratio of DORI/CHOL 7/3 and the lipid formulation used to transfect COS.7 cells at a density of 40,000 cells/well with pSV2-lacZ
according to the procedure of Example 14B. The same cells 25 were transfected using DORI/DOPE_for a comparative value.
The formulation were evaluated for their comparative transfective efficiency by the expression of p-galactosidase activity as indicated in Figure 9 and the Tables below:
SUBSTITUTE SHEET
20'~9$1~
DORI/CHOL (10/0) Cationic lipid (pmole) DNA(pmole) 16.8 8.4 4.2 2.1 1.05 0.53 0.26 0.13 6.06 864.2 622.2 1243.8 447.6 116.4 166.1 13.2 69.3 3.03 721.5 1121.5 1527.9 703.7 lOl.I -39.0 -26.2 91.0 1.52 173.8 1073.1 939.4 577.6 194.1 12.0 38.7 89.7 0.76 -30.1 484.6 613.2 162.3 148.3 27.3 -3.3 -27.5 0.38 -45.4 180.1 327.9 175.0 116.4 17.1 47.6 19.6 0.19 -70.8 40.0 130.4 201.8 536.8 -33.9 23.4 19.6 0.095 -51.7 -39.0 55.3 54.0 243.8 -3.3 -32.6 -28.8 0.047 -109.0 -75.9 20.9 10.7 186.5 15.8 23.4 -37.7 DORI/CHOL (7/3) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 131 6060 669.0 1445.1 1810.3 680.5 55.6 0.0 0.0 0.0 3030 5.7 1232.5 1784.6 723.3 89.9 0.0 0.0 0.0 1515 0.0 626.2 1437.9 720.4 131.2 0.0 38.5 0.0 758 0.0 164.1 1047.1 547.8 14T.2 0.0 0.0 0.0 379 0.0 0.0 319.5 342.4 101.3 0.0 0.0 0.0 189 0.0 0.0 71.3 138.4 302.4 0.0 0.0 0.0 95 0.0 0.0 37.1 0.0 117.0 0.0 0.0 0.0 47 0.0 0.0 0.0 0.0 64.2 0.0 0.0 0.0 DORZ/DOPE (5/5) Cationic lipid (pmole) DNA(pmole) 16800 8400 4200 2100 1050 525 262.5 13I
6060 596.9 1858.9 2010.5 1917.0 1283.9 445.3 273.9 0.6 3030 162.0 1914.2 1936.8 1921.2 965.2 265.4 271.1 30.3 1515 109.6 1624.0 1646.5 1775.4 1109.6 462.3 91.2 34.6 758 11.9 598.3 722.9 1064.3 1432.6 218.7 99.7 21.8 379 -19.3 441.1 385.8 837.7 1077.1 486.4 237.1 20.4 189 -85.8 145.0 356.1 333.4 582.7 391.5 85.6 150.7 95 -151.0 40.2 78.5 21.8 210.2 54.4 33.1 170.5 47 -173.7 -26.3 10.5 -34.8 292.4 79.9 11.9 -67.4 SUBSTITUi'E SHEE'~' ~:);17 2~79g14 There will be various modifications, improvements, and applications of the disclosed invention that will be apparent to those skilled in the art, and the present application is intended to cover such embodiments. Although the present invention has been described in the context of cer~ain preferred embodiments, it is intended that the full scone of the disclosure be measured by reference to the following claims.
SUBSTITUTE eus=e~.
Claims (49)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A cationic lipid having formula (I):
wherein:
(a) Y1 and Y2 are the same or different and are -O-CH2, -O-C(O)-, or -O-;
(b) R1 and R2 are the same or different and are H, or C1 to C23 alkyl or alkenyl;
(c) R3 and R4 are the same or different and are C1 to C24 alkyl, or H;
(d) R5 is C1 to C24 saturated alkylene straight chain or branched chain;
(e) R6 is -C(O)-(CH2)m-NH-, a diaminocarboxylic acid which is alkyl, aryl, or aralkyl, or -C(O)-(CH2)m-NH- linked to said diaminocarboxylic acid or is absent;
(f) R7 is:
(i) H, spermine, spermidine, a histone, or a protein with DNA-binding specificity wherein the amines of the R7 moiety are optionally quaternized with R3 or R4 groups or C1 to C24 alkyl straight chain or branched chain groups;
(ii) one or more L- or D-alpha amino acids having a positively charged group on the side chain, said amino acids comprising arginine, histidine, lysine, or ornithine or analogues thereof, wherein the amines of the R7 moiety are optionally quaternized with R3 or R4 groups or C1 to C24 alkyl straight chain or branched chain groups; or (iii) a polypeptide comprising amino acids selected from the group consisting of L-alpha amino acids and D-alpha amino acids, wherein at least one amino acid is arginine, histidine, lysine, ornithine, or an analogue thereof;
(g) n is 1 to 8;
(h) m is 1 to 18; and (i) X- is a non-toxic anion;
with the proviso that the following compounds are excluded:
(x) the salt of DL-(2,3-distearoyloxypropyl) (dimethyl) (2-hydroxyethyl) ammonium with a non-toxic anion;
(y) (1,2-bis(palmitoyloxy)-3-propyl)dimethyl(.beta.-hydroxyethyl)ammonium bromide; and (z) compounds with formula (I) wherein Y1 is -O- and R1 is C18 alkyl or alkenyl or Y1 is -O-CH2- and R1 is C16 alkyl or alkenyl, Y2 is -O-, and R2 is H; or Y1 is -O- and R1 is C16 alkyl or alkenyl or Y1 is -O-CH2- and R2 is C15 alkyl or alkenyl, Y2 is -O- and R2 is C1 to C2 alkyl or Y2 is -O-CH2- and R2 is H or C1 alkyl;
R3 and R4 are C1 alkyl; R5 is C2 alkylene; R6 is absent;
R7 is H;
n is 1; and X- is I-.
wherein:
(a) Y1 and Y2 are the same or different and are -O-CH2, -O-C(O)-, or -O-;
(b) R1 and R2 are the same or different and are H, or C1 to C23 alkyl or alkenyl;
(c) R3 and R4 are the same or different and are C1 to C24 alkyl, or H;
(d) R5 is C1 to C24 saturated alkylene straight chain or branched chain;
(e) R6 is -C(O)-(CH2)m-NH-, a diaminocarboxylic acid which is alkyl, aryl, or aralkyl, or -C(O)-(CH2)m-NH- linked to said diaminocarboxylic acid or is absent;
(f) R7 is:
(i) H, spermine, spermidine, a histone, or a protein with DNA-binding specificity wherein the amines of the R7 moiety are optionally quaternized with R3 or R4 groups or C1 to C24 alkyl straight chain or branched chain groups;
(ii) one or more L- or D-alpha amino acids having a positively charged group on the side chain, said amino acids comprising arginine, histidine, lysine, or ornithine or analogues thereof, wherein the amines of the R7 moiety are optionally quaternized with R3 or R4 groups or C1 to C24 alkyl straight chain or branched chain groups; or (iii) a polypeptide comprising amino acids selected from the group consisting of L-alpha amino acids and D-alpha amino acids, wherein at least one amino acid is arginine, histidine, lysine, ornithine, or an analogue thereof;
(g) n is 1 to 8;
(h) m is 1 to 18; and (i) X- is a non-toxic anion;
with the proviso that the following compounds are excluded:
(x) the salt of DL-(2,3-distearoyloxypropyl) (dimethyl) (2-hydroxyethyl) ammonium with a non-toxic anion;
(y) (1,2-bis(palmitoyloxy)-3-propyl)dimethyl(.beta.-hydroxyethyl)ammonium bromide; and (z) compounds with formula (I) wherein Y1 is -O- and R1 is C18 alkyl or alkenyl or Y1 is -O-CH2- and R1 is C16 alkyl or alkenyl, Y2 is -O-, and R2 is H; or Y1 is -O- and R1 is C16 alkyl or alkenyl or Y1 is -O-CH2- and R2 is C15 alkyl or alkenyl, Y2 is -O- and R2 is C1 to C2 alkyl or Y2 is -O-CH2- and R2 is H or C1 alkyl;
R3 and R4 are C1 alkyl; R5 is C2 alkylene; R6 is absent;
R7 is H;
n is 1; and X- is I-.
2. The cationic lipid of claim 1, wherein R3 and R4 are individually C1 to C23 alkyl groups, R5 is -(CH2)m-, R6 is absent, R7 is H, and R1 and R2 individually have from 0 to 6 sites of unsaturation, and have the structure CH3-(CH2)a-(CH=CH-CH2)b-(CH2)c-wherein the sum of a and c is from 1 to 23, and b is 0 to 6.
3. The cationic lipid of any one of claims 1 or 2, wherein Y1 and Y2 are alike and are -O-C(O)-.
4. The cationic lipid of claim 3, which is DL-1,2-dioleoyl-3-dimethylaminopropyl-.beta.-hydroxyethylammonium, or a salt thereof.
5. The cationic lipid of any one of claims 1 or 2, wherein Y1 and Y2 are alike and are -O-CH2-.
6. The cationic lipid of claim 5, which is 1,2-O-dioleoyl-3-dimethylaminopropyl-.beta.-hydroxyethylammonium, or a salt thereof.
7. The cationic lipid of any one of claims 1 or 2, wherein Y1 and Y2 are different and are either -O-CH2- or -O-C(O)-.
8. The cationic lipid of claim 7, which is 1-O-oleoyl-2-oleoyl-3-dimethylaminopropyl-.beta.-hydroxyethylammonium, or a salt thereof.
9. The cationic lipid of claim 1, wherein said cationic lipid is selected from the group consisting of:
(a) 3,5-(N,N-dilysyl)-diaminobenzoyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-.beta.-hydroxyethylamine);
(b) 3,5-(N,N-dilysyl)-diaminobenzoylglycyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-.beta.-hydroxyethylamine); and (c) salts thereof.
(a) 3,5-(N,N-dilysyl)-diaminobenzoyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-.beta.-hydroxyethylamine);
(b) 3,5-(N,N-dilysyl)-diaminobenzoylglycyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-.beta.-hydroxyethylamine); and (c) salts thereof.
10. A cationic lipid having formula (II):
or an optical isomer thereof, wherein:
(a) Y1 and Y2 are different and are -O-C(O)-, or -O-;
(b) R1 and R2 are individually C1 to C23 alkyl or alkenyl, or H;
(c) R3, R4 and R5 are the same or different and are H, C1 to C14 alkyl, C7 to C11 aryl or aralkyl, or at least two of R3, R4 and R5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; and (d) X- is a non-toxic anion;
with the proviso that the following compounds are excluded:
(x) compounds with formula (II), wherein Y1 is -O-C(O)- and Y2 is -O-, R1 is C13 to C21 alkyl or alkenyl, R2 is H, R3 and R4 are C1 to C6 alkyl, and R5 is C14 alkyl, and X- is a softener compatible anion; and (y) compounds with formula (II), wherein Y1 and Y2 are different and are -O-C(O)- or -O-, R1 and R2 are individually C8 to C23 alkyl or alkenyl, R3, R4, and R5 are H, and X- is Cl-, Br or H3C-COO-.
or an optical isomer thereof, wherein:
(a) Y1 and Y2 are different and are -O-C(O)-, or -O-;
(b) R1 and R2 are individually C1 to C23 alkyl or alkenyl, or H;
(c) R3, R4 and R5 are the same or different and are H, C1 to C14 alkyl, C7 to C11 aryl or aralkyl, or at least two of R3, R4 and R5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; and (d) X- is a non-toxic anion;
with the proviso that the following compounds are excluded:
(x) compounds with formula (II), wherein Y1 is -O-C(O)- and Y2 is -O-, R1 is C13 to C21 alkyl or alkenyl, R2 is H, R3 and R4 are C1 to C6 alkyl, and R5 is C14 alkyl, and X- is a softener compatible anion; and (y) compounds with formula (II), wherein Y1 and Y2 are different and are -O-C(O)- or -O-, R1 and R2 are individually C8 to C23 alkyl or alkenyl, R3, R4, and R5 are H, and X- is Cl-, Br or H3C-COO-.
11. A cationic lipid comprising L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethyl-aminopropyl-.beta.-hydroxyethylamine).
12. A cationic lipid comprising L-spermine-5-carboxyl-3-(DL-1,2-dioleoyl-dimethyl-aminopropyl-(3-hydroxyethylamine).
13. A lipid formulation comprising a cationic lipid selected from the group consisting of:
(A) a cationic lipid having formula (I):
wherein:
(a) Y1 and Y2 are the same or different and are -O-CH2, -O-C(O)-, or -O-;
(b) R1 and R2 are the same or different and are H, or C1 to C23 alkyl or alkenyl;
(c) R3 and R4 are the same or different and are C1 to C24 alkyl, or H;
(d) R5 is C1 to C24 saturated alkylene straight chain or branched chain;
(e) R6 is -C(O)-(CH2)m-NH-, a diaminocarboxylic acid which is alkyl, aryl, or aralkyl, or -C(O)-(CH2)m-NH- linked to said diaminocarboxylic acid or is absent;
(f) R7 is:
(i) H, spermine, spermidine, a histone, or a protein with DNA-binding specificity wherein the amines of the R7 moiety are optionally quaternized with R3 or R4 groups or C1 to C24 alkyl straight chain or branched chain groups;
(ii) one or more L- or D-alpha amino acids having a positively charged group on the side chain, said amino acids comprising arginine, histidine, lysine, or ornithine or analogues thereof, wherein the amines of the R7 moiety are optionally quaternized with R3 or R4 groups or C1 to C24 alkyl straight chain or branched chain groups; or (iii) a polypeptide comprising amino acids selected from the group consisting of L-alpha amino acids and D-alpha amino acids, wherein at least one amino acid is arginine, histidine, lysine, ornithine, or an analogue thereof;
(g) n is 1 to 8;
(h) m is 1 to 18; and (i) X- is a non-toxic anion;
with the proviso that the salt of DL-(2,3-distearoyloxypropyl) (dimethyl) (2-hydroxyethyl) ammonium with a non-toxic anion is excluded;
(B) a cationic lipid having formula (II):
or an optical isomer thereof, wherein:
(a) Y1 and Y2 are different and are -O-C(O)-, or -O-;
(b) R1 and R2 are individually C1 to C23 alkyl or alkenyl, or H;
(c) R3, R4 and R5 are the same or different and are H, C1 to C14 alkyl, C7 to C11 aryl or aralkyl, or at least two of R3, R4 and R5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; and (d) X- is a non-toxic anion;
(C) a cationic lipid comprising L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethyl-aminopropyl-.beta.-hydroxyethylamine); and (D) a cationic lipid comprising L-spermine-5-carboxyl-3-(DL-1,2-dioleoyl-dimethyl-aminopropyl-(3-hydroxyethylamine); or a lipid formulation comprising a mixture of said cationic lipids;
and a carrier.
(A) a cationic lipid having formula (I):
wherein:
(a) Y1 and Y2 are the same or different and are -O-CH2, -O-C(O)-, or -O-;
(b) R1 and R2 are the same or different and are H, or C1 to C23 alkyl or alkenyl;
(c) R3 and R4 are the same or different and are C1 to C24 alkyl, or H;
(d) R5 is C1 to C24 saturated alkylene straight chain or branched chain;
(e) R6 is -C(O)-(CH2)m-NH-, a diaminocarboxylic acid which is alkyl, aryl, or aralkyl, or -C(O)-(CH2)m-NH- linked to said diaminocarboxylic acid or is absent;
(f) R7 is:
(i) H, spermine, spermidine, a histone, or a protein with DNA-binding specificity wherein the amines of the R7 moiety are optionally quaternized with R3 or R4 groups or C1 to C24 alkyl straight chain or branched chain groups;
(ii) one or more L- or D-alpha amino acids having a positively charged group on the side chain, said amino acids comprising arginine, histidine, lysine, or ornithine or analogues thereof, wherein the amines of the R7 moiety are optionally quaternized with R3 or R4 groups or C1 to C24 alkyl straight chain or branched chain groups; or (iii) a polypeptide comprising amino acids selected from the group consisting of L-alpha amino acids and D-alpha amino acids, wherein at least one amino acid is arginine, histidine, lysine, ornithine, or an analogue thereof;
(g) n is 1 to 8;
(h) m is 1 to 18; and (i) X- is a non-toxic anion;
with the proviso that the salt of DL-(2,3-distearoyloxypropyl) (dimethyl) (2-hydroxyethyl) ammonium with a non-toxic anion is excluded;
(B) a cationic lipid having formula (II):
or an optical isomer thereof, wherein:
(a) Y1 and Y2 are different and are -O-C(O)-, or -O-;
(b) R1 and R2 are individually C1 to C23 alkyl or alkenyl, or H;
(c) R3, R4 and R5 are the same or different and are H, C1 to C14 alkyl, C7 to C11 aryl or aralkyl, or at least two of R3, R4 and R5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; and (d) X- is a non-toxic anion;
(C) a cationic lipid comprising L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethyl-aminopropyl-.beta.-hydroxyethylamine); and (D) a cationic lipid comprising L-spermine-5-carboxyl-3-(DL-1,2-dioleoyl-dimethyl-aminopropyl-(3-hydroxyethylamine); or a lipid formulation comprising a mixture of said cationic lipids;
and a carrier.
14. The lipid formulation of claim 13, further comprising an effective transfection-promoting amount of a lysophosphatide, having the structure wherein Y is -O-CH2- or -O-C(O)-;
R is C10 to C23 alkyl or alkenyl; and Z is choline or ethanolamine.
R is C10 to C23 alkyl or alkenyl; and Z is choline or ethanolamine.
15. The lipid formulation of claim 14, wherein said lysophosphatide is mono-oleoyl lysophophatidylcholine.
16. The lipid formulation of any one of claims 14 or 15, wherein the molar ratio of said lysophosphatide to cationic lipid is less than about 0.50.
17. The lipid formulation of any one of claims 13-16, further comprising a cationic lipid selected from the group consisting of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium (DOTMA) and DL-1,2-dioleoyl-3-propyl-N,N,N-trimethylammonium (DOTAP).
18. The lipid formulation of any one of claims 13-17, wherein up to about one-third of the total cationic lipids are selected from the group consisting of:
(a) cationic lipids of formula (I) or (II), wherein Y1 and R1 together form a hydroxyl group;
(b) cationic lipids of formula (I) or (II), wherein Y2 and R2 together form a hydroxyl group;
(c) lyso forms of DOTMA;
(d) lyso forms of DOTAP;
(e) lyso forms of L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethyl-aminopropyl-.beta.-hydroxyethylamine);
(f) lyso forms of L-spermine-5-carboxyl-3-(DL-1,2-dioleoyl-dimethyl-aminopropyl-(3-hydroxyethylamine); and (g) a mixture of any of the cationic lipids of (a) through (f).
(a) cationic lipids of formula (I) or (II), wherein Y1 and R1 together form a hydroxyl group;
(b) cationic lipids of formula (I) or (II), wherein Y2 and R2 together form a hydroxyl group;
(c) lyso forms of DOTMA;
(d) lyso forms of DOTAP;
(e) lyso forms of L-spermine-5-carboxyl-3-(DL-1,2-dipalmitoyl-dimethyl-aminopropyl-.beta.-hydroxyethylamine);
(f) lyso forms of L-spermine-5-carboxyl-3-(DL-1,2-dioleoyl-dimethyl-aminopropyl-(3-hydroxyethylamine); and (g) a mixture of any of the cationic lipids of (a) through (f).
19. The lipid formulation of any one of claims 13-18, which is a liposomal formulation in the form of vesicles in an aqueous medium.
20. The lipid formulation of claim 19, further comprising a neutral lipid selected from the group consisting of phosphatidylethanolamine, phosphatidylcholine, sphingomyelin, and cholesterol.
21. The lipid formulation of claim 20 wherein the molar ratio of said cationic lipid to said neutral lipid is from about 9/1 to 1/9.
22. The lipid formulation of claim 21, wherein said molar ratio is about 5/5.
23. A pharmaceutical composition comprising the lipid formulation of any one of claims 13-22, and a pharmacologically effective amount of a therapeutic agent.
24. The pharmaceutical composition of claim 23, wherein said therapeutic agent is selected from the group consisting of:
(a) a corticosteroid;
(b) a nonsteroidal anti-inflammatory agent;
(c) a nucleoside analogue;
(d) a nucleotide analogue;
(e) a polynucleotide;
(f) an antibiotic;
(g) an antifungal agent;
(h) an oxidant, and (i) a protein or polypeptide.
(a) a corticosteroid;
(b) a nonsteroidal anti-inflammatory agent;
(c) a nucleoside analogue;
(d) a nucleotide analogue;
(e) a polynucleotide;
(f) an antibiotic;
(g) an antifungal agent;
(h) an oxidant, and (i) a protein or polypeptide.
25. The pharmaceutical composition of claim 24 wherein said nucleoside analogue is a dideoxynucleoside, a didehydronucleoside, a halogenated or azido-derivative of a nucleoside or an acyclic nucleoside.
26. The pharmaceutical composition of claim 24, wherein said nucleoside analogue is an antiviral nucleoside analogue.
27. The pharmaceutical composition of claim 26, wherein said antiviral nucleoside analogue is selected from the group consisting of 3'-azido-2', 3'-dideoxy-pyrimidine, 3'-halopyrimidine dideoxynucleoside, 2',3'-didehydro-2',3'-dideoxynucleoside, 3'-azido-3'-deoxythymidine (AZT), acyclovir, gancyclovir, 1-(2-deoxy-2'-fluoro-1-.beta.-D-arabinofuranosyl)-5-iodocytosine (FIAC), and 1-(2'-deoxy-2'-fluoro-1-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU).
28. The pharmaceutical composition of any one of claims 24 to 26, wherein said therapeutic agent is a phosphatidyl derivative or diphosphate diglyceride derivative of said nucleoside or nucleotide analogue.
29. The pharmaceutical composition of claim 24, wherein said therapeutic agent is a polynucleotide selected from the group consisting of:
(a) a ribozyme;
(b) an antisense RNA or DNA; and (c) a polynucleotide which encodes a therapeutic polypeptide or protein.
(a) a ribozyme;
(b) an antisense RNA or DNA; and (c) a polynucleotide which encodes a therapeutic polypeptide or protein.
30. The pharmaceutical composition of claim 29 wherein said polynucleotide, or expression product thereof, is directed against HIV.
31. The pharmaceutical composition of claim 30, wherein said polynucleotide, or expression product thereof, is directed against the rev transactivator.
32. The pharmaceutical composition of claim 31, wherein said therapeutic polynucleotide is a 28-mer phosphorothioate antisense polynucleotide.
33. The pharmaceutical composition of any one of claims 24 or 29, wherein said therapeutic polypeptide is selected from the group consisting of:
(a) a polypeptide which is deficient or absent in a disease state;
(b) a natural hormone or a synthetic analogue thereof; and (c) an immunogen.
(a) a polypeptide which is deficient or absent in a disease state;
(b) a natural hormone or a synthetic analogue thereof; and (c) an immunogen.
34. Use of a pharmaceutical composition comprising: (a) the cationic lipid of any one of claims 1-12, and (b) a pharmacologically effective amount of a therapeutic agent, as a topical agent for use as an anti-inflammatory, antibiotic, antifungal, anti-acne, antiviral, anesthetic, cytostatic, immunomodulatory, sunscreen or cosmetic agent.
35. The use according to claim 34 wherein said therapeutic agent is as defined in any one of claims 24-33.
36. The use according to claim 34 to treat Herpes simplex virus infection, wherein said therapeutic agent is selected from the group consisting of acyclovir, gancyclovir, 1-(2-deoxy-2'-fluoro-1-.beta.-D-arabinofuranosyl)-5-iodocytosine (FIAC) and 1-(2'-deoxy-2'-fluoro-1-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU).
37. Use of a pharmaceutical composition comprising: (a) the cationic lipid of any one of claims 1-12, and (b) a biologically active agent as an intracellular delivery vehicle, for intracellular delivery of said biologically active agent into an animal cell.
38. The use of claim 37 wherein said delivery occurs in vitro.
39. Use according to claim 37, wherein said composition is applied to cells of a vertebrate in vitro, and wherein said cells are for return to said vertebrate or a second vertebrate.
40. Use according to claim 37, wherein said composition is formulated for topical application to skin or a mucosal surface.
41. Use according to claim 37, where said composition is an injectable composition.
42. Use according to claim 37, wherein said composition is formulated for oral administration.
43. An in vitro method of introducing a biologically active agent into a cell of an animal comprising:
(a) preparing lipid vesicles comprising a cationic lipid as set out in any one of claims 1-12, and containing said biologically active agent;
(b) contacting said cell with said lipid vesicles whereby said biologically active agent is taken up into said cell.
(a) preparing lipid vesicles comprising a cationic lipid as set out in any one of claims 1-12, and containing said biologically active agent;
(b) contacting said cell with said lipid vesicles whereby said biologically active agent is taken up into said cell.
44. An in vitro method for introducing a biologically active agent into a cell of an animal comprising:
(a) preparing lipid vesicles comprising a cationic lipid as set out in any one of claims 1-12;
(b) contacting said cell with said biologically active agent in the presence of said lipid vesicles, whereby said biologically active agent is taken up into said cell.
(a) preparing lipid vesicles comprising a cationic lipid as set out in any one of claims 1-12;
(b) contacting said cell with said biologically active agent in the presence of said lipid vesicles, whereby said biologically active agent is taken up into said cell.
45. A method for the preparation of a cationic lipid as set out in any one of claims 1, or 4-12, comprising appending an acyl or alkyl group to the oxygens of the primary and/or secondary alcohol groups of 3-dimethylamino-1,2-propanediol or an amine substituted analogue thereof followed by quarternization of the amino group by the halo derivative of the quarternizing group of R5-O-R6-R7 of formula (I) or R5 of formula (II).
46. A method for the preparation of a lipid formulation as set out in any one of claims 13 to 22, comprising combining said cationic lipid with an additional lipid.
47. The method of claim 46, wherein said additional lipid is selected from the group consisting of:
(a) a lysophosphatide as set out in any one of claims 14-15; and (b) a cationic lipid as defined in claim 18.
(a) a lysophosphatide as set out in any one of claims 14-15; and (b) a cationic lipid as defined in claim 18.
48. A method for the preparation of a lipid formulation according to any one of claims 19-22, comprising dissolving the cationic lipid as set out in any one of claims 1-12 in a solvent;
dissolving along with said cationic lipid a lipid selected from the group consisting of:
(a) a lysophosphatide as set out in any one of claims 14-15;
(b) a cationic lipid as defined in claim 18;
(c) a neutral lipid as set forth in claim 20; and (d) a mixture two or more of lipids (a)-(c);
evaporating to dryness; and suspending in an aqueous solvent.
dissolving along with said cationic lipid a lipid selected from the group consisting of:
(a) a lysophosphatide as set out in any one of claims 14-15;
(b) a cationic lipid as defined in claim 18;
(c) a neutral lipid as set forth in claim 20; and (d) a mixture two or more of lipids (a)-(c);
evaporating to dryness; and suspending in an aqueous solvent.
49. A method for the preparation of the pharmaceutical composition of claim 23, comprising combining the lipid formulation as set out in any one of claims with a pharmacologically effective amount of a therapeutic agent as defined in any one of claims 24 to 33.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51121990A | 1990-04-19 | 1990-04-19 | |
US511,219 | 1990-04-19 | ||
US56344490A | 1990-08-07 | 1990-08-07 | |
US563,444 | 1990-08-07 | ||
US686,746 | 1991-04-16 | ||
US07/686,746 US5264618A (en) | 1990-04-19 | 1991-04-16 | Cationic lipids for intracellular delivery of biologically active molecules |
PCT/US1991/002691 WO1991016024A1 (en) | 1990-04-19 | 1991-04-18 | Cationic lipids for intracellular delivery of biologically active molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2079814A1 CA2079814A1 (en) | 1991-10-20 |
CA2079814C true CA2079814C (en) | 2005-09-27 |
Family
ID=27414476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002079814A Expired - Lifetime CA2079814C (en) | 1990-04-19 | 1991-04-18 | Cationic lipids for intracellular delivery of biologically active molecules |
Country Status (11)
Country | Link |
---|---|
US (2) | US5264618A (en) |
EP (1) | EP0523189B1 (en) |
JP (1) | JP2538474B2 (en) |
AT (1) | ATE181319T1 (en) |
AU (1) | AU7854791A (en) |
CA (1) | CA2079814C (en) |
DE (1) | DE69131347T2 (en) |
DK (1) | DK0523189T3 (en) |
ES (1) | ES2134775T3 (en) |
GR (1) | GR3030974T3 (en) |
WO (1) | WO1991016024A1 (en) |
Families Citing this family (1459)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU641361B2 (en) * | 1988-05-02 | 1993-09-23 | Zynaxis Technologies, Incorporated | Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
CA2489769A1 (en) * | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5256641A (en) * | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
US6156304A (en) * | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
US20020123476A1 (en) * | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
US7202225B1 (en) * | 1993-10-15 | 2007-04-10 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
US5693769A (en) * | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
EP0625207A1 (en) * | 1991-12-17 | 1994-11-23 | The Regents Of The University Of California | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr) |
US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
CA2128616A1 (en) * | 1992-01-23 | 1993-08-05 | Gary H. Rhodes | Ex vivo gene transfer |
US5885970A (en) * | 1992-03-16 | 1999-03-23 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against human protein kinase C |
US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
EP1236473A3 (en) * | 1992-04-03 | 2003-01-15 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US20020108136A1 (en) * | 1997-03-21 | 2002-08-08 | Sri | Transgenic animals produced by homologous sequence targeting |
US6806084B1 (en) * | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
IL105914A0 (en) * | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
JPH07502753A (en) * | 1992-07-13 | 1995-03-23 | ユーカリオン,インコーポレイティド | Transvascular and intracellular transport of lipidated proteins |
US7105574B1 (en) | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
IL107150A0 (en) * | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
US5329029A (en) * | 1992-11-05 | 1994-07-12 | Wan Barbara Y | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates |
US5552155A (en) * | 1992-12-04 | 1996-09-03 | The Liposome Company, Inc. | Fusogenic lipsomes and methods for making and using same |
US5705655A (en) * | 1992-12-17 | 1998-01-06 | Megabios Corporation | Amphiphilic nitrogen containing imidazolinium derivative compounds and uses |
US5631237A (en) * | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
DK0809110T3 (en) * | 1993-03-09 | 2004-05-24 | Baxter Int | Macromolecular microparticles and methods of preparation |
EP1624068A1 (en) * | 1993-06-01 | 2006-02-08 | Life Technologies Inc. | Genetic immunization with cationic lipids |
US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
US5563111A (en) * | 1993-08-03 | 1996-10-08 | Kao Corporation | Agricultural chemical composition comprising amine surfactants with at least one ester or amide linkage |
US6348449B1 (en) | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
AU691226B2 (en) * | 1993-11-24 | 1998-05-14 | Megabios Corporation | Amphiphilic derivatives of guanidine |
JPH09505593A (en) * | 1993-11-24 | 1997-06-03 | メガバイオス・コーポレイション | Amphiphilic derivatives of piperazine |
US5665879A (en) * | 1993-11-24 | 1997-09-09 | Megabios Corporation | Amphiphilic derivatives of piperazine |
US6613351B1 (en) * | 1993-12-20 | 2003-09-02 | Biotech Tools S.A. | Compound capable of introducing at least one molecule into a cell |
US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
US6057299A (en) * | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6075012A (en) * | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5763416A (en) | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
US6074840A (en) | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
EP0759768A4 (en) * | 1994-04-07 | 2000-08-09 | Proteinix Company | Vasoactive intestinal polypeptide |
AU2589095A (en) * | 1994-05-16 | 1995-12-05 | Washington University | Cell membrane fusion composition and method |
CA2194221C (en) * | 1994-06-22 | 2001-01-02 | Timothy D. Heath | Cationic amphiphiles |
US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
FR2722506B1 (en) * | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | COMPOSITION CONTAINING NUCLEIC ACIDS, PREPARATION AND USES |
DE4426429A1 (en) * | 1994-07-26 | 1996-02-01 | Boehringer Ingelheim Int | Method for introducing DNA into higher eukaryotic cells |
US7592317B1 (en) * | 1994-08-11 | 2009-09-22 | The University Of Chicago | Constitutive gene expression in conjuction with ionizing radiation |
AUPM747694A0 (en) * | 1994-08-16 | 1994-09-08 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids and peptides |
US5892071A (en) * | 1994-09-30 | 1999-04-06 | The Reagents Of The University Of California | Cationic transport reagents |
US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5785992A (en) * | 1994-09-30 | 1998-07-28 | Inex Pharmaceuticals Corp. | Compositions for the introduction of polyanionic materials into cells |
US6911216B1 (en) | 1994-10-12 | 2005-06-28 | Genzyme Corporation | Targeted delivery via biodegradable polymers |
US5641665A (en) * | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US6071890A (en) * | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5767099A (en) * | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
US5747471A (en) * | 1994-12-09 | 1998-05-05 | Genzyme Corporation | Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules |
US5650096A (en) * | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948767A (en) * | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
US6331524B1 (en) | 1994-12-09 | 2001-12-18 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy |
US5910487A (en) * | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
US6383814B1 (en) | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5719131A (en) * | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
US5840710A (en) * | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US5939401A (en) * | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
US6630455B1 (en) | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5929043A (en) | 1995-01-31 | 1999-07-27 | Pangene Corporation | Recombinase mediated DNA therapies |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US20020103147A1 (en) * | 1997-09-05 | 2002-08-01 | Hammond H. Kirk | Gene therapy for congestive heart failure |
CN1136920C (en) | 1995-02-28 | 2004-02-04 | 加利福尼亚大学董事会 | Gene transfer-mediated angiogenesis therapy |
US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
US20020183288A1 (en) * | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
JPH11504631A (en) * | 1995-04-25 | 1999-04-27 | バイカル インコーポレイテッド | Single vial formulation of DNA / lipid complex |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
JPH11507352A (en) | 1995-06-07 | 1999-06-29 | ジンタ・インコーポレイテッド | New carbamate-based cationic lipids |
US5869040A (en) * | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
EP0832271B8 (en) * | 1995-06-07 | 2005-03-02 | INEX Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5759519A (en) * | 1995-06-07 | 1998-06-02 | Gen-Probe Incorporated | Method for the intracellular delivery of biomolecules using thiocationic lipids |
US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
US5711964A (en) * | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
US20030069173A1 (en) * | 1998-03-16 | 2003-04-10 | Life Technologies, Inc. | Peptide-enhanced transfections |
US5756352A (en) * | 1995-06-07 | 1998-05-26 | Gen-Probe Incorporated | Thiocationic lipid-nucleic acid conjugates |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5739271A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Thiocationic lipids |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
KR19990022597A (en) * | 1995-06-07 | 1999-03-25 | 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 | Thiocationic lipids, pharmaceutical compositions and methods of using the same |
US5851548A (en) * | 1995-06-07 | 1998-12-22 | Gen-Probe Incorporated | Liposomes containing cationic lipids and vitamin D |
JPH11507815A (en) | 1995-06-07 | 1999-07-13 | ジンタ・インコーポレイテッド | Phosphonate-based cationic lipids |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
AU5979296A (en) * | 1995-06-07 | 1996-12-30 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
DE19521412A1 (en) * | 1995-06-14 | 1996-12-19 | Boehringer Mannheim Gmbh | New cationic and polycationic amphiphiles, reagents containing them and their use |
US5931809A (en) * | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
US6339173B1 (en) | 1996-07-22 | 2002-01-15 | Promega Biosciences, Inc. | Amide-based cationic lipids |
US6020526A (en) * | 1995-07-21 | 2000-02-01 | Genta, Incorporated | Amide-based cationic lipids |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
NO953680D0 (en) * | 1995-09-18 | 1995-09-18 | Hans Prydz | Cell cycle Enzymes |
US6120794A (en) * | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
AU7078396A (en) * | 1995-09-27 | 1997-04-30 | Regents Of The University Of California, The | Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes |
US5869715A (en) * | 1995-09-27 | 1999-02-09 | The Reagents Of The University Of California | Polyfunctional cationic cytofectins |
US6086913A (en) * | 1995-11-01 | 2000-07-11 | University Of British Columbia | Liposomal delivery of AAV vectors |
EP0863749A2 (en) | 1995-11-30 | 1998-09-16 | Vical Incorporated | Complex cationic lipids |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US6126964A (en) * | 1996-01-04 | 2000-10-03 | Mirus Corporation | Process of making a compound by forming a polymer from a template drug |
AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
AU2112697A (en) * | 1996-02-09 | 1997-08-28 | Pi-Wan Cheng | Receptor ligand-facilitated delivery of biologically active molecules |
US5783566A (en) * | 1996-05-10 | 1998-07-21 | California Institute Of Technology | Method for increasing or decreasing transfection efficiency |
WO1997034483A1 (en) * | 1996-03-18 | 1997-09-25 | California Institute Of Technology | Methods for increasing or decreasing transfection efficiency |
US5994317A (en) * | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US5798250A (en) * | 1996-04-15 | 1998-08-25 | Icn Pharmaceuticals, Inc. | Facilitating hepatitus virus infection in cell culture using a membrane stressor |
JP2001507207A (en) * | 1996-05-01 | 2001-06-05 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | Methods for delivering compounds to cells |
KR100536983B1 (en) * | 1996-05-08 | 2006-06-29 | 니카 헬스 프로덕츠 리미티드 | Some genes for delivery of genetic material |
WO1997042819A1 (en) * | 1996-05-13 | 1997-11-20 | Alberto Haces | Cationic lipids for transfection of negatively charged or neutral molecules into living cells |
US5980935A (en) * | 1996-05-15 | 1999-11-09 | Kirpotin; Dmitri | Cationic lipids and methods of use therefor |
US8323963B2 (en) * | 1996-05-29 | 2012-12-04 | University Of Southern California | Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease |
US6274136B1 (en) | 1996-05-29 | 2001-08-14 | University Of Southern California | Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease |
US5935936A (en) * | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
WO1998000554A1 (en) * | 1996-07-03 | 1998-01-08 | Genetics Institute, Inc. | Protease fmh-1, an ice/ced-like protease |
CA2261887C (en) * | 1996-07-23 | 2007-10-02 | Oregon Health Sciences University | Covalent polar lipid conjugates with biologically-active compounds for use in salves |
CA2271388C (en) * | 1996-09-13 | 2007-11-06 | The School Of Pharmacy, University Of London | Liposomes encapsulating polynucleotides operatively coding for immunogenic polypeptides |
US7384923B2 (en) * | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
WO1998014592A2 (en) | 1996-10-01 | 1998-04-09 | Geron Corporation | Telomerase reverse transcriptase |
US5861397A (en) * | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
FR2754828B1 (en) * | 1996-10-23 | 1998-12-24 | Univ Toulouse | ARTIFICIAL MEMBRANE STRUCTURE, METHOD AND POLYMER FOR PREPARING IT, METHOD FOR PREPARING THIS POLYMER, PARTICLE AND FILM COMPRISING THIS STRUCTURE |
US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
AU729655B2 (en) * | 1996-11-12 | 2001-02-08 | Regents Of The University Of California, The | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
US5965441A (en) * | 1996-11-13 | 1999-10-12 | The General Hospital Coporation | HSV/AAV hybrid amplicon vectors |
EP0958380A4 (en) * | 1996-12-06 | 2004-03-17 | Univ California | Macromolecule-lipid complexes and methods for making and using |
WO1998024888A2 (en) | 1996-12-06 | 1998-06-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Polypeptides encoded by a human lipase-like gene, compositions and methods |
US7008776B1 (en) | 1996-12-06 | 2006-03-07 | Aventis Pharmaceuticals Inc. | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
US6527716B1 (en) | 1997-12-30 | 2003-03-04 | Altea Technologies, Inc. | Microporation of tissue for delivery of bioactive agents |
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
AU750451B2 (en) * | 1997-02-13 | 2002-07-18 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
FR2760193B1 (en) * | 1997-02-28 | 1999-05-28 | Transgene Sa | LIPIDS AND COMPLEXES OF CATIONIC LIPIDS AND ACTIVE SUBSTANCES, IN PARTICULAR FOR THE TRANSFECTION OF CELLS |
US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US7112338B2 (en) * | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US5965542A (en) * | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5958894A (en) * | 1997-04-04 | 1999-09-28 | Megabios Corporation | Amphiphilic biguanide derivatives |
US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
US5912239A (en) * | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
FR2761912B1 (en) * | 1997-04-14 | 1999-07-02 | Capsulis | PROCESS FOR ADHERING A PRODUCT TO A SURFACE |
AU753781B2 (en) | 1997-04-28 | 2002-10-31 | Aventis Pharma S.A. | Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
WO1998049350A1 (en) * | 1997-04-30 | 1998-11-05 | Regents Of The University Of Minnesota | In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes |
US5948925A (en) * | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
US5952516A (en) * | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
US20030104044A1 (en) * | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
US6287591B1 (en) * | 1997-05-14 | 2001-09-11 | Inex Pharmaceuticals Corp. | Charged therapeutic agents encapsulated in lipid particles containing four lipid components |
WO1999002192A1 (en) | 1997-07-11 | 1999-01-21 | Brandeis University | Method of inducing apoptosis by reducing the level of thiamin |
US20090239940A1 (en) * | 1997-07-22 | 2009-09-24 | Del Monte Federica | Treating heart failure and ventricular arrhythmias |
EP1007673B1 (en) | 1997-07-30 | 2008-12-17 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
DE69838584T2 (en) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE |
WO1999008110A1 (en) * | 1997-08-08 | 1999-02-18 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
ES2167939T3 (en) * | 1997-08-13 | 2002-05-16 | Biontex Lab Gmbh | NEW POLYAMINS, ITS PREPARATION AND USES. |
US6818627B1 (en) | 1997-08-14 | 2004-11-16 | The Trustees Of The University Of Pennsylvania | Functional fragments of HIV-1 Vpr protein and methods of using the same |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US6884842B2 (en) | 1997-10-14 | 2005-04-26 | Alnis Biosciences, Inc. | Molecular compounds having complementary surfaces to targets |
US6875606B1 (en) * | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
US5998482A (en) * | 1997-11-10 | 1999-12-07 | David; Sunil A. | Use of synthetic polycationic amphiphilic substances with fatty acid or hydrocarbon substituents as anti-sepsis agents |
EP1987845B1 (en) | 1997-11-20 | 2012-03-21 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor. |
WO1999027964A1 (en) * | 1997-12-01 | 1999-06-10 | Cfy Biomedicals, Inc. | Multivalent recombinant antibodies for treating hrv infections |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
FR2772047B1 (en) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
AU2324999A (en) * | 1998-01-16 | 1999-08-02 | California Pacific Medical Center Research Institute | Methods and compositions for gene delivery |
EP1045897B1 (en) | 1998-01-23 | 2002-01-30 | Newbiotics Inc. | Enzyme catalyzed therapeutic agents |
US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
US6410328B1 (en) * | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
WO1999047538A1 (en) | 1998-03-19 | 1999-09-23 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
US6271209B1 (en) * | 1998-04-03 | 2001-08-07 | Valentis, Inc. | Cationic lipid formulation delivering nucleic acid to peritoneal tumors |
US6043390A (en) | 1998-04-03 | 2000-03-28 | The Regents Of The University Of California | Pentaerythritol lipid derivatives and nucleic-acid complexes |
DE69928244T2 (en) | 1998-05-06 | 2006-08-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | INHIBITORS OF NF-KB ACTIVATION |
US6225456B1 (en) | 1998-05-07 | 2001-05-01 | University Technololy Corporation | Ras suppressor SUR-5 |
US6506889B1 (en) | 1998-05-19 | 2003-01-14 | University Technology Corporation | Ras suppressor SUR-8 and related compositions and methods |
SK287330B6 (en) * | 1998-05-29 | 2010-07-07 | The Scripps Research Institute | Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src |
US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US20040077603A1 (en) * | 1998-08-28 | 2004-04-22 | Wilhelm Stoffel | Synthetic tear fluid |
ES2394458T3 (en) * | 1998-09-09 | 2013-01-31 | Genzyme Corporation | Methylation of plasmid vectors |
US6135976A (en) | 1998-09-25 | 2000-10-24 | Ekos Corporation | Method, device and kit for performing gene therapy |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
EP1829856A3 (en) | 1998-11-12 | 2009-02-25 | Invitrogen Corporation | Transfection reagents |
DE69918711T2 (en) * | 1998-11-25 | 2005-07-21 | Gene Therapy Systems, Inc., San Diego | AMPHIPHILE POLYAMINE COMPOUNDS |
US6656498B1 (en) | 1998-11-25 | 2003-12-02 | Vanderbilt University | Cationic liposomes for gene transfer |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US20020032164A1 (en) | 1998-12-30 | 2002-03-14 | Dale Roderic M. K. | Antimicrobial compounds and methods for their use |
US6441156B1 (en) * | 1998-12-30 | 2002-08-27 | The United States Of America As Represented By The Department Of Health And Human Services | Calcium channel compositions and methods of use thereof |
US7868162B2 (en) | 1998-12-30 | 2011-01-11 | Lakewood-Amedex, Inc. | Antimicrobial and antiviral compounds and methods for their use |
US6627215B1 (en) | 1998-12-30 | 2003-09-30 | Oligos Etc. Inc. | Devices for improved wound management |
US6570003B1 (en) * | 2001-01-09 | 2003-05-27 | Lexion Genetics Incorporated | Human 7TM proteins and polynucleotides encoding the same |
AU776150B2 (en) * | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
DE50000562D1 (en) | 1999-02-25 | 2002-10-31 | Von Strandmann Elke Pogge | AGENTS FOR TREATING PIGMENTATION DISORDERS |
CN1348332A (en) | 1999-03-03 | 2002-05-08 | 宾夕法尼亚大学理事会 | Vaccines and gene therapy compositions and methods of making and using the same |
US7393548B2 (en) * | 1999-03-22 | 2008-07-01 | J.P. M.E.D. Ltd. | Nano oil in glycerin emulsion |
US6280977B1 (en) | 1999-03-24 | 2001-08-28 | Gene Therapy Systems | Method for generating transcriptionally active DNA fragments |
ATE272410T1 (en) | 1999-03-26 | 2004-08-15 | Vical Inc | ADJUVANT COMPOSITIONS FOR INCREASE THE IMMUNE RESPONSE TO POLYNUCLEOTIDE-BASED VACCINES |
US6379698B1 (en) | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US6696424B1 (en) | 1999-05-28 | 2004-02-24 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
JP4723097B2 (en) * | 1999-05-28 | 2011-07-13 | バイカル インコーポレイテッド | Cytofectin dimer and method of use thereof |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
US20010048940A1 (en) * | 1999-06-18 | 2001-12-06 | Jennifer D. Tousignant | Cationic amphiphile micellar complexes |
FR2797402B1 (en) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | USE OF A POLYPEPTIDE FOR DETECTING, PREVENTING OR TREATING A CONDITION ASSOCIATED WITH A DEGENERATIVE, NEUROLOGICAL OR AUTOIMMUNE DISEASE |
US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
WO2001007088A2 (en) | 1999-07-22 | 2001-02-01 | Newbiotics, Inc. | Methods for treating therapy-resistant tumors |
US20030078499A1 (en) * | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
US20050249794A1 (en) * | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
US6448388B1 (en) | 2000-08-16 | 2002-09-10 | Lexicon Genetics Incorporated | Human proteases and polynucleotides encoding the same |
US6716614B1 (en) | 1999-09-02 | 2004-04-06 | Lexicon Genetics Incorporated | Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof |
US20080003673A1 (en) * | 1999-09-02 | 2008-01-03 | Alejandro Abuin | Novel human proteases and polynucleotides encoding the same |
US20030166902A1 (en) * | 2001-02-20 | 2003-09-04 | Yi Hu | Novel human protease and polynucleotides encoding the same |
US20050153323A1 (en) * | 2000-07-28 | 2005-07-14 | Yi Hu | Novel human proteases and polynucleotides encoding the same |
US20020151047A1 (en) * | 2001-01-08 | 2002-10-17 | Yi Hu | Novel human protease and polynucleotides encoding the same |
US20030050464A1 (en) * | 2000-07-28 | 2003-03-13 | Yi Hu | Novel human proteases and polynucleotides encoding the same |
EE200200127A (en) * | 1999-09-09 | 2003-04-15 | The Regents Of The University Of California | Delivering taxanes to angiogenic blood vessels with cationic liposomes |
US20020107382A1 (en) * | 2000-09-27 | 2002-08-08 | Friddle Carl Johan | Novel human protease inhibitor proteins and polynucleotides encoding the same |
US6867291B1 (en) * | 2000-09-15 | 2005-03-15 | Lexicon Genetics Incorporated | Human hemicentin proteins and polynucleotides encoding the same |
US6790660B1 (en) * | 2001-09-18 | 2004-09-14 | Lexicon Genetics Incorporated | Human kielin-like proteins and polynucleotides encoding the same |
US6541252B1 (en) | 2000-05-19 | 2003-04-01 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US6841377B1 (en) * | 2001-06-13 | 2005-01-11 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6864079B2 (en) | 2001-04-06 | 2005-03-08 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6720173B1 (en) | 1999-11-08 | 2004-04-13 | Lexicon Genetics Incorporated | Human kinase protein and polynucleotides encoding the same |
US6734009B2 (en) | 2000-12-27 | 2004-05-11 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US20080050809A1 (en) * | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
US6759527B2 (en) | 2001-03-20 | 2004-07-06 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6586230B1 (en) * | 2000-10-27 | 2003-07-01 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6511840B1 (en) | 2000-06-15 | 2003-01-28 | Lexicon Genetics Incorporated | Human kinase proteins and polynucleotides encoding the same |
US6797510B1 (en) | 2001-05-24 | 2004-09-28 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US6734010B2 (en) * | 2001-05-09 | 2004-05-11 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US7892541B1 (en) | 1999-09-30 | 2011-02-22 | Tumor Biology Investment Group, Inc. | Soluble epidermal growth factor receptor isoforms |
US20080213878A1 (en) * | 1999-10-19 | 2008-09-04 | Gregory Donoho | Novel human membrane proteins and polynucleotides encoding the same |
AU783948B2 (en) * | 1999-11-12 | 2006-01-05 | Lexicon Genetics Incorporated | Novel human proteases and polynucleotides encoding the same |
AU1920601A (en) * | 1999-11-19 | 2001-05-30 | Lexicon Genetics Incorporated | Novel human secreted proteins and polynucleotides encoding the same |
ES2170622B1 (en) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS. |
AU785082B2 (en) * | 1999-12-07 | 2006-09-14 | Lexicon Pharmaceuticals, Inc. | Novel human kinase proteins and polynucleotides encoding the same |
AU2070701A (en) * | 1999-12-07 | 2001-06-18 | Lexicon Genetics Incorporated | Novel human membrane proteins and polynucleotides encoding the same |
EP1263966A1 (en) * | 1999-12-13 | 2002-12-11 | Lexicon Genetics Incorporated | Novel human transferase proteins and polynucleotides encoding the same |
US20030008813A1 (en) * | 1999-12-17 | 2003-01-09 | Felgner Philip L. | Intracellular protein delivery compositions and methods of use |
AU783901B2 (en) * | 1999-12-22 | 2005-12-22 | Lexicon Pharmaceuticals, Inc. | Human membrane proteins and polynucleotides encoding the same having Homology to CD20 Proteins and IGE Receptors |
WO2001046407A1 (en) * | 1999-12-22 | 2001-06-28 | Lexicon Genetics Incorporated | Polynucleotides encoding human protease homologs |
FR2802925B1 (en) * | 1999-12-23 | 2002-03-22 | Commissariat Energie Atomique | CATIONIC AMPHIPHILES, THEIR APPLICATIONS AND THEIR SYNTHESIS METHOD |
CN1433478A (en) * | 1999-12-30 | 2003-07-30 | 诺瓦提斯公司 | Novel colloid synthetic vectors for gene therapy |
EP1244795A1 (en) * | 2000-01-06 | 2002-10-02 | Lexicon Genetics Incorporated | Novel human proteases and polynucleotides encoding the same |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
AU784540B2 (en) * | 2000-01-18 | 2006-04-27 | Lexicon Pharmaceuticals, Inc. | Novel human kinase protein and polynucleotides encoding the same |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US7078388B2 (en) * | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US20040002472A1 (en) * | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
DE60118703T2 (en) * | 2000-01-26 | 2006-12-14 | Lexicon Genetics Inc., The Woodlands | HUMAN NEUREXIN-SIMILAR PROTEINS AND POLYNUCLEOTIDES THAT CODE |
AU9256001A (en) * | 2000-01-28 | 2001-12-17 | Lexicon Genetics Incorporated | Novel human enzymes and polynucleotides encoding the same |
US20020115837A1 (en) * | 2000-01-28 | 2002-08-22 | Turner C. Alexander | Novel human membrane proteins and polynucleotides encoding the same |
CA2399663A1 (en) * | 2000-02-04 | 2001-08-09 | Lexicon Genetics Incorporated | Novel human enzymes and polynucleotides encoding the same |
WO2001057086A2 (en) * | 2000-02-04 | 2001-08-09 | Lexicon Genetics Incorporated | Novel human g protein coupled receptor proteins and polynucleotides encoding the same |
US6689558B2 (en) | 2000-02-08 | 2004-02-10 | Sangamo Biosciences, Inc. | Cells for drug discovery |
JP2003522530A (en) | 2000-02-11 | 2003-07-29 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human protease and polynucleotide encoding the protease |
KR100388332B1 (en) | 2000-02-16 | 2003-06-25 | 세이코 엡슨 가부시키가이샤 | Ink cartridge for ink jet recording device, connection unit and ink jet recording device |
AU2001238503A1 (en) * | 2000-02-17 | 2001-08-27 | Lexicon Genetics Incorporated | Novel human thrombospondin repeat proteins and polynucleotides encoding the same |
WO2001064903A2 (en) * | 2000-02-29 | 2001-09-07 | Lexicon Genetics Incorporated | Novel human transferase proteins and polynucleotides encoding the same |
JP2003531582A (en) * | 2000-02-29 | 2003-10-28 | レキシコン・ジェネティクス・インコーポレーテッド | Human transporter protein and polynucleotide encoding the same |
AU2001247283A1 (en) * | 2000-03-06 | 2001-09-17 | Lexicon Genetics Incorporated | Human transporter proteins and polynucleotides encoding the same |
CA2402227A1 (en) | 2000-03-10 | 2001-09-20 | Lexicon Genetics Incorporated | Human g-coupled protein receptor kinases and polynucleotides encoding the same |
EP1317551B1 (en) * | 2000-03-13 | 2007-02-28 | Lexicon Genetics Incorporated | Human phospholipases and polynucleotides encoding the same |
ATE511856T1 (en) | 2000-03-13 | 2011-06-15 | Cornell Res Foundation Inc | BLOCKING LEUKOCYTE EMIGRATION AND INFLAMMATION DUE TO DISRUPTION WITH CD99/HEC2 |
CN102151337B (en) | 2000-03-13 | 2014-03-12 | 恩根尼公司 | Compositions and methods for regulated protein expression in gut |
EP1268538A2 (en) * | 2000-03-20 | 2003-01-02 | Lexicon Genetics Incorporated | Human secreted proteins and polynucleotides encoding the same |
US20040033600A1 (en) * | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
WO2001070763A1 (en) * | 2000-03-22 | 2001-09-27 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
WO2001075108A1 (en) * | 2000-04-03 | 2001-10-11 | Lexicon Genetics Incorporated | Human ion channel protein and polynucleotides encoding the same |
CA2405729A1 (en) * | 2000-04-12 | 2001-10-25 | Lexicon Genetics Incorporated | Human metalloprotease and polynucleotides encoding the same |
EP1832599A3 (en) | 2000-04-12 | 2007-11-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP2003531149A (en) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | Enhancement of antibody-derived immune response |
US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
CA2407074A1 (en) * | 2000-04-21 | 2001-11-01 | Jukka Hartikka | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
EP1276873A2 (en) | 2000-04-25 | 2003-01-22 | Lexicon Genetics Incorporated | Human kinase proteins and polynucleotides encoding the same |
JP2003533205A (en) * | 2000-05-12 | 2003-11-11 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human lipocalin homologs and polynucleotides encoding the same |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
WO2001088133A2 (en) | 2000-05-18 | 2001-11-22 | Lexicon Genetics Incorporated | Human semaphorin homologs and polynucleotides encoding the same |
WO2001090179A2 (en) * | 2000-05-23 | 2001-11-29 | Lexicon Genetics Incorporated | Novel human thrombospondin-like proteins and polynucleotides encoding the same |
US6790667B1 (en) * | 2000-05-30 | 2004-09-14 | Lexicon Genetics Incorporated | Human mitochondrial proteins and polynucleotides encoding the same |
EP2230253B1 (en) | 2000-06-05 | 2013-08-07 | The Brigham & Women's Hospital, Inc. | Antibodies against a homologue of the MDR p-glycoprotein on chromosome 7p15-21 and uses thereof |
AU2001275337A1 (en) * | 2000-06-07 | 2001-12-17 | Lexicon Genetics Incorporated | Novel human transporter proteins and polynucleotides encoding the same |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
PT1295611E (en) * | 2000-06-20 | 2010-09-14 | Dainippon Sumitomo Pharma Co | Oligonucleotide-transferring preparations |
US7074591B2 (en) * | 2000-06-27 | 2006-07-11 | Lexicon Genetics Incorporated | Polynucleotides encoding human GABA receptors |
AU2001278956B2 (en) * | 2000-07-18 | 2007-04-05 | Genzyme Corporation | Stabilized 1alpha-hydroxy vitamin d |
EP1315800A2 (en) * | 2000-07-21 | 2003-06-04 | Incyte Genomics, Inc. | Human proteases |
US6887685B1 (en) | 2000-07-25 | 2005-05-03 | Lexicon Genetics Incorporated | Human thymosin protein and polynucleotides encoding the same |
AU2001284672B2 (en) * | 2000-07-27 | 2007-05-24 | The Trustees Of The University Of Pennsylvania | Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses |
US20020076780A1 (en) * | 2000-08-16 | 2002-06-20 | Turner C. Alexander | Novel human ion channel proteins and polynucleotides encoding the same |
EP1311676A2 (en) * | 2000-08-22 | 2003-05-21 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding the same |
JP2004531201A (en) * | 2000-08-22 | 2004-10-14 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human protease and polynucleotide encoding the protease |
EP2157183A1 (en) | 2000-08-25 | 2010-02-24 | BASF Plant Science GmbH | Plant polynucleotides encoding prenyl proteases |
WO2002018555A2 (en) * | 2000-08-31 | 2002-03-07 | Lexicon Genetics Incorporated | Human kinase proteins and polynucleotides encoding the same |
WO2002020753A2 (en) * | 2000-09-01 | 2002-03-14 | Lexicon Genetics Incorporated | Human gaba transporter protein and polynucleotides encoding the same |
AU2001293019B2 (en) * | 2000-09-27 | 2007-01-18 | Lexicon Pharmaceuticals, Inc. | Human ion-exchanger proteins and polynucleotides encoding the same |
US6777232B1 (en) * | 2000-10-02 | 2004-08-17 | Lexicon Genetics Incorporated | Human membrane proteins and polynucleotides encoding the same |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
US20050059031A1 (en) | 2000-10-06 | 2005-03-17 | Quantum Dot Corporation | Method for enhancing transport of semiconductor nanocrystals across biological membranes |
WO2002031129A2 (en) | 2000-10-12 | 2002-04-18 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US7001763B1 (en) | 2000-10-17 | 2006-02-21 | Lexicon Genetics Incorporated | Human semaphorin proteins and polynucleotides encoding the same |
US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
EP1624062A3 (en) * | 2000-10-27 | 2006-02-22 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding them |
JP2004521614A (en) * | 2000-10-27 | 2004-07-22 | インヴィトロジェン コーポレーション | Methods for introducing antisense oligonucleotides into eukaryotic cells |
US7060442B2 (en) * | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
CA2427701A1 (en) * | 2000-10-30 | 2002-05-10 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding the same |
ATE336571T1 (en) * | 2000-11-01 | 2006-09-15 | Lexicon Genetics Inc | POLYNUCLEOTIDES THAT CODE FOR HUMAN MELTRIN BETA (ADAM19) METALLOENDOPEPTIDASES |
WO2002050278A2 (en) * | 2000-11-15 | 2002-06-27 | Lexicon Genetics Incorporated | Novel human secreted proteins and polynucleotides encoding the same |
AU2002228633A1 (en) * | 2000-11-20 | 2002-06-03 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
CZ301427B6 (en) * | 2000-11-29 | 2010-02-24 | Pci Biotech As | Method for introducing a molecule into a cell cytosol |
PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
JP2004517622A (en) | 2000-12-11 | 2004-06-17 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human kinase and polynucleotide encoding the kinase |
JP2004530417A (en) * | 2000-12-12 | 2004-10-07 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human kinase and polynucleotide encoding it |
US6583269B1 (en) | 2000-12-18 | 2003-06-24 | Lexicon Genetics Incorporated | Human protease inhibitor and polynucleotides encoding the same |
US6852844B1 (en) * | 2000-12-20 | 2005-02-08 | Lexicon Genetics Incorporated | Human protocadherin proteins and polynucleotides encoding the same |
CA2432737A1 (en) * | 2000-12-20 | 2002-06-27 | Lexicon Genetics Incorporated | Human ion channel protein and polynucleotides encoding the same |
DE10064870B4 (en) * | 2000-12-27 | 2004-10-07 | G.O.T. Gesellschaft Zur Therapieoptimierung Und Targeting Entwicklungs Mbh | Sulfur-containing amphiphiles for the transfer of biologically active molecules into cells |
MXPA03005386A (en) | 2000-12-28 | 2004-04-20 | Wyeth Corp | Recombinant protective protein from $i(streptococcus pneumoniae). |
WO2002053753A2 (en) * | 2001-01-05 | 2002-07-11 | Lexicon Genetics Incorporated | Novel human lipase and polynucleotides encoding the same |
AU2002241911B9 (en) * | 2001-01-19 | 2007-01-25 | Celmed Oncology (Usa), Inc. | Methods to treat autoimmune and inflammatory conditions |
JP2004524835A (en) * | 2001-01-23 | 2004-08-19 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human kinase and polynucleotide encoding it |
CA2434897A1 (en) * | 2001-01-24 | 2002-08-01 | Lexicon Genetics Incorporated | Human lipase and polynucleotides encoding the same |
US20020132257A1 (en) * | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
WO2002063002A2 (en) * | 2001-02-02 | 2002-08-15 | Lexicon Genetics Incorporated | Novel human transporter protein and polynucleotides encoding the same |
DK1373470T3 (en) | 2001-02-20 | 2013-07-29 | Intrexon Corp | HIS UNKNOWN SUBSTITUTION MUTANTE RECEPTORS AND THEIR USE IN A CELL CEREAL RECEPTOR-BASED INDUCTIONAL Gene EXPRESSION SYSTEM |
DK1456346T3 (en) | 2001-02-20 | 2012-05-29 | Intrexon Corp | NEW INDUCERABLE Gene EXPRESSION SYSTEM BASED ON ECDYSON RECEPTOR / INVERTEBRATE-RETINOID-X RECEPTOR |
EP1572862B1 (en) | 2001-02-20 | 2012-08-01 | Intrexon Corporation | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
JP4994563B2 (en) | 2001-02-20 | 2012-08-08 | イントレキソン コーポレーション | Novel substitution mutant receptors and their use in nuclear receptor-based inducible gene expression systems |
US20030039660A1 (en) | 2001-03-02 | 2003-02-27 | The Rockefeller University | Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
JP3929250B2 (en) * | 2001-03-08 | 2007-06-13 | 株式会社ルネサステクノロジ | Semiconductor device |
US7252990B2 (en) * | 2001-03-12 | 2007-08-07 | Lexicon Genetics Incorporated | Human dectin proteins and polynucleotides encoding the same |
US20020164627A1 (en) * | 2001-03-12 | 2002-11-07 | Wilganowski Nathaniel L. | Novel human transporter proteins and polynucleotides encoding the same |
AU2002306696B2 (en) * | 2001-03-12 | 2007-12-20 | Lexicon Pharmaceuticals, Inc. | Novel human EGF-family proteins and polynucleotides encoding the same |
WO2002072019A2 (en) * | 2001-03-13 | 2002-09-19 | Vical Incorporated | Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
US6994995B1 (en) * | 2001-03-16 | 2006-02-07 | Lexicon Genetics Incorporated | Human synaptotagmin and polynucleotides encoding the same |
US6613534B2 (en) | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
US7294511B2 (en) | 2001-03-22 | 2007-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US20030186390A1 (en) * | 2001-03-22 | 2003-10-02 | De Jong Gary | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US6936469B2 (en) * | 2001-03-22 | 2005-08-30 | Chromos Molecular Systems Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
US20040028651A1 (en) * | 2001-03-29 | 2004-02-12 | Karrupiah Muthumani | Composition and methods of using hiv vpr |
EP1383879A4 (en) * | 2001-04-06 | 2005-05-11 | Lexicon Genetics Inc | Novel human kinases and polynucleotides encoding the same |
US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
ATE541937T1 (en) * | 2001-04-06 | 2012-02-15 | Univ Chicago | CHEMOTHERAPEUTIC INTRODUCTION OF EGR-1 PROMOTER ACTIVITY IN GENE THERAPY |
US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
US6644173B2 (en) * | 2001-04-11 | 2003-11-11 | Keuring, Incorporated | Beverage filter cartridge holder |
US20070128229A1 (en) * | 2002-04-12 | 2007-06-07 | Wyeth | Surface proteins of Streptococcus pyogenes |
JP2004533236A (en) * | 2001-04-13 | 2004-11-04 | ワイエス | Surface protein of Streptococcus pyogenes |
EP2228389B1 (en) | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
US6607895B2 (en) * | 2001-04-16 | 2003-08-19 | Lexicon Genetics Incorporated | Human adenylsuccinate synthetase and polynucleotides encoding the same |
US20020165175A1 (en) * | 2001-04-17 | 2002-11-07 | Xiaowu Liang | Fast and enzymeless cloning of nucleic acid fragments |
US20030203865A1 (en) * | 2001-04-30 | 2003-10-30 | Pierrot Harvie | Lipid-comprising drug delivery complexes and methods for their production |
US20030077829A1 (en) * | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
WO2002088313A2 (en) * | 2001-04-30 | 2002-11-07 | Lexicon Genetics Incorporated | Novel human nuclear transporters and polynucleotides encoding the same |
US20020193585A1 (en) * | 2001-05-25 | 2002-12-19 | Walke D. Wade | Novel human transporter proteins and polynucleotides encoding the same |
EP1461425B1 (en) | 2001-05-29 | 2008-02-13 | Lexicon Pharmaceuticals, Inc. | Novel human hydroxylases and polynucleotides encoding the same |
US7745398B2 (en) * | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 and treatment of cancer |
US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
JP2004531268A (en) * | 2001-06-14 | 2004-10-14 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human transporter protein and polynucleotide encoding the same |
WO2003000297A1 (en) * | 2001-06-20 | 2003-01-03 | Sumitomo Pharmaceuticals Company, Limited | Method of promoting nucleic acid transfer |
DK2000545T3 (en) | 2001-06-20 | 2011-11-28 | Genentech Inc | Compositions and methods for diagnosis and treatment of lung tumor |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
CA2451643C (en) | 2001-06-21 | 2012-11-13 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
EP1397154B1 (en) | 2001-06-22 | 2006-08-02 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Abin-mediated hepatitis protection |
CA2452088A1 (en) * | 2001-06-26 | 2003-01-03 | Elka Touitou | Compositions and methods for intracellular delivery |
AU2002318186A1 (en) * | 2001-07-03 | 2003-01-21 | Lexicon Genetics Incorporated | Novel human kielin-like proteins and polynucleotides encoding the same |
EP1414841B1 (en) | 2001-07-10 | 2012-11-14 | Lakewood-Amedex, Inc | Oligonucleotide-containing pharmacological compositions and their use |
WO2003062370A2 (en) | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
AU2002327430A1 (en) * | 2001-08-08 | 2003-02-24 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
US20040143104A1 (en) * | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
JP2005500060A (en) * | 2001-08-14 | 2005-01-06 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human collagen protein and polynucleotide encoding the same |
CA2460120A1 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2003027247A2 (en) | 2001-09-24 | 2003-04-03 | Sangamo Biosciences, Inc. | Modulation of stem cells using zinc finger proteins |
WO2003030125A1 (en) * | 2001-09-25 | 2003-04-10 | Werner Keber | Method and device for preventing unpermitted approach of airplanes to objects on the ground which are to be protected |
WO2003027266A2 (en) * | 2001-09-26 | 2003-04-03 | Rheogene Holdings, Inc. | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
WO2003027289A1 (en) | 2001-09-26 | 2003-04-03 | Rheo Gene Holdings, Inc. | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
US20040023910A1 (en) * | 2001-09-28 | 2004-02-05 | Zhiming Zhang | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
CA2462876A1 (en) * | 2001-10-05 | 2003-04-17 | The Trustees Of The University Of Pennsylvania | Compositions for and methods of treating and preventing sirs/sepsis |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
ATE516364T1 (en) | 2001-10-09 | 2011-07-15 | Isis Pharmaceuticals Inc | ANTISENSE MODULATION OF EXPRESSION OF THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEY S 5 |
MX339524B (en) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. |
US20030138407A1 (en) * | 2001-11-02 | 2003-07-24 | Patrick Lu | Therapeutic methods for nucleic acid delivery vehicles |
AU2002368202B2 (en) | 2001-11-02 | 2008-06-05 | Insert Therapeutics, Inc | Methods and compositions for therapeutic use of RNA interference |
US7488313B2 (en) * | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
US20050152959A1 (en) * | 2001-12-14 | 2005-07-14 | Transgene S. A. | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell |
TR201910060T4 (en) * | 2001-12-20 | 2019-07-22 | Merck Sharp & Dohme | SYN3 compositions and methods. |
US7255874B1 (en) | 2001-12-21 | 2007-08-14 | Closure Medical Corporation | Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto |
DK1463751T3 (en) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albumin Fusion Proteins. |
JP2005525095A (en) | 2002-01-02 | 2005-08-25 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
AU2003205615B2 (en) | 2002-01-10 | 2008-09-25 | Universiteit Gent | A novel splice variant of MyD88 and uses thereof |
EP2128248B2 (en) | 2002-02-01 | 2017-01-11 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
WO2003070905A2 (en) * | 2002-02-15 | 2003-08-28 | Zycos, Inc. | Electroporation methods for introducing bioactive agents into cells |
DE10207177A1 (en) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Optionally cationic lipids |
EP1490027A4 (en) * | 2002-03-05 | 2010-11-10 | Transave Inc | Methods for entrapment of bioactive agent in a liposome or lipid complex |
US8116860B2 (en) * | 2002-03-11 | 2012-02-14 | Altea Therapeutics Corporation | Transdermal porator and patch system and method for using same |
ES2612779T3 (en) * | 2002-03-11 | 2017-05-18 | Nitto Denko Corporation | System of transdermal patches of drug administration, method of manufacture thereof and method of use thereof |
US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
AU2003230874A1 (en) | 2002-04-16 | 2003-11-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040180438A1 (en) * | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
US7519418B2 (en) * | 2002-04-30 | 2009-04-14 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
WO2003093469A2 (en) * | 2002-05-01 | 2003-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
EP1549352A4 (en) * | 2002-05-06 | 2005-07-27 | Nucleonics Inc | Methods for delivery of nucleic acids |
US7598421B2 (en) * | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
EP2316922B1 (en) | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
EA200401565A1 (en) * | 2002-05-24 | 2005-04-28 | Неофарм, Инк. | METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS) |
WO2003099830A2 (en) * | 2002-05-24 | 2003-12-04 | Neopharm, Inc. | Cardiolipin compositions, methods of preparation and use |
AU2003245160B2 (en) | 2002-06-28 | 2009-09-24 | Arbutus Biopharma Corporation | Method and apparatus for producing liposomes |
AU2003261103A1 (en) * | 2002-07-02 | 2004-01-23 | Uab Research Foundation | Compounds promoting delivery of genes |
ES2279127T3 (en) | 2002-07-05 | 2007-08-16 | Lipoxen Technologies Limited | PROCEDURE TO INCREASE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION. |
US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
EP1540004A4 (en) * | 2002-07-31 | 2007-10-03 | Nucleonics Inc | Double stranded rna structures and constructs, and methods for generating and using the same |
US20040034336A1 (en) * | 2002-08-08 | 2004-02-19 | Neal Scott | Charged liposomes/micelles with encapsulted medical compounds |
US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
US7135324B2 (en) | 2002-09-04 | 2006-11-14 | The University Of Connecticut | Viral recombinases, related articles, and methods of use thereof |
AU2003273271A1 (en) * | 2002-09-09 | 2004-03-29 | The Brigham And Women's Hospital, Inc. | Genes and proteins altering tau-related neurodegeneration |
WO2004024067A2 (en) * | 2002-09-10 | 2004-03-25 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
BR0314236A (en) | 2002-09-13 | 2005-08-09 | Replicor Inc | Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster |
US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
US20060189554A1 (en) * | 2002-09-24 | 2006-08-24 | Russell Mumper | Nanoparticle-Based vaccine delivery system containing adjuvant |
EP2272958A1 (en) | 2002-09-26 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
US20050277611A1 (en) * | 2002-10-16 | 2005-12-15 | Neopharm, Inc. | Cationic cardiolipin analoges and its use thereof |
US6863731B2 (en) * | 2002-10-18 | 2005-03-08 | Controls Corporation Of America | System for deposition of inert barrier coating to increase corrosion resistance |
CN1747738B (en) * | 2002-10-29 | 2010-11-24 | 川塞夫有限公司 | Sustained release of antifectives |
US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
JP3447009B1 (en) * | 2002-10-29 | 2003-09-16 | 實 平垣 | Construct structure and method for producing the same |
US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
WO2004044138A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
JP4986109B2 (en) | 2002-11-13 | 2012-07-25 | ジェンザイム・コーポレーション | Antisense regulation of apolipoprotein B expression |
DK1569695T3 (en) | 2002-11-13 | 2013-08-05 | Genzyme Corp | ANTISENSE MODULATION OF APOLIPOPROTEIN-B EXPRESSION |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
EP1903056A3 (en) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof |
CA2508228C (en) | 2002-12-23 | 2013-12-17 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
EP1578193A4 (en) * | 2002-12-23 | 2011-06-15 | Vical Inc | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
CA2508281C (en) * | 2002-12-23 | 2011-08-09 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
US20040138154A1 (en) * | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
US20070269891A9 (en) * | 2003-01-13 | 2007-11-22 | Yasunobu Tanaka | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
WO2004065551A2 (en) * | 2003-01-21 | 2004-08-05 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
DK1597366T3 (en) | 2003-02-11 | 2013-02-25 | Antisense Therapeutics Ltd | Modulation of expression of insulin-like growth factor receptor I |
CA2516188C (en) * | 2003-02-14 | 2012-04-17 | University Of South Florida | Chitosan-derivatives for gene delivery and expression |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
EP2216407B1 (en) | 2003-03-07 | 2016-01-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
US20040242502A1 (en) * | 2003-04-08 | 2004-12-02 | Galenica Pharmaceuticals, Inc. | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines |
CA2522751A1 (en) * | 2003-04-16 | 2004-11-04 | Wyeth Holdings Corporation | Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
EP1620112A4 (en) * | 2003-04-17 | 2007-04-25 | Univ Columbia | Desmoglein 4 is a novel gene involved in hair growth |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
JP4846588B2 (en) * | 2003-05-22 | 2011-12-28 | モレキュラー、トランスファー、インコーポレイテッド | Novel lipids for nucleic acid transfection |
AU2004253455B2 (en) | 2003-06-03 | 2011-03-03 | Eli Lilly And Company | Modulation of survivin expression |
CN101396555A (en) * | 2003-06-04 | 2009-04-01 | 坎基股份有限公司 | Methods and compositions for interferon therapy |
EP2284268A3 (en) | 2003-06-12 | 2012-05-30 | Alnylam Pharmaceuticals Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US20060078560A1 (en) * | 2003-06-23 | 2006-04-13 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
JP4951338B2 (en) * | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | Interfering RNA encapsulated in lipid |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
WO2005014791A2 (en) | 2003-08-08 | 2005-02-17 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7330851B2 (en) * | 2003-08-18 | 2008-02-12 | Eaglehawk, Limited | Data security through dissembly of data elements or connections between elements |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
EP1656453A2 (en) * | 2003-08-22 | 2006-05-17 | Nucleonics, Inc. | Eukaryotic expression systems for expression of inhibitory rna in multiple intracellular compartments |
US7291604B2 (en) * | 2003-09-03 | 2007-11-06 | The General Hospital Corporation | Methods of treating restenosis |
AU2004272646B2 (en) * | 2003-09-15 | 2011-11-24 | Arbutus Biopharma Corporation | Polyethyleneglycol-modified lipid compounds and uses thereof |
SG146682A1 (en) | 2003-09-18 | 2008-10-30 | Isis Pharmaceuticals Inc | Modulation of eif4e expression |
CA2539439C (en) | 2003-09-19 | 2012-10-23 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for regulation of gene expression |
US7662929B2 (en) | 2003-10-10 | 2010-02-16 | Alchemia Oncology Pty Limited | Antibody that specifically binds hyaluronan synthase |
DE10347710B4 (en) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Recombinant vaccines and their use |
AU2003284327A1 (en) * | 2003-10-22 | 2005-06-08 | Neal Scott | Charged liposomes/micelles with encapsulated medical compounds |
US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
ITMI20032185A1 (en) * | 2003-11-12 | 2005-05-13 | Chemi Spa | PROCESS FOR THE SYNTHESIS OF CATIONIC LIPIDS. |
US20050107318A1 (en) * | 2003-11-17 | 2005-05-19 | Samuel Wadsworth | Methods of treating diabetes and other blood sugar disorders |
CA2747871C (en) | 2003-11-17 | 2018-04-10 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
EP1696034A4 (en) * | 2003-12-19 | 2006-12-27 | Dainippon Sumitomo Pharma Co | Novel method of nucleic acid transfer |
SE0303588D0 (en) | 2003-12-30 | 2003-12-30 | Bioactive Polymers Ab C O Lund | Surface protection of exposed biological tissues |
WO2005071080A2 (en) | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US7432057B2 (en) * | 2004-01-30 | 2008-10-07 | Michigan State University | Genetic test for PSE-susceptible turkeys |
AU2005214091B2 (en) * | 2004-02-24 | 2010-08-12 | Abbvie B.V. | Method for determining the risk of developing a neurological disease |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
EP2700720A3 (en) | 2004-03-15 | 2015-01-28 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNASE H |
ATE480550T1 (en) * | 2004-03-25 | 2010-09-15 | California Inst Of Techn | HYBRIDIZATION CHAIN REACTION |
CA2561221C (en) * | 2004-03-26 | 2016-09-20 | Curis, Inc. | Rna interference modulators of hedgehog signaling and uses thereof |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
JP4564052B2 (en) | 2004-04-08 | 2010-10-20 | サンガモ バイオサイエンシズ インコーポレイテッド | Methods and compositions for modulating myocardial contractility |
US20050260652A1 (en) * | 2004-04-15 | 2005-11-24 | The General Hospital Corporation | Compositions and methods that modulate RNA interference |
WO2005103713A2 (en) | 2004-04-20 | 2005-11-03 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
ES2427177T3 (en) | 2004-04-27 | 2013-10-29 | Galapagos N.V. | Methods, agents and tests for the detection of compounds to induce differentiation of undifferentiated mammalian cells to give rise to osteoblasts |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
KR101462819B1 (en) | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | Liposomes useful for drug delivery |
JP5331340B2 (en) * | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | Influenza virus vaccine composition and method of use thereof |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
EP1766035B1 (en) * | 2004-06-07 | 2011-12-07 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
ATE537263T1 (en) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | CATIONIC LIPIDS AND METHODS OF USE |
US7306923B2 (en) | 2004-06-14 | 2007-12-11 | Galapagos N.V. | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases |
EP1759203A2 (en) | 2004-06-21 | 2007-03-07 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
JP2008504827A (en) * | 2004-07-02 | 2008-02-21 | プロチバ バイオセラピューティクス インコーポレイティッド | Immunostimulatory siRNA molecules and methods of use thereof |
CA2573176A1 (en) * | 2004-07-09 | 2006-01-19 | Bc Cancer Agency | Nup98-hox fusions for expansion of hemopoietic stem cells |
US7604798B2 (en) * | 2004-07-15 | 2009-10-20 | Northwestern University | Methods and compositions for importing nucleic acids into cell nuclei |
EP1784416B1 (en) | 2004-07-16 | 2011-10-05 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccines against aids comprising cmv/r nucleic acid constructs |
WO2006007712A1 (en) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
EA013752B1 (en) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
JP4804467B2 (en) | 2004-08-23 | 2011-11-02 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Multiple RNA polymerase III promoter expression construct |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
EP1789095A2 (en) | 2004-09-16 | 2007-05-30 | Sangamo Biosciences Inc. | Compositions and methods for protein production |
DE602005027479D1 (en) | 2004-09-24 | 2011-05-26 | Alnylam Pharmaceuticals Inc | TARGETING OF INTERMEDIATE PRODUCTS TO REPRODUCTION OF INDIVIDUAL VIRUSES BY RNAI |
ATE514776T1 (en) | 2004-10-05 | 2011-07-15 | California Inst Of Techn | APTAMER-REGULATED NUCLEIC ACIDS AND USES THEREOF |
US7485468B2 (en) | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
ATE435025T1 (en) * | 2004-10-18 | 2009-07-15 | Sinai School Medicine | INHIBITION OF TUMOR GROWTH AND METASTASIS FORMATION WITH PEPTIDES DERIVED FROM ATF2 |
CN101048139A (en) * | 2004-10-28 | 2007-10-03 | 艾德克斯实验室公司 | Compositions for controlled delivery of pharmaceutically active compounds |
US20060147449A1 (en) * | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
DE102004057303A1 (en) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stable crystal modifications of DOTAP chloride |
WO2006060723A2 (en) * | 2004-12-03 | 2006-06-08 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
EP2316942B1 (en) | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
JP4988606B2 (en) | 2005-02-28 | 2012-08-01 | サンガモ バイオサイエンシズ インコーポレイテッド | Anti-angiogenic methods and compositions |
US7727721B2 (en) * | 2005-03-08 | 2010-06-01 | California Institute Of Technology | Hybridization chain reaction amplification for in situ imaging |
RU2007137489A (en) | 2005-03-10 | 2009-04-20 | Дженентек, Инк. (Us) | METHODS AND COMPOSITIONS FOR MODULATION OF VESSEL INTEGRITY |
US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
ATE541928T1 (en) | 2005-03-31 | 2012-02-15 | Calando Pharmaceuticals Inc | RIBONUCLEOTIDE REDUCTASE SUBUNITY 2 INHIBITORS AND USES THEREOF |
US20070026061A1 (en) * | 2005-05-25 | 2007-02-01 | Nahid Ali | Liposomal formulation and use thereof |
LT2816118T (en) | 2005-05-31 | 2018-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Methods for delivering genes |
CA2610791C (en) | 2005-06-08 | 2015-12-01 | Cangene Corporation | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
CN101437539B (en) * | 2005-07-05 | 2013-10-02 | 康奈尔研究基金会(有限公司) | Blocking leukocyte emigration and inflammation by interfering with CD99l2 |
SG10201508995QA (en) | 2005-07-26 | 2015-11-27 | Sangamo Biosciences Inc | Targeted integration and expression of exogenous nucleic acid sequences |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
US7666584B2 (en) * | 2005-09-01 | 2010-02-23 | Philadelphia Health & Education Coporation | Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer |
CN101268194A (en) | 2005-09-20 | 2008-09-17 | 巴斯福植物科学有限公司 | Methods for controlling gene expression using ta-siRNA |
DE102005046490A1 (en) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency |
US7312079B1 (en) | 2005-10-06 | 2007-12-25 | Lexicon Pharmaceuticals, Inc. | Variants of FAM3C |
ATE526975T1 (en) | 2005-10-07 | 2011-10-15 | California Inst Of Techn | PKR ACTIVATION USING HYBRIDIZATION CHAIN REACTION |
JP5671206B2 (en) | 2005-10-21 | 2015-02-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Mutation of c-KIT oncogene in melanoma |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
US8114440B2 (en) | 2005-11-16 | 2012-02-14 | Idexx Laboratories Inc. | Pharmaceutical compositions for the administration of aptamers |
US7754679B2 (en) * | 2005-11-16 | 2010-07-13 | Idexx Laboratories, Inc. | Pharmaceutical compositions for the administration of aptamers |
CA2630602A1 (en) | 2005-11-21 | 2007-05-31 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
DK1962805T3 (en) | 2005-12-08 | 2016-09-26 | Insmed Inc | Lipid-based compositions of the anti-infective agents for the treatment of lung infections |
US10647960B2 (en) * | 2005-12-13 | 2020-05-12 | The Trustees Of The University Of Pennsylvania | Transcriptome transfer produces cellular phenotype conversion |
US9149543B2 (en) | 2005-12-15 | 2015-10-06 | The Trustees Of The University Of Pennsylvania | Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors |
US8669418B2 (en) | 2005-12-22 | 2014-03-11 | Vib Vzw | Means and methods for mediating protein interference |
WO2007073489A2 (en) * | 2005-12-22 | 2007-06-28 | Trustees Of Boston University | Molecules for gene delivery and gene therapy, and methods of use thereof |
WO2007071789A1 (en) | 2005-12-22 | 2007-06-28 | Vib Vzw | Means and methods for mediating protein interference |
SI2161038T1 (en) | 2006-01-26 | 2014-05-30 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
WO2008001166A2 (en) * | 2006-02-07 | 2008-01-03 | Council Of Scientific & Industrial Research | Process for synthesis of glycomimicking cationic amphiphiles |
JP2009525757A (en) | 2006-02-10 | 2009-07-16 | ザ ユニバーシティ オブ シンシナティ | Phosphatase inhibitor protein-1 as a regulator of cardiac function |
EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
AU2007243442A1 (en) * | 2006-04-24 | 2007-11-08 | Shantha West, Inc. | AgRM2 antigen |
CN101437943A (en) | 2006-05-03 | 2009-05-20 | 波罗的科技发展有限公司 | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
EP2015780B1 (en) | 2006-05-05 | 2012-12-12 | Molecular Transfer, Inc. | Novel reagents for transfection of eukaryotic cells |
EP2027262B1 (en) | 2006-05-25 | 2010-03-31 | Sangamo Biosciences Inc. | Variant foki cleavage half-domains |
GB0610636D0 (en) | 2006-05-30 | 2006-07-05 | Univ London | Materials and complexes for the delivery of biologically-active material to cells |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US20080004410A1 (en) * | 2006-06-30 | 2008-01-03 | Yu-Chin Lai | Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same |
JP5072275B2 (en) | 2006-07-03 | 2012-11-14 | テルモ株式会社 | Method for separating closed vesicles, method for producing preparation and evaluation method |
WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
JP2009544731A (en) * | 2006-07-28 | 2009-12-17 | サノフィ−アベンティス | Compositions and methods for tumor therapy |
PL2068922T3 (en) | 2006-10-19 | 2012-11-30 | Csl Ltd | Anti-il-13r alpha 1 antibodies and their uses thereof |
ES2658239T3 (en) | 2006-10-19 | 2018-03-08 | Csl Limited | Interleukin-13 alpha 1 receptor high affinity antibody antagonists |
US8466154B2 (en) * | 2006-10-27 | 2013-06-18 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
WO2008058291A2 (en) | 2006-11-09 | 2008-05-15 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
AU2007355108B2 (en) | 2006-11-27 | 2013-07-11 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
EP1938843A1 (en) * | 2006-12-19 | 2008-07-02 | Novosom AG | Lipids and lipid assemblies comrising transfection enhancer elements |
AR064642A1 (en) * | 2006-12-22 | 2009-04-15 | Wyeth Corp | POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD |
EP2118118B1 (en) * | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
WO2008094945A2 (en) | 2007-01-29 | 2008-08-07 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
US9603922B2 (en) | 2007-02-21 | 2017-03-28 | Vaccinex, Inc. | Modulation of NKT cell activity with antigen-loaded CD1d molecules |
CN101663407B (en) | 2007-02-22 | 2017-08-08 | 健泰科生物技术公司 | method for detecting inflammatory bowel disease |
ES2570182T3 (en) | 2007-02-23 | 2016-05-17 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2008106658A2 (en) | 2007-03-01 | 2008-09-04 | California Institute Of Technology | TRIGGERED RNAi |
WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
DE102007015598A1 (en) * | 2007-03-29 | 2008-10-02 | Heinrich-Heine-Universität Düsseldorf | Use of fluorochemical compounds for diagnostic purposes using imaging techniques |
WO2008124768A1 (en) | 2007-04-09 | 2008-10-16 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
EP2157982B1 (en) | 2007-05-04 | 2014-12-17 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
EP2155770B1 (en) | 2007-05-16 | 2013-10-16 | California Institute of Technology | A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways |
BRPI0811870A2 (en) * | 2007-05-16 | 2014-10-21 | Mat Malta Advanced Technologies Ltd | INFLUENCE TREATMENT AND PREVENTION |
CA2688346A1 (en) | 2007-05-23 | 2008-12-04 | Vical Incorporated | Compositions and methods for enhancing immune responses to vaccines |
DK2167458T3 (en) | 2007-05-29 | 2018-06-18 | Intrexon Corp | CHIRAL DIACYL HYDRAZINE LIGANDS FOR MODULATING EXPRESSION OF EXOGENEOUS GENES OF AN ECDYSON RECEPTOR COMPLEX |
US20080312174A1 (en) * | 2007-06-05 | 2008-12-18 | Nitto Denko Corporation | Water soluble crosslinked polymers |
MX2009013766A (en) | 2007-06-20 | 2010-02-01 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases. |
US20090069266A1 (en) * | 2007-06-27 | 2009-03-12 | Northwestern University | Methods and compositions for nucleic acid transfer into cells |
KR101510778B1 (en) | 2007-07-12 | 2015-04-10 | 상가모 바이오사이언스 인코포레이티드 | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut8) gene expression |
WO2009011855A2 (en) * | 2007-07-16 | 2009-01-22 | California Institute Of Technology | Selection of nucleic acid-based sensor domains within nucleic acid switch platform |
US8828960B2 (en) * | 2007-07-17 | 2014-09-09 | Idexx Laboratories, Inc. | Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
KR20100049084A (en) | 2007-08-23 | 2010-05-11 | 인트렉손 코포레이션 | Methods and compositions for diagnosing disease |
US8367815B2 (en) | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
US20120165387A1 (en) | 2007-08-28 | 2012-06-28 | Smolke Christina D | General composition framework for ligand-controlled RNA regulatory systems |
US8865667B2 (en) | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
AU2008302504B2 (en) * | 2007-09-17 | 2014-08-14 | Agrofresh Inc. | Compositions and methods for the modification of physiological responses in plants |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
NZ584848A (en) | 2007-09-28 | 2012-09-28 | Intrexon Corp | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
JP2010539978A (en) | 2007-10-02 | 2010-12-24 | アムジェン インコーポレイテッド | Increased erythropoietin using nucleic acids that can hybridize to micro-RNA and its precursors |
AU2008308509B2 (en) | 2007-10-04 | 2014-10-23 | Zymogenetics, Inc. | B7 family member zB7H6 and related compositions and methods |
BRPI0818287A2 (en) | 2007-10-08 | 2015-11-03 | Intrexon Corp | manipulated dendritic cells and uses for cancer treatment. |
GB0720486D0 (en) * | 2007-10-19 | 2007-11-28 | Univ Edinburgh | Cationic lipids |
WO2009058881A1 (en) * | 2007-10-29 | 2009-05-07 | The University Of California | Osteoarthritis gene therapy |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
DE102007056488A1 (en) | 2007-11-22 | 2009-07-23 | Biontex Laboratories Gmbh | Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense |
WO2009065618A2 (en) | 2007-11-22 | 2009-05-28 | Biontex Laboratories Gmbh | Improvement of transfection results of non-viral gene delivery systems by influencing the congenital immune system |
DE102008016275A1 (en) | 2008-03-28 | 2009-11-19 | Biontex Laboratories Gmbh | Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense |
DE102008023913A1 (en) | 2008-05-16 | 2009-11-19 | Biontex Laboratories Gmbh | Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense |
AU2008340355B2 (en) | 2007-12-04 | 2015-01-22 | Tekmira Pharmaceuticals Corporation | Targeting lipids |
US9029524B2 (en) | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
EP2610341B1 (en) | 2007-12-11 | 2014-09-17 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
WO2009078799A1 (en) | 2007-12-17 | 2009-06-25 | Marfl Ab | New vaccine for the treatment of mycobacterium related disorders |
EP2238251B1 (en) | 2007-12-27 | 2015-02-11 | Protiva Biotherapeutics Inc. | Silencing of polo-like kinase expression using interfering rna |
HUE025560T2 (en) | 2007-12-28 | 2016-03-29 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
CN102016036B (en) | 2008-02-11 | 2015-04-08 | 阿克赛医药公司 | Modified RNAi polynucleotides and uses thereof |
US8497364B2 (en) * | 2008-02-27 | 2013-07-30 | California Institute Of Technology | Triggered RNAi |
US20110045001A1 (en) * | 2008-03-28 | 2011-02-24 | Biontex Laboratories Gmbh | Transfection results of non-viral gene delivery systems by influencing of the innate immune system |
EP2283133A2 (en) | 2008-04-04 | 2011-02-16 | Calando Pharmaceuticals, Inc. | Compositions and use of epas1 inhibitors |
JP5788312B2 (en) | 2008-04-11 | 2015-09-30 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomal degradable components |
NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
CA2721380A1 (en) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Silencing of csn5 gene expression using interfering rna |
CN102137675A (en) | 2008-04-17 | 2011-07-27 | Pds生物科技公司 | Stimulation of an immune response by enantiomers of cationic lipids |
US20100021904A1 (en) * | 2008-05-21 | 2010-01-28 | Pierce Niles A | Shielded cross-linking probes |
US8241854B2 (en) * | 2008-05-22 | 2012-08-14 | California Institute Of Technology | Triggered RNAi |
US20100021901A1 (en) * | 2008-05-22 | 2010-01-28 | Peng Yin | Compositions and methods for detecting analytes |
EP2296669B1 (en) | 2008-05-30 | 2012-03-21 | Yale University | Targeted oligonucleotide compositions for modifying gene expression |
EP2910568B1 (en) | 2008-06-10 | 2018-08-22 | Sangamo Therapeutics, Inc. | Methods and compositions for generation of BAX- and BAK-deficient cell lines |
RU2010151562A (en) | 2008-06-20 | 2012-07-27 | ВАЙЕТ ЭлЭлСи (US) | COMPOSITIONS AND METHODS OF APPLICATION OF ORF1358 FROM BETA-HEMOLYTIC STRAPTOCOK STRAINS |
WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
KR20160015400A (en) | 2008-08-22 | 2016-02-12 | 상가모 바이오사이언스 인코포레이티드 | Methods and compositions for targeted single-stranded cleavage and targeted integration |
JP5420668B2 (en) | 2008-08-25 | 2014-02-19 | エクスカリアード・ファーマシューティカルズ,インコーポレイテッド | Antisense oligonucleotides for connective tissue growth factor and uses thereof |
EP2816113A3 (en) | 2008-09-11 | 2015-03-25 | Galapagos N.V. | Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator |
CA2753338A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
JP2012505913A (en) | 2008-10-16 | 2012-03-08 | マリーナ バイオテック,インコーポレイテッド | Processes and compositions for efficient delivery by liposomes in therapy to suppress gene expression |
AU2009313615B2 (en) | 2008-11-05 | 2012-11-29 | Regents Of The University Of Minnesota | Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease |
WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
WO2010065662A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
RU2746478C2 (en) | 2008-12-04 | 2021-04-14 | КьюРНА, Инк. | Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene |
KR101829469B1 (en) | 2008-12-04 | 2018-03-30 | 큐알엔에이, 인크. | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
US9206404B2 (en) | 2008-12-04 | 2015-12-08 | Sangamo Biosciences, Inc. | Method of deleting an IgM gene in an isolated rat cell |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
FR2941152B1 (en) * | 2009-01-20 | 2013-10-18 | Centre Nat Rech Scient | VECTORS COMPRISING ANIONIC MACROMOLECULE AND CATIONIC LIPID FOR THE ADMINISTRATION OF SMALL NUCLEIC ACIDS |
JP5827132B2 (en) | 2009-02-04 | 2015-12-02 | サンガモ バイオサイエンシズ インコーポレイテッド | Methods and compositions for treating neuropathy |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
ES2658626T3 (en) | 2009-02-12 | 2018-03-12 | Curna, Inc. | Treatment of diseases related to glial cell-derived neurotrophic factor (GDNF) by inhibition of natural antisense transcript to GDNF |
KR101682735B1 (en) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
JP2012517821A (en) | 2009-02-19 | 2012-08-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | Identification method and compound useful for diagnosis and treatment of diseases including inflammation |
US20120035245A1 (en) | 2009-02-19 | 2012-02-09 | Richard Antonius Jozef Janssen | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation |
JP2012517822A (en) | 2009-02-19 | 2012-08-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | Identification method and compound useful for diagnosis and treatment of diseases including inflammation |
JP6250263B2 (en) | 2009-03-04 | 2017-12-20 | クルナ・インコーポレーテッド | Treatment of SIRT1-related diseases by suppression of natural antisense transcripts against sirtuin 1 (SIRT1) |
ES2656290T3 (en) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2 |
EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
US8993509B2 (en) | 2009-03-31 | 2015-03-31 | Robert Zimmerman | Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity |
WO2010112569A1 (en) | 2009-03-31 | 2010-10-07 | Robert Zimmermann | Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor |
EP2414829A1 (en) | 2009-04-01 | 2012-02-08 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
CA2756833C (en) | 2009-04-09 | 2019-11-19 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
JP5748653B2 (en) | 2009-04-10 | 2015-07-15 | 協和発酵キリン株式会社 | Hematological tumor therapy using anti-TIM-3 antibody |
CN102724993B (en) | 2009-04-17 | 2016-04-27 | 纽约大学 | Targeting TNF family receptors the peptide, compositions, method and uses thereof of antagonism TNF effect |
EP3524275A1 (en) | 2009-04-22 | 2019-08-14 | Massachusetts Institute Of Technology | Innate immune supression enables repeated delivery of long rna molecules |
US20100273203A1 (en) * | 2009-04-23 | 2010-10-28 | Board Of Trustees Of The University Of Arkansas | Methods and compositions for detecting metabolites |
KR101732201B1 (en) | 2009-04-27 | 2017-05-02 | 교와 핫꼬 기린 가부시키가이샤 | Anti-il-3r antibody for use in treatment of blood tumor |
US8044215B2 (en) * | 2009-04-29 | 2011-10-25 | Juvaris Biotherapeutics, Inc. | Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds |
EP2424987B1 (en) | 2009-05-01 | 2017-11-15 | CuRNA, Inc. | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
JP5883782B2 (en) | 2009-05-06 | 2016-03-15 | クルナ・インコーポレーテッド | Treatment of lipid transport metabolism gene-related diseases by suppression of natural antisense transcripts on lipid transport metabolism genes |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
WO2010135207A1 (en) | 2009-05-16 | 2010-11-25 | Agave Pharma, Incorporated | Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
CN103221541B (en) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene |
BRPI1011236A2 (en) | 2009-06-15 | 2019-07-09 | 4S3 Bioscience Inc | methods and compositions for treating myotubular myopathy using chimeric polypeptides comprising miotubularih1 (mtm1) polypeptides |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
JP6128846B2 (en) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1) |
US8859515B2 (en) | 2009-06-24 | 2014-10-14 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 |
EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
WO2011003834A1 (en) | 2009-07-09 | 2011-01-13 | Marina Biotech, Inc. | Amphoteric liposomes comprising imino lipids |
WO2011011447A1 (en) | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
EP2461819A4 (en) | 2009-07-28 | 2013-07-31 | Sangamo Biosciences Inc | Methods and compositions for treating trinucleotide repeat disorders |
WO2011015573A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
AU2010279572B2 (en) | 2009-08-03 | 2017-02-02 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
WO2011015572A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US8410064B2 (en) * | 2009-08-24 | 2013-04-02 | The Board Of Trustees Of The University Of Arkansas | Classical cannabinoid metabolites and methods of use thereof |
CN102482671B (en) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP) |
CA2772715C (en) | 2009-09-02 | 2019-03-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP2480668A2 (en) | 2009-09-23 | 2012-08-01 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing genes expressed in cancer |
CA2780741C (en) | 2009-10-12 | 2023-04-04 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
WO2011050194A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
WO2011056682A1 (en) | 2009-10-27 | 2011-05-12 | The University Of British Columbia | Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids |
WO2011056234A1 (en) | 2009-11-06 | 2011-05-12 | Fibrogen, Inc. | Treatment for radiation-induced disorders |
WO2011060233A1 (en) | 2009-11-11 | 2011-05-19 | The Trustees Of The University Of Pennsylvania | Anti-tem1 antibodies and uses thereof |
TWI507524B (en) | 2009-11-30 | 2015-11-11 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
NZ733634A (en) | 2009-12-01 | 2022-10-28 | Translate Bio Inc | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
AU2010329847A1 (en) | 2009-12-11 | 2012-07-26 | Genecode As | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators |
WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
KR101891352B1 (en) | 2009-12-23 | 2018-08-24 | 큐알엔에이, 인크. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
RU2619185C2 (en) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2 |
EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
JP5982288B2 (en) | 2009-12-29 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63) |
NO2521784T3 (en) | 2010-01-04 | 2018-05-05 | ||
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
ES2664866T3 (en) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg |
US8883739B2 (en) | 2010-01-19 | 2014-11-11 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
WO2011090804A1 (en) | 2010-01-22 | 2011-07-28 | Dow Agrosciences Llc | Targeted genomic alteration |
CA2786568A1 (en) | 2010-01-25 | 2011-07-28 | Curna, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
EP4328304A2 (en) | 2010-02-08 | 2024-02-28 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
AU2011215557B2 (en) | 2010-02-09 | 2016-03-10 | Sangamo Therapeutics, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
JP5976548B2 (en) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcripts against PYCR1 |
SG183335A1 (en) | 2010-02-23 | 2012-09-27 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
WO2011109427A2 (en) | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
AU2011224570B2 (en) | 2010-03-08 | 2014-08-14 | Monsanto Technology Llc | Polynucleotide molecules for gene regulation in plants |
EP2547368A4 (en) | 2010-03-19 | 2014-08-06 | Univ South Alabama | Methods and compositions for the treatment of cancer |
EP3284821B1 (en) | 2010-03-23 | 2022-01-05 | Precigen, Inc. | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
US9247720B2 (en) | 2010-03-24 | 2016-02-02 | Institut National de la Santé et de la Recherche Médicale | Primate model from the family cercopithecidae infected by a HBV strain of human genotype |
CA2794189C (en) | 2010-03-24 | 2022-01-11 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
CN106074591B (en) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | RNA interference in ocular symptoms |
EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | Reduced size self-delivering rnai compounds |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US8883218B2 (en) * | 2010-03-26 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Anti-cancer nanoparticle compositions and methods of use |
WO2011120023A1 (en) | 2010-03-26 | 2011-09-29 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting survivin gene expression uses thereof |
WO2011127337A2 (en) | 2010-04-09 | 2011-10-13 | Opko Curna Llc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
US8790621B2 (en) * | 2010-04-12 | 2014-07-29 | Iowa State University Research Foundation, Inc. | Nanoparticles and nanoparticle compositions |
AU2011239386B2 (en) | 2010-04-16 | 2015-03-19 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using FGF |
WO2011133584A2 (en) | 2010-04-19 | 2011-10-27 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
WO2011139843A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Multi-sirna compositions for reducing gene expression |
US9408914B2 (en) | 2010-04-28 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
US20130129811A1 (en) | 2010-04-28 | 2013-05-23 | Takeshi Kuboyama | Cationic lipid |
SI2563920T1 (en) | 2010-04-29 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
SG185027A1 (en) | 2010-05-03 | 2012-11-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
JP5866106B2 (en) | 2010-05-12 | 2016-02-17 | コロンビア ユニヴァーシティ | Method for producing enteroendocrine cells that produce and secrete insulin |
CA2799091A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
US8658780B2 (en) | 2010-05-18 | 2014-02-25 | California Institute Of Technology | Triggered covalent probes for imaging and silencing genetic expression |
RU2585229C2 (en) | 2010-05-26 | 2016-05-27 | Курна, Инк. | Treatment of diseases associated with atonal homolog 1 (aton1) by inhibiting natural antisense transcript of gene aton1 |
CA2802017A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
EP2582387A2 (en) | 2010-06-17 | 2013-04-24 | The United States Of America As Represented By The Secretary, National Institutes Of Health | Compositions and methods for treating inflammatory conditions |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US20130171241A1 (en) | 2010-07-06 | 2013-07-04 | Novartis Ag | Liposomes with lipids having an advantageous pka-value for rna delivery |
AU2011276236B2 (en) | 2010-07-06 | 2016-03-10 | Glaxosmithkline Biologicals S.A. | Cationic oil-in-water emulsions |
HUE047796T2 (en) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | Delivery of rna to trigger multiple immune pathways |
RU2611190C2 (en) | 2010-07-14 | 2017-02-21 | Курна, Инк. | Treatment of diseases related with gene dlg by inhibition of natural antisense transcript of dlg gene |
US8962241B2 (en) | 2010-07-20 | 2015-02-24 | California Institute Of Technology | Triggered molecular geometry based bioimaging probes |
US8877438B2 (en) | 2010-07-20 | 2014-11-04 | California Institute Of Technology | Self-assembled polynucleotide structure |
US9834439B2 (en) | 2010-07-20 | 2017-12-05 | California Institute Of Technology | Biomolecular self-assembly |
US9057057B2 (en) | 2010-07-27 | 2015-06-16 | The Johns Hopkins University | Obligate heterodimer variants of foki cleavage domain |
HUE052850T2 (en) | 2010-08-23 | 2021-05-28 | Wyeth Llc | Stable formulations of neisseria meningitidis rlp2086 antigens |
SI3970742T1 (en) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
MX362802B (en) | 2010-09-10 | 2019-02-13 | Wyeth Llc Star | Non-lipidated variants of neisseria meningitidis orf2086 antigens. |
US8703824B2 (en) | 2010-09-14 | 2014-04-22 | Council Of Scientific & Industrial Research | Cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof |
EP3511420B1 (en) | 2010-09-27 | 2021-04-07 | Sangamo Therapeutics, Inc. | Compositions for inhibiting viral entry into cells |
JP5974012B2 (en) | 2010-10-05 | 2016-08-23 | ジェネンテック, インコーポレイテッド | Mutant smoothened and method of using the same |
ES2640755T3 (en) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Treatment of diseases related to Sialidase 4 (neu4) by inhibition of the natural antisense transcript to the neu4 gene |
MX363307B (en) | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Antigen delivery platforms. |
WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
RU2611195C2 (en) | 2010-10-27 | 2017-02-21 | Курна, Инк. | Treatment of interferon-related developmental regulator 1 (ifrd1) associated diseases by inhibition of natural antisense transcript to ifrd1 |
US20140134181A1 (en) | 2010-11-05 | 2014-05-15 | Kenneth E. Lipson | Treatment Method For Lung Remodeling Diseases |
CA2818824A1 (en) | 2010-11-23 | 2012-05-31 | Joseph Collard | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
AU2011336467A1 (en) | 2010-12-01 | 2013-07-04 | Spinal Modulation, Inc. | Agent delivery systems for selective neuromodulation |
AU2011338548B2 (en) | 2010-12-06 | 2016-09-29 | The Penn State Research Foundation | Compositions and methods relating to proliferative diseases |
WO2012076715A1 (en) | 2010-12-09 | 2012-06-14 | Institut Pasteur | Mgmt-based method for obtaining high yield of recombinant protein expression |
US9095598B2 (en) | 2010-12-28 | 2015-08-04 | The Board Of Trustees Of The University Of Arkansas | Stilbenoid derivatives and their uses |
WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
KR101697396B1 (en) | 2011-02-02 | 2017-01-17 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
EP2681327B1 (en) | 2011-03-04 | 2018-11-21 | Intrexon Corporation | Vectors conditionally expressing protein |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9458456B2 (en) | 2011-04-01 | 2016-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
WO2012142458A1 (en) | 2011-04-13 | 2012-10-18 | Isis Pharmaceuticals, Inc. | Antisense modulation of ptp1b expression |
WO2012149515A2 (en) * | 2011-04-29 | 2012-11-01 | Northwestern University | Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use |
PT2709981T (en) * | 2011-05-20 | 2019-05-30 | Merck Patent Gmbh | Preparation of stable crystal modifications of dotap chloride |
SG193553A1 (en) | 2011-05-24 | 2013-10-30 | Biontech Ag | Individualized vaccines for cancer |
RS59037B1 (en) | 2011-06-08 | 2019-08-30 | Translate Bio Inc | Lipid nanoparticle compositions and methods for mrna delivery |
ES2653247T3 (en) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Treatment of frataxin-related diseases (FXN) by inhibiting the natural antisense transcript to the FXN gene |
LT2691530T (en) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2839437A1 (en) | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
CN103890000B (en) | 2011-06-21 | 2017-09-01 | 阿尔尼拉姆医药品有限公司 | (ANGPTL3) the iRNA compositions of angiopoietin-like 3 and its application method |
MX350198B (en) | 2011-07-06 | 2017-08-30 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids. |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
SG10201605500TA (en) | 2011-07-06 | 2016-08-30 | Novartis Ag | Cationic oil-in-water emulsions |
US20140274812A1 (en) | 2011-07-15 | 2014-09-18 | The General Hospital Corporation | Methods of Transcription Activator Like Effector Assembly |
EP2546358A1 (en) | 2011-07-15 | 2013-01-16 | Laboratorios Del. Dr. Esteve, S.A. | Methods and reagents for efficient control of HIV progression |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2755466A4 (en) | 2011-09-13 | 2015-04-15 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
DK2758433T3 (en) | 2011-09-19 | 2018-01-15 | Axon Neuroscience Se | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE |
PT2760463T (en) | 2011-09-20 | 2019-02-27 | Univ North Carolina Chapel Hill | Regulation of sodium channels by plunc proteins |
WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
CN108410868A (en) | 2011-09-20 | 2018-08-17 | Ionis制药公司 | The antisense of GCGR expression is adjusted |
CA2848417C (en) | 2011-09-21 | 2023-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
WO2013053765A1 (en) | 2011-10-11 | 2013-04-18 | Proyecto De Biomedicina Cima, S.L. | A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma |
KR20140084232A (en) | 2011-10-25 | 2014-07-04 | 아이시스 파마수티컬즈 인코포레이티드 | Antisense modulation of gccr expression |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
JP2013095755A (en) | 2011-11-02 | 2013-05-20 | Kyowa Hakko Kirin Co Ltd | Cationic lipid |
MX359548B (en) | 2011-11-18 | 2018-10-02 | Alnylam Pharmaceuticals Inc | Modified rnai agents. |
KR102385013B1 (en) | 2011-11-18 | 2022-04-12 | 알닐람 파마슈티칼스 인코포레이티드 | RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES |
EP2788316B1 (en) * | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
ES2921724T1 (en) | 2011-12-07 | 2022-08-31 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the administration of active agents |
KR102007061B1 (en) | 2011-12-09 | 2019-08-02 | 앵스띠뛰 파스퇴르 | Multiplex immuno screening assay |
AU2012353463B2 (en) | 2011-12-12 | 2017-08-24 | Kyowa Hakko Kirin Co., Ltd. | Lipid nanoparticles containing combinations of cationic lipids |
US9839616B2 (en) | 2011-12-12 | 2017-12-12 | Kyowa Hakko Kirin Co., Ltd. | Lipid nano particles comprising cationic lipid for drug delivery system |
WO2013090648A1 (en) * | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
PL2794627T3 (en) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
US9464291B2 (en) | 2012-01-06 | 2016-10-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
EP2802338B1 (en) | 2012-01-09 | 2018-03-07 | Serpin Pharma, LLC | Peptides and methods of using same |
KR102384791B1 (en) | 2012-02-24 | 2022-04-08 | 아뷰터스 바이오파마 코포레이션 | Trialkyl cationic lipids and methods of use thereof |
RU2639277C2 (en) | 2012-02-29 | 2017-12-20 | Сангамо Байосайенсиз, Инк. | Methods and compositions for huntington disease treatment |
MY198910A (en) | 2012-03-09 | 2023-10-02 | Pfizer | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (en) | 2012-03-09 | 2017-04-12 | فايزر انك | Neisseria meningitidis compositions and methods thereof |
CA2867262C (en) | 2012-03-15 | 2021-03-16 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
LT2852391T (en) | 2012-05-21 | 2022-03-10 | Insmed Incorporated | Systems for treating pulmonary infections |
AU2013264742B2 (en) | 2012-05-24 | 2018-10-04 | A.B. Seeds Ltd. | Compositions and methods for silencing gene expression |
US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
RS62288B9 (en) * | 2012-06-08 | 2021-12-31 | Nitto Denko Corp | Lipids for therapeutic agent delivery formulations |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
TW201726599A (en) | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | Cationic lipid |
EP3196301B1 (en) | 2012-07-11 | 2018-10-17 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of monogenic diseases |
CA2878037C (en) | 2012-07-11 | 2021-08-31 | Sangamo Biosciences, Inc. | Methods and compositions for delivery of biologics |
US9913907B2 (en) | 2012-07-16 | 2018-03-13 | Kyowa Hakko Kirin Co., Ltd. | RNAi pharmaceutical composition for suppressing expression of KRAS gene |
US9708607B2 (en) | 2012-08-03 | 2017-07-18 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
CA2882499C (en) | 2012-08-29 | 2023-09-26 | Sangamo Biosciences, Inc. | Cells genetically modified within the bcl11a gene by a nuclease and various aspects related thereto |
EP2890720B1 (en) | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Compositions and methods for treating cancer |
US9365856B2 (en) | 2012-09-14 | 2016-06-14 | The Board Of Trustees Of The University Of Arkansas | Methods of using a serum response factor isoform |
WO2014041179A1 (en) | 2012-09-17 | 2014-03-20 | Chemedest Ltd. | Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists |
AU2013317805B2 (en) | 2012-09-21 | 2018-07-26 | Pds Biotechnology Corporation | Improved vaccine compositions and methods of use |
EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
EP3483185B1 (en) | 2012-10-12 | 2020-09-09 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
CA2892391C (en) | 2012-11-28 | 2023-10-17 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
AU2013352259B2 (en) | 2012-11-29 | 2018-06-14 | Insmed Incorporated | Stabilized vancomycin formulations |
WO2014089313A1 (en) | 2012-12-05 | 2014-06-12 | Alnylam Pharmaceuticals | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
US20140179770A1 (en) | 2012-12-12 | 2014-06-26 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
CA2894684A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes |
DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
EP4279588A3 (en) | 2012-12-12 | 2024-01-17 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
DK2896697T3 (en) | 2012-12-12 | 2015-12-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
JP2016505256A (en) | 2012-12-12 | 2016-02-25 | ザ・ブロード・インスティテュート・インコーポレイテッ | CRISPR-Cas component system, method and composition for sequence manipulation |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
BR112015015976A2 (en) | 2013-01-01 | 2018-04-10 | A. B. Seeds Ltd. | method for introducing dsrna into seeds to modulate gene expression |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
AU2014214719B2 (en) | 2013-02-07 | 2020-02-13 | The General Hospital Corporation | Tale transcriptional activators |
EP2953970A4 (en) | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | Transthyretin antibodies and uses thereof |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
WO2014130723A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of pompe disease |
CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
CA2940513C (en) | 2013-03-11 | 2023-08-15 | University Of Florida Research Foundation, Inc. | Delivery of card protein as therapy for ocular inflammation |
JP6698015B2 (en) | 2013-03-12 | 2020-05-27 | ザ ジェネラル ホスピタル コーポレイション | Modified mullerian inhibitory substance (MIS) protein and use thereof for the treatment of diseases |
WO2014164761A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
MX2015012334A (en) | 2013-03-13 | 2016-02-05 | Monsanto Technology Llc | Methods and compositions for weed control. |
BR112015022260B1 (en) | 2013-03-13 | 2023-05-16 | Prothena Biosciences Limited | MONOCLONAL ANTIBODY THAT BINDS TO TAU, POLYNUCLEOTIDE, PHARMACEUTICAL COMPOSITION AND USE OF AN ANTIBODY |
WO2014139883A1 (en) | 2013-03-14 | 2014-09-18 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases |
PE20160046A1 (en) | 2013-03-14 | 2016-02-14 | Alnylam Pharmaceuticals Inc | COMPOSITION OF RNAi AGAINST THE C5 COMPONENT OF THE COMPLEMENT AND METHODS FOR ITS USE |
KR20210122917A (en) | 2013-03-14 | 2021-10-12 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna compositions and related methods and uses |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
JP2016518812A (en) | 2013-03-14 | 2016-06-30 | ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. | Molecular targets useful in the treatment of fibrosis and inhibitors of said targets |
DK2970955T3 (en) | 2013-03-14 | 2019-02-11 | Translate Bio Inc | METHODS FOR CLEANING MESSENGER RNA |
JP2016522675A (en) | 2013-03-14 | 2016-08-04 | ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. | Molecular targets useful in the treatment of diseases associated with epithelial-mesenchymal transition and inhibitors of said targets |
US9127024B2 (en) | 2013-03-15 | 2015-09-08 | Intrexon Corporation | Boron-containing diacylhydrazines |
US10010504B2 (en) | 2013-03-15 | 2018-07-03 | The Penn State Research Foundation | Compositions and methods including celecoxib and plumbagin relating to treatment of cancer |
US9999603B2 (en) | 2013-03-15 | 2018-06-19 | The Penn State Research Foundation | Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer |
WO2014145042A1 (en) | 2013-03-15 | 2014-09-18 | Loma Linda University | Treatment of autoimmune diseases |
US10052364B2 (en) | 2013-03-15 | 2018-08-21 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
WO2014186585A2 (en) | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
SG10201913872XA (en) | 2013-05-22 | 2020-03-30 | Alnylam Pharmaceuticals Inc | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
SG11201510565TA (en) | 2013-05-22 | 2016-01-28 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
WO2014190181A1 (en) | 2013-05-22 | 2014-11-27 | Northwestern University | Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis |
US20160130585A1 (en) | 2013-05-28 | 2016-05-12 | The Johns Hopkins University | Aptamers for the treatment of sickle cell disease |
EP3007704B1 (en) | 2013-06-13 | 2021-01-06 | Antisense Therapeutics Ltd | Combination therapy for acromegaly |
EP3011030B1 (en) | 2013-06-17 | 2023-11-08 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
CN106062197A (en) | 2013-06-17 | 2016-10-26 | 布罗德研究所有限公司 | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
CN114015726A (en) | 2013-06-17 | 2022-02-08 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases with viral components |
BR112015031608A2 (en) | 2013-06-17 | 2017-08-22 | Massachusetts Inst Technology | APPLICATION AND USE OF CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR LIVER TARGETING AND THERAPY |
MX2015017311A (en) | 2013-06-17 | 2017-04-10 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells. |
EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
US20160152952A1 (en) | 2013-06-25 | 2016-06-02 | Temple University-Of The Commonwealth System Of Higher Education | Cortical Bone-Derived Stem Cells |
US9856472B2 (en) | 2013-07-01 | 2018-01-02 | California Institute Of Technology | Small conditional RNAs |
EP3030663B1 (en) | 2013-07-19 | 2019-09-04 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
CA2919226A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US10568898B2 (en) * | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
WO2015031645A1 (en) | 2013-08-28 | 2015-03-05 | Washington University | Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv |
CA3131284C (en) | 2013-08-28 | 2023-09-19 | David Paschon | Compositions for linking dna-binding domains and cleavage domains |
US11236338B2 (en) | 2013-09-05 | 2022-02-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
RU2662968C2 (en) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Immunogenic composition for neisseria meningitidis (options) |
EP3047023B1 (en) | 2013-09-19 | 2019-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for inhibiting jc virus (jcv) |
WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
JP6821429B2 (en) | 2013-09-25 | 2021-01-27 | ゾエティス・サービシーズ・エルエルシー | PCV2B branched vaccine composition and usage |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
AU2014337248B2 (en) | 2013-10-17 | 2020-09-24 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
AU2014340083B2 (en) | 2013-10-22 | 2019-08-15 | Translate Bio, Inc. | mRNA therapy for phenylketonuria |
CN106413811A (en) | 2013-10-22 | 2017-02-15 | 夏尔人类遗传性治疗公司 | Mrna therapy for argininosuccinate synthetase deficiency |
EP3066200A1 (en) | 2013-11-04 | 2016-09-14 | Monsanto Technology LLC | Compositions and methods for controlling arthropod parasite and pest infestations |
US9469650B2 (en) | 2013-11-08 | 2016-10-18 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide B derivatives |
US9487536B2 (en) | 2013-11-08 | 2016-11-08 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide B derivatives |
NZ719477A (en) | 2013-11-11 | 2022-05-27 | Sangamo Therapeutics Inc | Methods and compositions for treating huntington’s disease |
RS58671B1 (en) | 2013-11-13 | 2019-06-28 | Childrens Medical Center | Nuclease-mediated regulation of gene expression |
CN112107693B (en) | 2013-12-03 | 2023-05-26 | 西北大学 | Liposome particles, method for preparing said liposome particles and use thereof |
JP6883987B2 (en) | 2013-12-04 | 2021-06-09 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | Methods for wound healing procedures utilizing chemically modified oligonucleotides |
DK3080274T3 (en) | 2013-12-09 | 2020-08-31 | Sangamo Therapeutics Inc | Methods and compositions for genome manipulation |
UA119253C2 (en) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Compositions and methods for virus control in varroa mite and bees |
ES2912283T3 (en) | 2013-12-11 | 2022-05-25 | Massachusetts Gen Hospital | Use of müllerian inhibitory substance (MIS)-type proteins for contraception and preservation of ovarian reserve |
AU2014361781B2 (en) | 2013-12-12 | 2021-04-01 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing |
KR20160089530A (en) | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
CA2931090A1 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
WO2015106128A2 (en) | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
UA121462C2 (en) | 2014-01-15 | 2020-06-10 | Монсанто Текнолоджі Елелсі | Methods and compositions for weed control using epsps polynucleotides |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
PL3102673T3 (en) | 2014-02-03 | 2020-11-02 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a beta thalessemia |
AU2015214264B2 (en) | 2014-02-04 | 2018-12-20 | Curis, Inc. | Mutant Smoothened and methods of using the same |
WO2015123264A1 (en) | 2014-02-11 | 2015-08-20 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
WO2015127094A1 (en) | 2014-02-19 | 2015-08-27 | University Of Florida Research Foundation, Inc. | Delivery of nrf2 as therapy for protection against reactive oxygen species |
EP3110401A4 (en) | 2014-02-25 | 2017-10-25 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
KR101605421B1 (en) | 2014-03-05 | 2016-03-23 | 국립암센터 | A monoclonal antibody which specifically recognizes B cell lymphoma and use thereof |
US9624498B2 (en) | 2014-03-18 | 2017-04-18 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
US11091770B2 (en) | 2014-04-01 | 2021-08-17 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
EP3134506B1 (en) | 2014-04-25 | 2019-08-07 | Translate Bio, Inc. | Methods for purification of messenger rna |
CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
US20170051290A1 (en) | 2014-05-01 | 2017-02-23 | Rxi Pharmaceuticals Corporation | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules |
CN106456699B (en) | 2014-05-05 | 2021-07-02 | 生物风险投资有限责任公司 | Compositions and methods for inhibiting anti-apoptotic Bcl-2 proteins as anti-aging agents |
WO2015171918A2 (en) | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
US11110154B2 (en) | 2014-05-08 | 2021-09-07 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's Disease |
ES2926985T3 (en) | 2014-05-15 | 2022-10-31 | Insmed Inc | Methods for treating nontuberculous mycobacterial lung infections |
EA201692370A1 (en) | 2014-05-22 | 2017-03-31 | Элнилэм Фармасьютикалз, Инк. | COMPOSITIONS of mRNA ANGIOTENZINOGENA (AGT) AND METHODS OF THEIR USE |
AU2015266767A1 (en) | 2014-05-30 | 2016-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods to treat latent viral infections |
PL3164113T3 (en) | 2014-06-04 | 2019-09-30 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
CA2952697A1 (en) | 2014-06-16 | 2015-12-23 | The Johns Hopkins University | Compositions and methods for the expression of crispr guide rnas using the h1 promoter |
AU2015280252A1 (en) | 2014-06-23 | 2017-01-12 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
EP3169773B1 (en) | 2014-07-15 | 2023-07-12 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
US10195280B2 (en) | 2014-07-15 | 2019-02-05 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
WO2016014625A1 (en) | 2014-07-22 | 2016-01-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells |
US10449261B2 (en) | 2014-07-24 | 2019-10-22 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
KR102330593B1 (en) | 2014-07-28 | 2021-11-26 | 에스케이이노베이션 주식회사 | Novel Isoprene Synthase and Method of Preparing Isoprene Using Thereof |
CA2955842A1 (en) | 2014-07-29 | 2016-02-04 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
EP3686279B1 (en) | 2014-08-17 | 2023-01-04 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
EP3186377A1 (en) | 2014-08-20 | 2017-07-05 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
CN107073017A (en) | 2014-09-10 | 2017-08-18 | 华盛顿大学 | Composition and method for treating precancerous dermatosis change |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
PT3194570T (en) | 2014-09-16 | 2021-08-06 | Sangamo Therapeutics Inc | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
MX2017003403A (en) | 2014-09-17 | 2017-06-19 | Intrexon Corp | Boron-containing diacylhydrazine compounds. |
WO2016049024A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
AU2015328012A1 (en) | 2014-10-02 | 2017-05-11 | Arbutus Biopharma Corporation | Compositions and methods for silencing Hepatitis B virus gene expression |
MX2017004448A (en) | 2014-10-06 | 2017-10-23 | Exicure Inc | Anti-tnf compounds. |
US20170304459A1 (en) | 2014-10-10 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
JOP20200115A1 (en) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
US10918629B2 (en) | 2014-10-20 | 2021-02-16 | The Curators Of The University Of Missouri | Method for treating lymphedema |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
CN113846101A (en) | 2014-11-17 | 2021-12-28 | 阿尔尼拉姆医药品有限公司 | Apolipoprotein C3(APOC3) iRNA compositions and methods of use thereof |
JP7175608B2 (en) | 2014-11-19 | 2022-11-21 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Osteocalcin as a treatment for age-related frailty |
WO2016085986A1 (en) | 2014-11-24 | 2016-06-02 | Northwestern University | High density lipoprptein nanoparticles for inflammation |
WO2016090166A1 (en) | 2014-12-03 | 2016-06-09 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide b dimers |
CN107001238B (en) * | 2014-12-08 | 2019-04-26 | 日油株式会社 | The manufacturing method of cation lipid |
WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
US10793613B2 (en) | 2014-12-15 | 2020-10-06 | Washington University | Compositions and methods for targeted cytokine delivery |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
EP3237615B2 (en) | 2014-12-24 | 2023-07-26 | The Broad Institute, Inc. | Crispr having or associated with destabilization domains |
WO2016108926A1 (en) | 2014-12-30 | 2016-07-07 | The Broad Institute Inc. | Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis |
PL3256589T3 (en) | 2015-01-22 | 2022-02-21 | Monsanto Technology Llc | Compositions and methods for controlling leptinotarsa |
KR20220159498A (en) | 2015-01-28 | 2022-12-02 | 카리부 바이오사이언시스 인코포레이티드 | Crispr hybrid dna/rna polynucleotides and methods of use |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
US10736845B2 (en) * | 2015-03-03 | 2020-08-11 | Cureport Inc. | Dual loaded liposomal pharmaceutical formulations |
US9895313B2 (en) | 2015-03-03 | 2018-02-20 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP4335918A2 (en) | 2015-04-03 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
US20180112006A1 (en) | 2015-04-17 | 2018-04-26 | The General Hospital Corporation | Agents, systems and methods for treating cancer |
MX2017014075A (en) | 2015-05-01 | 2018-07-06 | Onl Therapeutics Inc | Peptide compositions and methods of use. |
CN115322991A (en) | 2015-05-06 | 2022-11-11 | 阿尔尼拉姆医药品有限公司 | Factor XII, kallikrein B, plasma Freuey factor 1 and kininogen 1 iRNA compositions and methods of use thereof |
RU2021132397A (en) | 2015-05-16 | 2022-02-24 | Джензим Корпорейшн | GENE EDITING OF DEEP INRON MUTATIONS |
US10716827B2 (en) | 2015-05-20 | 2020-07-21 | Syracuse University | Compositions and methods for enhancing peptide stability against protease digestion |
WO2016187499A1 (en) | 2015-05-20 | 2016-11-24 | Syracuse University | Improved glycemic control using intrinsic factor bound to a vitamin b12 conjugate of a glucagon-like peptide- 1 receptor agonist |
JP6949728B2 (en) | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | Compositions and Methods for Modulating Inhibitory Interactions in Genetically Engineered Cells |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
EP3302497A4 (en) | 2015-06-01 | 2019-01-16 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
EP3302053B1 (en) | 2015-06-02 | 2021-03-17 | Monsanto Technology LLC | Compositions and methods for delivery of a polynucleotide into a plant |
EP3302030A4 (en) | 2015-06-03 | 2019-04-24 | Monsanto Technology LLC | Methods and compositions for introducing nucleic acids into plants |
WO2016197132A1 (en) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
TW201710503A (en) | 2015-06-12 | 2017-03-16 | 長庚醫療財團法人林口長庚紀念醫院 | Novel polynucleotides, vactor, pharmaceutical compositions and use thereof |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2016205728A1 (en) | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Crispr mediated recording of cellular events |
EP3430134B1 (en) | 2015-06-18 | 2022-09-21 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
WO2017007813A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
WO2017007825A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
MA42895A (en) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | MODIFIED CELLS FOR ADOPTIVE CELL THERAPY |
WO2017011728A1 (en) | 2015-07-15 | 2017-01-19 | Washington University | ANTIBODIES TO TUMOR ASSOCIATED COMPLEX N-GLYCANS WITH TERMINAL GlcNAcBeta RESIDUES AND METHODS OF USE THEREOF |
US20180208932A1 (en) | 2015-07-29 | 2018-07-26 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis b virus gene expression |
WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
WO2017035278A1 (en) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
US11020462B2 (en) | 2015-08-28 | 2021-06-01 | Serpin Pharma | Methods for treatment of diseases |
US10889813B2 (en) | 2015-09-02 | 2021-01-12 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof |
EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
CN108289966A (en) | 2015-09-24 | 2018-07-17 | 北卡罗来纳-查佩尔山大学 | Method and composition for reducing transfer |
WO2017058881A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
CN108513579B (en) | 2015-10-09 | 2022-10-04 | 孟山都技术公司 | Novel RNA-guided nucleases and uses thereof |
MA45819A (en) | 2015-10-09 | 2018-08-15 | Sarepta Therapeutics Inc | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCLE DYSTROPHY AND RELATED DISORDERS |
WO2017062953A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
MA42991A (en) | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN |
CA3002744A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
US20170211142A1 (en) | 2015-10-22 | 2017-07-27 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
CN108513575A (en) | 2015-10-23 | 2018-09-07 | 哈佛大学的校长及成员们 | Nucleobase editing machine and application thereof |
WO2017079429A1 (en) | 2015-11-05 | 2017-05-11 | Board Of Trustees Of The University Of Arkansas | Hetero-substituted cyclic lactone analogues and uses thereof |
AU2016349954B2 (en) | 2015-11-05 | 2022-08-25 | Antisense Therapeutics Ltd | Mobilizing leukemia cells |
EP3374496A4 (en) | 2015-11-13 | 2019-07-10 | PDS Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
AU2016367712B2 (en) | 2015-12-09 | 2021-10-07 | Jingang Medicine (Australia) Pty Ltd | Immunomodulating composition for treatment |
EP3387129A1 (en) | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
CN108778297B (en) | 2015-12-18 | 2024-02-09 | 桑格摩生物治疗股份有限公司 | Targeted disruption of T cell receptors |
US20190233814A1 (en) | 2015-12-18 | 2019-08-01 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
KR20180088911A (en) | 2015-12-18 | 2018-08-07 | 상가모 테라퓨틱스, 인코포레이티드 | Targeted Collapse of MHC Cell Receptors |
CA3009131A1 (en) | 2015-12-25 | 2017-06-29 | Kyowa Hakko Kirin Co., Ltd. | Compounds as cationic lipids and their use in nucleic acid delivery compositions |
US11938193B2 (en) | 2016-01-08 | 2024-03-26 | Washington University | Compositions comprising chemerin and methods of use thereof |
CA3010738A1 (en) | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
WO2017132528A1 (en) | 2016-01-29 | 2017-08-03 | Bioventures, Llc | Triazole derivatives of melampomagnolide b and methods of use thereof |
CN109069568B (en) | 2016-02-02 | 2023-07-07 | 桑格摩生物治疗股份有限公司 | Compositions for linking DNA binding domains and cleavage domains |
CN109071625A (en) | 2016-02-04 | 2018-12-21 | 柯瑞斯公司 | Smooth mutant and its application method |
JP7220458B2 (en) | 2016-02-05 | 2023-02-10 | ワシントン・ユニバーシティ | Compositions and methods for targeted cytokine delivery |
EP3653709B1 (en) | 2016-02-22 | 2020-12-09 | Caribou Biosciences, Inc. | Methods for modulating dna repair outcomes |
GB201604235D0 (en) | 2016-03-11 | 2016-04-27 | Ucl Business Plc | Lipids and complexes for the delivery of biologically-active material to cells |
CA3018572A1 (en) | 2016-03-24 | 2017-09-28 | Marquette University | Quantitative flagellar fluorescent markers and standards |
US10213448B2 (en) | 2016-03-25 | 2019-02-26 | Novazoi Theranostics | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof |
EP3445405A4 (en) | 2016-04-18 | 2019-12-18 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
AU2017253089B2 (en) | 2016-04-19 | 2023-07-20 | Massachusetts Institute Of Technology | Novel CRISPR enzymes and systems |
US20200263190A1 (en) | 2016-04-19 | 2020-08-20 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2017184786A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Cpf1 complexes with reduced indel activity |
WO2017184995A1 (en) | 2016-04-21 | 2017-10-26 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
UA124148C2 (en) | 2016-05-02 | 2021-07-28 | Протена Біосайенсіс Лімітед | Antibodies recognizing tau |
KR102533675B1 (en) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | Tau recognition antibody |
CN109415432B (en) | 2016-05-02 | 2022-07-08 | 普罗塞纳生物科学有限公司 | TAU immunotherapy |
JP7186094B2 (en) | 2016-05-06 | 2022-12-08 | イグジキュア オペレーティング カンパニー | Liposomal Spherical Nucleic Acid (SNA) Constructs Presenting Antisense Oligonucleotides (ASOs) for Specific Knockdown of Interleukin 17 Receptor mRNA |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
CA3028074A1 (en) | 2016-06-16 | 2018-12-20 | Oslo Universitetssykehus Hf | Improved gene editing |
KR20230156150A (en) | 2016-06-17 | 2023-11-13 | 더 브로드 인스티튜트, 인코퍼레이티드 | Type vi crispr orthologs and systems |
US20210222164A1 (en) | 2016-06-29 | 2021-07-22 | The Broad Institute, Inc. | Crispr-cas systems having destabilization domain |
JP7086870B2 (en) | 2016-06-30 | 2022-06-20 | アルブータス・バイオファーマー・コーポレイション | Compositions and Methods for Delivering Messenger RNA |
EP3943613A1 (en) | 2016-07-05 | 2022-01-26 | California Institute of Technology | Fractional initiator hybridization chain reaction |
CA3029860A1 (en) | 2016-07-05 | 2018-01-11 | The Johns Hopkins University | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter |
AU2017295720B2 (en) | 2016-07-13 | 2021-07-22 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
JP2019524098A (en) | 2016-07-15 | 2019-09-05 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Methods and compositions for genome editing of non-dividing cells |
CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
KR20230095129A (en) | 2016-08-03 | 2023-06-28 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Adenosine nucleobase editors and uses thereof |
EP3493834A1 (en) | 2016-08-07 | 2019-06-12 | Novartis AG | Mrna-mediated immunization methods |
EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
CN110312799A (en) | 2016-08-17 | 2019-10-08 | 博德研究所 | Novel C RISPR enzyme and system |
WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
SG10202007392SA (en) | 2016-08-24 | 2020-09-29 | Sangamo Therapeutics Inc | Engineered target specific nucleases |
DK3504229T3 (en) | 2016-08-24 | 2021-12-20 | Sangamo Therapeutics Inc | REGULATION OF GENEPRESSION USING MANIPULATED NUCLEASES |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
AU2017321492A1 (en) | 2016-08-30 | 2019-03-14 | California Institute Of Technology | Immunohistochemistry via hybridization chain reaction |
EP3519578B1 (en) * | 2016-10-03 | 2021-12-22 | Precision Nanosystems Inc | Compositions for transfecting resistant cell types |
CA3038690A1 (en) | 2016-10-05 | 2018-04-12 | FUJIFILM Cellular Dynamics, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
CA3037387A1 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
US11219695B2 (en) | 2016-10-20 | 2022-01-11 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of Fabry disease |
EP3528827A4 (en) | 2016-10-21 | 2020-11-04 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
WO2018081388A1 (en) | 2016-10-26 | 2018-05-03 | Washington University | Compositions comprising desaminotyrosine and uses thereof to enhance type i interferon stimulation |
WO2018081775A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
US10011848B2 (en) | 2016-11-09 | 2018-07-03 | City University Of Hong Kong | System and method for delivery of substance into mammalian cells |
EA201990864A1 (en) | 2016-11-09 | 2019-11-29 | STRUCTURES FOR EXPRESSION OF FRATAXIN | |
TW202313978A (en) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | Serpina1 irna compositions and methods of use thereof |
AU2017367695A1 (en) | 2016-12-02 | 2019-06-13 | Juno Therapeutics, Inc. | Engineered B cells and related compositions and methods |
MA49610A (en) | 2016-12-08 | 2020-05-27 | Univ Case Western Reserve | METHODS AND COMPOSITIONS FOR IMPROVING FUNCTIONAL MYELIN PRODUCTION |
TWI790217B (en) | 2016-12-16 | 2023-01-21 | 美商阿尼拉製藥公司 | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS |
JP2020510443A (en) | 2016-12-20 | 2020-04-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Method for increasing the efficiency of homologous recombination repair (HDR) in a cell genome |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
KR102567845B1 (en) | 2017-01-31 | 2023-08-17 | 화이자 인코포레이티드 | Neisseria meningitidis compositions and methods thereof |
WO2018148595A1 (en) | 2017-02-10 | 2018-08-16 | Washington University | Antibodies to tip1 and methods of use thereof |
EA201991747A1 (en) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | NEW CODON-OPTIMIZED CFTR mRNA |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
JP2020510439A (en) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Base-editing factor from cytosine to guanine |
EP3596207B1 (en) | 2017-03-15 | 2023-12-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US10876101B2 (en) | 2017-03-28 | 2020-12-29 | Locanabio, Inc. | CRISPR-associated (Cas) protein |
US11840711B2 (en) | 2017-04-12 | 2023-12-12 | The Broad Institute, Inc. | Type VI CRISPR orthologs and systems |
TWI801377B (en) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
WO2018201091A1 (en) | 2017-04-27 | 2018-11-01 | Washington University | Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof |
WO2018201088A1 (en) | 2017-04-27 | 2018-11-01 | Washington University | Activation of natural cytotoxicity receptor 2 (ncr2) |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
CA3058848A1 (en) | 2017-05-09 | 2018-11-15 | Vib Vzw | Means and methods for treating bacterial infections |
WO2018208910A1 (en) | 2017-05-09 | 2018-11-15 | The Broad Institute Inc. | Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
US10994025B2 (en) | 2017-05-12 | 2021-05-04 | Massachusetts Institute Of Technology | Argonaute protein-double stranded RNA complexes and uses related thereto |
WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
WO2018231690A1 (en) | 2017-06-12 | 2018-12-20 | Washington University | Zika virus strains for treatment of glioblastoma |
RS61691B1 (en) | 2017-06-20 | 2021-05-31 | Inst Curie | Immune cells defective for suv39h1 |
CN111511906A (en) | 2017-06-23 | 2020-08-07 | 因思科瑞普特公司 | Nucleic acid-guided nucleases |
WO2019005884A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
JP2020526558A (en) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | Common and direct methods for preparing oligonucleotide functionalized metal-organic framework nanoparticles |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
JP7360171B2 (en) | 2017-07-31 | 2023-10-12 | ワシントン・ユニバーシティ | Pirfenidone derivatives for regulation of B lymphocyte activity and organ protection |
US20200375929A1 (en) | 2017-08-14 | 2020-12-03 | Washington University | Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
US11097018B2 (en) | 2017-09-06 | 2021-08-24 | Washington University | Organomedicinals for imaging and treatment of neurodegenerative disorders |
CA3073848A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
CN107827762B (en) * | 2017-11-14 | 2020-10-02 | 苏州东南药业股份有限公司 | (2, 3-dioleoyl-propyl) trimethyl ammonium chloride and preparation method and application thereof |
BR112020009663A2 (en) | 2017-11-17 | 2020-11-10 | Iovance Biotherapeutics, Inc. | method for the expansion of tumor infiltrating lymphocytes (tils) in a therapeutic population of tils, method for the treatment of an individual with cancer, composition |
WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
JP2021503885A (en) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood |
WO2019118806A1 (en) | 2017-12-14 | 2019-06-20 | Solid Biosciences Inc. | Non-viral production and delivery of genes |
AU2018392782B2 (en) | 2017-12-21 | 2023-08-31 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded RNA agents |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
CA3087771A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
BR112020014315A2 (en) | 2018-01-17 | 2020-12-08 | Vertex Pharmaceuticals Incorporated | DNA-PK INHIBITORS |
IL276082B2 (en) | 2018-01-17 | 2024-01-01 | Vertex Pharma | Dna-pk inhibitor compounds, compositions comprising same and uses thereof |
CN111770921B (en) | 2018-01-17 | 2024-03-22 | 沃泰克斯药物股份有限公司 | Quinoxalinone compounds, compositions, methods and kits for improving genome editing efficiency |
EP3743069A4 (en) | 2018-01-22 | 2021-06-09 | BioVentures, LLC | Bcl-2 proteins degraders for cancer treatment |
JP2021511356A (en) | 2018-01-29 | 2021-05-06 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Stabilized RSVF protein and its use |
CN108129338A (en) * | 2018-02-01 | 2018-06-08 | 爱斯特(成都)生物制药股份有限公司 | A kind of preparation method of cationic liposome DOTAP |
WO2019160383A1 (en) | 2018-02-19 | 2019-08-22 | 고려대학교 산학협력단 | Vaccine comprising epitope of heat shock protein, and use thereof |
EP3539975A1 (en) | 2018-03-15 | 2019-09-18 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Micropeptides and uses thereof |
EP3773505A4 (en) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
JP2021520781A (en) | 2018-04-06 | 2021-08-26 | チルドレンズ メディカル センター コーポレーションChildren’S Medical Center Corporation | Compositions and Methods for Somatic Cell Reprogramming and Imprinting Modulation |
US20210198330A1 (en) | 2018-05-23 | 2021-07-01 | The Broad Institute, Inc. | Base editors and uses thereof |
MX2020013124A (en) | 2018-06-05 | 2021-07-15 | Lifeedit Therapeutics Inc | Rna-guided nucleases and active fragments and variants thereof and methods of use. |
CN113286884A (en) | 2018-08-07 | 2021-08-20 | 博德研究所 | Novel CAS12B enzymes and systems |
US20210317461A1 (en) | 2018-08-09 | 2021-10-14 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
JP2021533755A (en) | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | Chimeric antigen receptor and CAR-T cells that bind to HLA-DR |
US20210317429A1 (en) | 2018-08-20 | 2021-10-14 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
JP2022500003A (en) | 2018-09-18 | 2022-01-04 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Ketohexokinase (KHK) iRNA composition and its usage |
CN113015741A (en) | 2018-09-18 | 2021-06-22 | 桑格摩生物治疗股份有限公司 | Programmed cell death 1(PD1) specific nucleases |
WO2020069029A1 (en) | 2018-09-26 | 2020-04-02 | Emendobio Inc. | Novel crispr nucleases |
KR20210068485A (en) | 2018-09-28 | 2021-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
GB201815820D0 (en) | 2018-09-28 | 2018-11-14 | Univ Wageningen | Off-target activity inhibitors for guided endonucleases |
JP2022505139A (en) | 2018-10-15 | 2022-01-14 | フォンダッツィオーネ・テレソン | Genome editing methods and constructs |
US20220389395A1 (en) | 2018-10-29 | 2022-12-08 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
JP2022506508A (en) | 2018-11-05 | 2022-01-17 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expanded culture of TIL using AKT pathway inhibitors |
TW202039829A (en) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | Selection of improved tumor reactive t-cells |
CR20210295A (en) | 2018-11-05 | 2021-07-09 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CN112969469A (en) | 2018-11-05 | 2021-06-15 | 艾欧凡斯生物治疗公司 | Treatment of anti-PD-1 antibody refractory NSCLC patients |
US20220282275A1 (en) | 2018-11-15 | 2022-09-08 | The Broad Institute, Inc. | G-to-t base editors and uses thereof |
US20220056444A1 (en) | 2018-12-05 | 2022-02-24 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
EP3898958A1 (en) | 2018-12-17 | 2021-10-27 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
AU2019406186A1 (en) | 2018-12-20 | 2021-07-15 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of KCNT1 related disorders |
EP4339286A2 (en) | 2018-12-27 | 2024-03-20 | LifeEDIT Therapeutics, Inc. | Polypeptides useful for gene editing and methods of use |
WO2020150265A1 (en) | 2019-01-15 | 2020-07-23 | Empirico Inc. | Prodrugs of alox-15 inhibitors and methods of using the same |
US20220098621A1 (en) | 2019-02-05 | 2022-03-31 | Emendobio Inc. | Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene |
WO2020163017A1 (en) | 2019-02-06 | 2020-08-13 | Klogenix Llc | Dna binding proteins and uses thereof |
WO2020163307A1 (en) | 2019-02-06 | 2020-08-13 | Emendobio Inc. | New engineered high fidelity cas9 |
WO2020172343A2 (en) | 2019-02-19 | 2020-08-27 | Massachusetts Institute Of Technology | Methods for treating injuries |
AU2020233284A1 (en) | 2019-03-01 | 2021-09-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
KR20210134943A (en) | 2019-03-03 | 2021-11-11 | 프로테나 바이오사이언시즈 리미티드 | Tau Recognizing Antibodies |
WO2020181178A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through thymine alkylation |
WO2020181195A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenine excision |
US20220170013A1 (en) | 2019-03-06 | 2022-06-02 | The Broad Institute, Inc. | T:a to a:t base editing through adenosine methylation |
WO2020181202A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to t:a base editing through adenine deamination and oxidation |
WO2020181180A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to c:g base editors and uses thereof |
AU2020236937B2 (en) | 2019-03-08 | 2023-06-15 | Obsidian Therapeutics, Inc. | CD40L compositions and methods for tunable regulation |
GB201903499D0 (en) | 2019-03-14 | 2019-05-01 | Ucl Business Plc | Minimal promoter |
WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
WO2020191249A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
CN113939586A (en) | 2019-04-02 | 2022-01-14 | 桑格摩生物治疗股份有限公司 | Methods of treating beta-thalassemia |
WO2020210542A1 (en) | 2019-04-09 | 2020-10-15 | The Regents Of The University Of California | Long-lasting analgesia via targeted in vivo epigenetic repression |
US20220204975A1 (en) | 2019-04-12 | 2022-06-30 | President And Fellows Of Harvard College | System for genome editing |
US20220307003A1 (en) | 2019-04-17 | 2022-09-29 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
EP3958868A4 (en) | 2019-04-22 | 2023-01-18 | The Penn State Research Foundation | Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer |
US20220213469A1 (en) | 2019-04-30 | 2022-07-07 | The Broad Institute, Inc. | Methods and compositions for barcoding nucleic acid libraries and cell populations |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2020232271A1 (en) | 2019-05-14 | 2020-11-19 | The Broad Institute, Inc. | Compositions and methods for targeting multinucleated cells |
EP3969052A1 (en) | 2019-05-17 | 2022-03-23 | Alnylam Pharmaceuticals Inc. | Oral delivery of oligonucleotides |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
US20220249697A1 (en) | 2019-05-20 | 2022-08-11 | The Broad Institute, Inc. | Aav delivery of nucleobase editors |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
CN114040976A (en) | 2019-05-29 | 2022-02-11 | 奥驰亚客户服务有限公司 | Compositions and methods for producing tobacco plants and products with reduced or eliminated smoke branches |
WO2020243485A1 (en) | 2019-05-29 | 2020-12-03 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
GB201909597D0 (en) | 2019-07-03 | 2019-08-14 | Univ Wageningen | Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof |
CN114222815A (en) | 2019-07-23 | 2022-03-22 | 记忆疗法公司 | SUV39H1 deficient immune cells |
WO2021025750A1 (en) | 2019-08-08 | 2021-02-11 | The Broad Institute, Inc. | Base editors with diversified targeting scope |
EP4013864A1 (en) | 2019-08-12 | 2022-06-22 | Lifeedit Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021030666A1 (en) | 2019-08-15 | 2021-02-18 | The Broad Institute, Inc. | Base editing by transglycosylation |
AU2020333667A1 (en) | 2019-08-16 | 2022-02-24 | Massachusetts Institute Of Technology | Targeted trans-splicing using CRISPR/Cas13 |
KR102099342B1 (en) | 2019-09-03 | 2020-04-10 | 주식회사 제노포커스 | Expression Method of CRM197 Protein |
WO2021072248A2 (en) | 2019-10-10 | 2021-04-15 | Altria Client Services Llc | Pale yellow locus and its applications in tobacco |
WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
MX2022004388A (en) | 2019-11-01 | 2022-05-06 | Alnylam Pharmaceuticals Inc | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF. |
US20230079440A1 (en) | 2019-11-01 | 2023-03-16 | Sangamo Therapeutics, Inc. | Compositions and methods for genome engineering |
CN115135765A (en) | 2019-11-08 | 2022-09-30 | 菲奥医药公司 | Chemically modified oligonucleotides targeting bromodomain-containing protein 4(BRD4) for immunotherapy |
US20230056569A1 (en) | 2019-11-22 | 2023-02-23 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
WO2021108717A2 (en) | 2019-11-26 | 2021-06-03 | The Broad Institute, Inc | Systems and methods for evaluating cas9-independent off-target editing of nucleic acids |
US20230220341A1 (en) | 2019-12-11 | 2023-07-13 | lovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
EP4073251A1 (en) | 2019-12-13 | 2022-10-19 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
CA3164996A1 (en) | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
CN115190912A (en) | 2019-12-30 | 2022-10-14 | 生命编辑制药股份有限公司 | RNA-guided nucleases, active fragments and variants thereof, and methods of use |
WO2021138537A1 (en) | 2019-12-31 | 2021-07-08 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved systemic delivery |
JP2023509770A (en) | 2020-01-08 | 2023-03-09 | オブシディアン セラピューティクス, インコーポレイテッド | Compositions and methods for regulatable control of transcription |
GB202000934D0 (en) | 2020-01-22 | 2020-03-04 | Ucl Business Ltd | Engineered immune cells |
CA3166153A1 (en) | 2020-01-28 | 2021-08-05 | The Broad Institute, Inc. | Base editors, compositions, and methods for modifying the mitochondrial genome |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
US20230108687A1 (en) | 2020-02-05 | 2023-04-06 | The Broad Institute, Inc. | Gene editing methods for treating spinal muscular atrophy |
US20230235309A1 (en) | 2020-02-05 | 2023-07-27 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
WO2021163191A1 (en) | 2020-02-10 | 2021-08-19 | Board Of Regents, The University Of Texas System | Methods for rapid cloning and expression of hla class i cells |
PE20230493A1 (en) | 2020-02-14 | 2023-03-23 | Merck Sharp And Dohme Llc | HPV VACCINE |
US11752199B1 (en) | 2020-02-25 | 2023-09-12 | Mallinckrodt Ard Ip Unlimited Company | Methods of modulating pericytes |
EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
EP3885440A1 (en) | 2020-03-26 | 2021-09-29 | Splicebio, S.L. | Split inteins and their uses |
TW202204615A (en) | 2020-03-26 | 2022-02-01 | 美商阿尼拉製藥公司 | Coronavirus irna compositions and methods of use thereof |
EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
TW202208626A (en) | 2020-04-24 | 2022-03-01 | 美商生命編輯公司 | Rna-guided nucleases and active fragments and variants thereof and methods of use |
EP4143319A1 (en) | 2020-04-27 | 2023-03-08 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
EP4143315A1 (en) | 2020-04-28 | 2023-03-08 | The Broad Institute Inc. | <smallcaps/>? ? ?ush2a? ? ? ? ?targeted base editing of thegene |
JP2023523855A (en) | 2020-05-04 | 2023-06-07 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Method for producing tumor-infiltrating lymphocytes and their use in immunotherapy |
CN111393595A (en) * | 2020-05-06 | 2020-07-10 | 东莞市竤穗实业投资有限公司 | Bio-based polycarbodiimide crosslinking agent with temperature-sensitive characteristic and preparation method thereof |
CN115715203A (en) | 2020-05-06 | 2023-02-24 | 塞勒克提斯公司 | Methods of genetically modifying cells to deliver therapeutic proteins |
AU2021268253A1 (en) | 2020-05-06 | 2022-12-08 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
DE112021002672T5 (en) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE |
WO2021231437A1 (en) | 2020-05-11 | 2021-11-18 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use |
WO2021231680A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
EP4150086A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231675A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
EP4150089A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1) |
IL298215A (en) | 2020-05-19 | 2023-01-01 | Othair Prothena Ltd | Multi-epitope vaccine for the treatment of alzheimer's disease |
US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
IL299771A (en) | 2020-07-10 | 2023-03-01 | Inst Nat Sante Rech Med | Methods and compositions for treating epilepsy |
CA3173949A1 (en) | 2020-07-15 | 2022-01-20 | LifeEDIT Therapeutics, Inc. | Uracil stabilizing proteins and active fragments and variants thereof and methods of use |
WO2022023576A1 (en) | 2020-07-30 | 2022-02-03 | Institut Curie | Immune cells defective for socs1 |
WO2022034374A2 (en) | 2020-08-11 | 2022-02-17 | University Of Oslo | Improved gene editing |
US20220064596A1 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
KR20230060509A (en) | 2020-09-04 | 2023-05-04 | 노바록 바이오테라퓨틱스 리미티드 | Nectin-4 Antibodies and Uses Thereof |
JP2023541400A (en) | 2020-09-11 | 2023-10-02 | ライフエディット セラピューティクス,インコーポレイティド | DNA modification enzymes, active fragments and variants thereof, and methods for using the same |
US20230348892A1 (en) | 2020-09-17 | 2023-11-02 | Northwestern University | Engineered mamalian genetic circuits and methods of using the same |
EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
EP3973978A1 (en) | 2020-09-25 | 2022-03-30 | Mallinckrodt Ard IP Unlimited Company | Methods of modulating corticosteroid response |
TW202229552A (en) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
EP4229074A1 (en) | 2020-10-16 | 2023-08-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Anti-tumor immunity induces the presentation of aberrant peptides |
AU2021365822A1 (en) | 2020-10-21 | 2023-06-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
TW202237150A (en) | 2020-12-01 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
CA3202483A1 (en) | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
JP2024500403A (en) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of cancer with tumor-infiltrating lymphocytes |
JP2024503437A (en) | 2021-01-11 | 2024-01-25 | ザ ブロード インスティテュート,インコーポレーテッド | Prime editing factor variants, constructs, and methods to improve prime editing efficiency and accuracy |
WO2022164796A1 (en) | 2021-01-26 | 2022-08-04 | California Institute Of Technology | Allosteric conditional guide rnas for cell-selective regulation of crispr/cas |
WO2022164319A1 (en) | 2021-01-29 | 2022-08-04 | Wageningen Universiteit | Crispr-associated base-editing of the complementary strand |
US20220243216A1 (en) | 2021-02-03 | 2022-08-04 | Altria Client Services Llc | Increasing trichome density and improving transport of metabolites in plant trichomes |
TW202245835A (en) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines |
BR112023015761A2 (en) | 2021-02-12 | 2023-11-07 | Alnylam Pharmaceuticals Inc | SUPEROXIDE DISMUTASE 1 (SOD1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF TO TREAT OR PREVENT NEURODEGENERATIVE DISEASES ASSOCIATED WITH SUPEROXIDE DISMUTASE 1 (SOD1) |
WO2022182864A1 (en) | 2021-02-25 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods and methods of use thereof |
EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
AU2022233182A1 (en) | 2021-03-12 | 2023-10-05 | Synthego Corporation | Genetically modified cells expressing antigen-containing fusion proteins and uses thereof |
AU2022242754A1 (en) | 2021-03-22 | 2023-11-02 | LifeEDIT Therapeutics, Inc. | Dna modifyng enzymes and active fragments and variants thereof and methods of use |
KR20230162024A (en) | 2021-03-29 | 2023-11-28 | 알닐람 파마슈티칼스 인코포레이티드 | Huntingtin (HTT) iRNA preparation composition and method of use thereof |
KR20240037185A (en) | 2021-04-19 | 2024-03-21 | 이오반스 바이오테라퓨틱스, 인크. | Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy |
EP4326873A1 (en) | 2021-04-22 | 2024-02-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
EP4341401A1 (en) | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
WO2022246023A1 (en) | 2021-05-20 | 2022-11-24 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
CA3218475A1 (en) | 2021-05-21 | 2022-11-24 | Shipra DAS | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
IL308743A (en) | 2021-06-04 | 2024-01-01 | Alnylam Pharmaceuticals Inc | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022261509A1 (en) | 2021-06-11 | 2022-12-15 | The Broad Institute, Inc. | Improved cytosine to guanine base editors |
WO2022261394A1 (en) | 2021-06-11 | 2022-12-15 | LifeEDIT Therapeutics, Inc. | Rna polymerase iii promoters and methods of use |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2023288288A1 (en) | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use |
US20230042860A1 (en) | 2021-07-15 | 2023-02-09 | Turn Biotechnologies, Inc. | Polycistronic expression vectors |
WO2023288287A2 (en) | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment |
GB202110646D0 (en) | 2021-07-23 | 2021-09-08 | Sisaf Ltd | Nucleic acid vector compositions |
KR20240037293A (en) | 2021-07-23 | 2024-03-21 | 알닐람 파마슈티칼스 인코포레이티드 | Beta-catenin (CTNNB1) iRNA composition and methods of use thereof |
GB202110644D0 (en) | 2021-07-23 | 2021-09-08 | Sisaf Ltd | Improved nucleic acid vector particles |
CA3226942A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
WO2023015265A2 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides |
CA3227004A1 (en) | 2021-08-06 | 2023-02-09 | The Broad Institute, Inc. | Improved prime editors and methods of use |
WO2023023152A1 (en) | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
CA3233460A1 (en) | 2021-10-01 | 2023-04-06 | Jeroen Petrus Wilhelmus Maria BAKKERS | Mammalian cardiac regeneration |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023069498A1 (en) | 2021-10-22 | 2023-04-27 | Senda Biosciences, Inc. | Mrna vaccine composition |
WO2023076898A1 (en) | 2021-10-25 | 2023-05-04 | The Broad Institute, Inc. | Methods and compositions for editing a genome with prime editing and a recombinase |
US20230187042A1 (en) | 2021-10-27 | 2023-06-15 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
TW202334418A (en) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Huntingtin (htt) irna agent compositions and methods of use thereof |
WO2023077148A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
CN114015674A (en) | 2021-11-02 | 2022-02-08 | 辉二(上海)生物科技有限公司 | Novel CRISPR-Cas12i system |
WO2023080788A1 (en) | 2021-11-05 | 2023-05-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
WO2023096494A1 (en) | 2021-11-26 | 2023-06-01 | Synvolux Ip B.V. | Conserved coronavirus t cell epitopes |
WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023122762A1 (en) | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
WO2023139557A1 (en) | 2022-01-24 | 2023-07-27 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023150637A1 (en) | 2022-02-02 | 2023-08-10 | Inscripta, Inc. | Nucleic acid-guided nickase fusion proteins |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
WO2023196802A1 (en) | 2022-04-04 | 2023-10-12 | The Broad Institute, Inc. | Cas9 variants having non-canonical pam specificities and uses thereof |
WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023212715A1 (en) | 2022-04-28 | 2023-11-02 | The Broad Institute, Inc. | Aav vectors encoding base editors and uses thereof |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
WO2023220457A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Receptor engagement-mediated enhancement of biologics delivery |
WO2023220459A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Active loading of cargo entity into lipid bilayer particles using dimerization domains |
WO2023220392A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Synthetic modular extracellular sensors that employ natural receptor ligand-binding domains |
EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023230433A1 (en) | 2022-05-23 | 2023-11-30 | Altria Client Services Llc | Methods and compositions for regulating alkaloids in tobacco field |
WO2023230613A1 (en) | 2022-05-27 | 2023-11-30 | The Broad Institute, Inc. | Improved mitochondrial base editors and methods for editing mitochondrial dna |
WO2023235818A2 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
US20230392188A1 (en) | 2022-06-02 | 2023-12-07 | Perkinelmer Health Sciences, Inc. | Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids |
EP4314267A1 (en) | 2022-06-07 | 2024-02-07 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
WO2023240074A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
WO2023240137A1 (en) | 2022-06-08 | 2023-12-14 | The Board Institute, Inc. | Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing |
WO2023240277A2 (en) | 2022-06-10 | 2023-12-14 | Camp4 Therapeutics Corporation | Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas |
WO2024003334A1 (en) | 2022-06-30 | 2024-01-04 | Cellectis S.A. | Enhancing safety of t-cell-mediated immunotherapy |
WO2024015383A1 (en) | 2022-07-12 | 2024-01-18 | Northwestern University | Engineered hypoxia biosensors and methods of using the same |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024031038A1 (en) | 2022-08-05 | 2024-02-08 | Altria Client Services Llc | Methods and compositions for regulating alkaloids in tobacco |
WO2024033901A1 (en) | 2022-08-12 | 2024-02-15 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2024040083A1 (en) | 2022-08-16 | 2024-02-22 | The Broad Institute, Inc. | Evolved cytosine deaminases and methods of editing dna using same |
WO2024042489A1 (en) | 2022-08-25 | 2024-02-29 | LifeEDIT Therapeutics, Inc. | Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing |
WO2024047587A1 (en) | 2022-08-31 | 2024-03-07 | Regel Therapeutics, Inc. | Cas-phi compositions and methods of use |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931397A (en) * | 1971-11-05 | 1976-01-06 | Beecham Group Limited | Biologically active material |
IT1196363B (en) * | 1984-12-10 | 1988-11-16 | Bracco Ind Chimica Spa | DERIVATIVES OF 5-ALCOXY-2,4,6-TRIIODE- OR -TRIBROME-ISOPHTHALIC ACID, METHOD FOR THEIR PREPARATION AND RELATED RADIOLOGICAL CONTRAST MEANS |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
CA1288774C (en) * | 1985-01-07 | 1991-09-10 | Deborah A. Eppstein | 1,2-dialkoxy-w-trialkylammonium cationic surfactants |
JPS63102682A (en) * | 1986-10-20 | 1988-05-07 | Medeisa Shinyaku Kk | Transduction of dna into eukaryocyte |
US4840738A (en) * | 1988-02-25 | 1989-06-20 | The Procter & Gamble Company | Stable biodegradable fabric softening compositions containing 2-hydroxypropyl monoester quaternized ammonium salts |
CA2001401A1 (en) * | 1988-10-25 | 1990-04-25 | Claude Piantadosi | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions |
JP2805092B2 (en) * | 1989-09-14 | 1998-09-30 | ソニー株式会社 | Disk drive device |
JP2604268B2 (en) * | 1990-04-09 | 1997-04-30 | 富士写真フイルム株式会社 | Liposomes and thin films using peptide derivative amphiphilic compounds, intermediates thereof, and peptide derivative amphiphilic compounds |
DE4013632A1 (en) * | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | LIPOSOMES WITH POSITIVE EXCESS CHARGE |
WO1991017424A1 (en) * | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
-
1991
- 1991-04-16 US US07/686,746 patent/US5264618A/en not_active Expired - Lifetime
- 1991-04-18 ES ES91908905T patent/ES2134775T3/en not_active Expired - Lifetime
- 1991-04-18 EP EP91908905A patent/EP0523189B1/en not_active Expired - Lifetime
- 1991-04-18 WO PCT/US1991/002691 patent/WO1991016024A1/en active IP Right Grant
- 1991-04-18 AU AU78547/91A patent/AU7854791A/en not_active Abandoned
- 1991-04-18 DE DE69131347T patent/DE69131347T2/en not_active Expired - Lifetime
- 1991-04-18 CA CA002079814A patent/CA2079814C/en not_active Expired - Lifetime
- 1991-04-18 DK DK91908905T patent/DK0523189T3/en active
- 1991-04-18 AT AT91908905T patent/ATE181319T1/en not_active IP Right Cessation
- 1991-04-18 JP JP3508835A patent/JP2538474B2/en not_active Expired - Lifetime
-
1993
- 1993-09-16 US US08/123,757 patent/US5459127A/en not_active Expired - Lifetime
-
1999
- 1999-08-13 GR GR990402051T patent/GR3030974T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2134775T3 (en) | 1999-10-16 |
US5459127A (en) | 1995-10-17 |
AU7854791A (en) | 1991-11-11 |
ATE181319T1 (en) | 1999-07-15 |
EP0523189A1 (en) | 1993-01-20 |
GR3030974T3 (en) | 1999-12-31 |
JPH05508626A (en) | 1993-12-02 |
EP0523189A4 (en) | 1995-04-26 |
DK0523189T3 (en) | 1999-12-13 |
CA2079814A1 (en) | 1991-10-20 |
EP0523189B1 (en) | 1999-06-16 |
JP2538474B2 (en) | 1996-09-25 |
DE69131347T2 (en) | 2000-03-30 |
DE69131347D1 (en) | 1999-07-22 |
US5264618A (en) | 1993-11-23 |
WO1991016024A1 (en) | 1991-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2079814C (en) | Cationic lipids for intracellular delivery of biologically active molecules | |
US6656498B1 (en) | Cationic liposomes for gene transfer | |
EP1019365B1 (en) | Novel compositions for the delivery of negatively charged molecules | |
Niculescu-Duvaz et al. | Structure-activity relationship in cationic lipid mediated gene transfection | |
CA2237316C (en) | Complex cationic lipids | |
US6110745A (en) | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method | |
AU738083B2 (en) | Cationic amphiphile/ DNA complexes | |
US5705385A (en) | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer | |
US5981501A (en) | Methods for encapsulating plasmids in lipid bilayers | |
EP0845981B1 (en) | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules | |
WO1991017424A1 (en) | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes | |
AU731503B2 (en) | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules | |
AU729288B2 (en) | Composition and method for delivery of nucleic acids | |
US20080306153A1 (en) | Lipids and lipid assemblies comprising transfection enhancer elements | |
WO1998002190A9 (en) | Cationic amphiphile/dna complexes | |
CA2426244A1 (en) | Lipid formulations for target delivery | |
US6649780B1 (en) | Cationic lipids | |
US6245520B1 (en) | Methods for introducing nucleic acids into mammalian cells using imidazolium lipids | |
AU716706B2 (en) | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules | |
Mok | Characterization of libid-based DNA delivery systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |